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Abstract
Cannabinoids have long been proposed to affect the immune system, especially as one 
of the cannabinoid receptors, the cannabinoid receptor-2 (CB2R) has been found 
almost exclusively on immune cells. Here, using human in vitro activated peripheral 
blood-derived T lymphocytes (PBLs) the long-term changes in cannabinoid receptor 
protein expression following cellular activation and the effects of cannabinoids on 
migration and proliferation were investigated. CB2R protein expression is 
upregulated in T lymphocytes following activation by the superantigen 
Staphylococcal enterotoxin B (SEB). This high level of expression peaks around day 
5 of culture and is maintained for several days before being downregulated. 
Activating the cells using CD3/CD28-coated beads results in a longer-lasting 
upregulation of receptor protein expression. In addition, PBLs also express an 83kD 
form of the cannabinoid receptor-1 (CBiR) but not the 53kD protein. Although the 
receptors were found to be coupled to downstream biochemical effectors (as assessed 
by the phosphorylation of the extracellular signal-regulated kinase 1/2), neither the 
endogenous cannabinoid 2-arachidonoylglycerol nor the CB2 R-selective synthetic 
agonist JWH-133 induced chemotaxis in day 5 or day 12 SEB-activated PBLs, when 
receptor expression was at its highest. However, they both inhibited CXCL12- 
induced chemotaxis of day 5 and 12 PBLs. In contrast, JWH-133 increased IL-2- 
induced proliferation of day 5, but not day 11, PBLs suggesting that changes in CB2R 
expression affects some but not all T lymphocyte functions. The data presented here 

















Arp2/3 actin-related protein 2/3
BSA bovine serum albumin
C5a activated complement component 5
CaM calmodulin
CaMK calmodulin-dependent kinase
cAMP cyclic adenosine mono-phosphate
CBiR cannabinoid receptor-1
CB2R cannabinoid receptor-2
CD cluster of differentiation
CNS central nervous system
COX-2 cyclooxygenase-2
cPKC conventional PKC
CRE cAMP response element
CRIP cannabinoid receptor interacting protein






Epac exchange factor directly activated by cAMP
ERK extracellular signal-regulated kinase
FAAH fatty acid amide hydrolase
F-actin filamentous actin
FAK focal adhesion kinase
FBS foetal bovine serum
fMLP formyl-metionyl-leucine-phenylalanine
FRNK focal adhesion kinase-related non-kinase
G-actin globular actin
GM-CSF granulocyte macrophage-colony stimulating factor
Go Go6976
GPCR G-protein-coupled receptor
Grb2 growth factor receptor-bound 2
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IP3 inositol 1,4,5 triphosphate
ITAM immunoreceptor tyrosine-based activation motif
IkB inhibitor of NFkB
JNK c-Jun N-terminal kinase
LAT linker for activation of T cells
Lck lymphocyte-specific protein tyrosine kinase
LFA-1 leukocyte function associated antigen-1
LPA lysophosphatidic acid
LPS lipopolysaccharide
l t b 4 leukotriene B4
LY LY294002
MAFP methyl arachidonoyl fluorophosphonate
MAGL monoacylglycerol lipase
MAPK mitogen-activated protein kinase
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MKK mitogen-activated protein kinase kinase
MLC myosin light-chain
MLCK MLC kinase
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NEMO NFkB essential modulator
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NK natural killer
nPKC novel PKC
PAK p21 activated kinase
PBL peripheral blood-derived T lymphocyte
PBMC peripheral blood mononuclear cell













PKA cAMP-dependent protein kinase
PKB protein kinase B
PKC protein kinase C
PLC phospholipase C
PLD phospholipase D
PMA phorbol 13-myristate 12-acetate
PMS phenazine methosulfate
PMSF phenylmethylsulphonyl fluoride
PPAR peroxisome proliferator-activated receptor
PS phosphatidylserine
PSGL-1 P-selectin glycoprotein ligand-1
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Pyk2 proline-rich tyrosine kinase-2





RTK receptor tyrosine kinase
SIP sphingosine-1-phosphate
SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SEB Staphylococcal enterotoxin B
She Src homology and collagen
SOS son of sevenless
TBS tris-buffered saline
TBST TBS-Tween
TCR T cell antigen receptor
TGF transforming growth factor
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TM transmembrane
TNFR1 TNFa receptor 1
TNFa tumour necrosis factor a
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TxA2 -EA thromboxane A2-ethanolamide
TxA2 -G thromboxane A2-glycerol ester
VR1 vanilloid receptor type 1
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Marijuana, or cannabis, from the plant Cannabis sativa L., has been used 
medicinally for thousands of years for a number of complaints such as 
gastrointestinal disorders and rheumatic pain. Yet its use therapeutically remains 
controversial due to the psychoactive effects that are associated with it. Much of 
the current research in the field is aimed at understanding how cannabinoids 
exert their effects on physiological properties such as memory, cardiovascular 
function, cognition, pain, reproduction, motor control and immune function, in 
order to improve our understanding of how they could be better exploited 
therapeutically (Carlini, 2004, Pertwee, 2006).
Many initial studies suggested that cannabinoids are immunosuppressive, 
although more recent data has shown that they can exert both pro and anti­
inflammatory actions and thus they are now commonly referred to as being 
immunomodulatory (Croxford & Yamamura, 2005). One of the targets of 
cannabinoids in the immune system is T lymphocytes. Although some research 
regarding the effects of cannabinoids on T lymphocyte functions has been carried 
out their role still remains unclear, especially as there is much conflicting data 
published. Thus, this study was undertaken to further investigate the role of 
cannabinoids in T lymphocytes, in particular with respect to migration and 
proliferation.
1.1 The cannabinoid system
1.1.1 Background
The field of cannabinoid research really began in the 1960s when the main active 
ingredient of Cannabis sativa L., A9-tetrahydrocannabinol (A9-THC), was 
isolated (Gaoni & Mechoulam, 1964). It is this natural plant derivative, as well 
as the many others like it such as cannabidiol and cannabinol, to which the term 
cannabinoid originally referred. The isolation of A9-THC led to the development 
of a number of synthetic cannabinoids. Initially, it was believed that these 
lipophilic compounds were acting by disrupting cellular membranes until the 
existence of specific cannabinoid binding sites in the rat brain was established 
(Devane et al., 1988). Two distinct cannabinoid receptors were rapidly cloned,
Introduction
the cannabinoid receptor-1 (CBiR; Matsuda et ah, 1990, Gerard et ah, 1991) 
which is located mainly in the central nervous system (CNS) and the cannabinoid 
receptor-2 (CB2R; Munro et ah, 1993) which is expressed in cells of the immune 
system. The discovery of these receptors led to the search for an endogenous 
ligand and so far several possible ‘endocannabinoids’ have been identified. N- 
arachidonoylethanolamide (AEA, anandamide; Devane et ah, 1992) and 2- 
arachidonoylglyercol (2-AG; Mechoulam et ah, 1995) have been the most widely 
studied. Thus the term cannabinoid now generally refers to all those compounds 
which activate the cannabinoid receptors and includes the natural plant derived, 
synthetic and endogenous compounds. The ‘cannabinoid system’ comprises not 
only the cannabinoid receptor and the endocannabinoids, but also a putative 
transporter and the enzymes involved in the inactivation of the 
endocannabinoids. The term ‘cannabinergic ligand’ is a general one used to 
describe those compounds that act on any of the proteins within the cannabinoid 
system, regardless of their chemical classification or type of resultant 
pharmacological activity.
1.1.2 The cannabinergic ligands
1.1.2.1 AEA & 2-AG
1.1.2.1.1 Synthesis
AEA belongs to a large family of lipid structures known collectively as the N- 
acylethanolamines (NAEs), many of which are cannabinoid receptor inactive. 
AEA, like all NAEs can be produced via a two step process involving the 
production of 7V-arachidonoyl phosphatidylethanolamine (NAPE) which is then 
hydrolysed to AEA and phosphatidic acid (Fig. 1.1; Sugiura et ah, 2002, Bisogno 
et ah, 2005). The mechanisms involved in the regulation of AEA biosynthesis 
are still unclear although AEA appears to be synthesised and immediately 
released rather than stored in vesicles (Goutopoulos & Makriyannis, 2002, 
Sugiura et ah, 2002, Bisogno et ah, 2005). AEA is thought to be locally 
produced to act on the same or neighbouring cells as an autocrine or paracrine 
mediator. Levels are thought to lie in the low pmol/g range for most tissues
18
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although these can change in pathological conditions (Goutopoulos & 
Makriyannis, 2002, Sugiura et al., 2002).
2-AG belongs to the family of monoacylglycerols and is potentially produced by 
several different pathways (Sugiura et al., 2002, Bisogno et al., 2005). The main 
one studied has been the conversion of 1,2-diacylglycerol (DAG) to 2-AG by a 
DAG lipase (DAGL; Fig. 1.1). DAG can be generated from membrane 
phosphoinositides (Pis) by phospholipase C (PLC). Like AEA, 2-AG is also 
synthesised and released on demand but levels of 2-AG generally exceed those of 








-► NAPE + lysophospholipid 
NAPE-PLD.
<4 Iys° -PLD /V-arachidonoyl-lyso-PEAEA
membrane
Pis






Figure 1.1: AEA and 2-AG synthesis. An outline of som e of the AEA and 2-AG 
biosynthesis pathways described to date. AEA is believed to be mainly generated from 
NAPE by a specific phospholipase D (PLD) selective for NAPEs (NAPE-PLD; Sugiura et 
al., 2002, Bisogno et al., 2005). Although the physiological relevance is unclear, it is 
possible that AEA is also generated from free arachidonic acid (AA) and ethanolamine 
by fatty acid amide hydrolase (FAAH; Sugiura et al., 2002). Finally, it may also be 
generated from A/-arachidonoyl-lyso-PE which is a product of phospholipase A2 action 
on NAPE (Sugiura et al., 2002, Bisogno et al., 2005). 2-AG also has several different 
possible biosynthetic pathways (Sugiura et al., 2002, Bisogno et al., 2005). The main 
one is its generation from diacylglycerol (DAG) by two sn-1 DAGLs, DAGLa and y. DAG 
itself can be generated from several different sources but only one is shown. 2-AG may 
also be generated from 2-arachidonoyl lysophosphatidic acid or from 
lysophosphatidylinositol. Abbreviations: PE, phosphatidylethanolamine.
Questions on how or whether these endocannabinoids are generated over each 
other or other members of their families still remain. The enzymes involved in
19
Introduction
AEA and 2-AG synthesis, such as the NAPE-PLD or DAGL are not selectively 
involved in the generation of AEA or 2-AG but rather NAEs and 
monoacylglycerols in general (Sugiura et a l, 2002, Bisogno et a l , 2005). In 
some instances AEA and 2-AG levels can be independently modified whereas in 
other cases levels of both are increased or decreased (Pertwee & Ross, 2002). 
Many of the cannabinoid receptor inactive NAEs and monoacylglycerols can 
elicit cannabinoid-like effects and it has been hypothesised that they may be 
acting through an ‘entourage effect’ (Schmid et al., 2002). That is to say that 
they interfere with AEA and 2-AG transport and inactivation, thereby enhancing 
the cannabimimetic activity of these endocannabinoids. However, this has only 
been reported in vitro and whether the entourage effect hold true in vivo remains 
controversial as topical administration of PEA in mice resulted in decreasing 
AEA levels in skin (Lo Verme et a l, 2005a). Furthermore, some NAEs, such as 
V-palmitoylethanolamine (PEA), may elicit actions through specific non- 
cannabinoid receptors (Lo Verme et a l, 2005b).
1.1.2.1.2 Transport
Once released AEA and 2-AG are rapidly removed from the extracellular space, 
limiting their pharmacological actions. Several different mechanisms for AEA 
transport have been proposed. A putative anandamide membrane transporter 
(AMT) has been pharmacologically characterised after it was shown that uptake 
of AEA is facilitated by a saturable, temperature-dependent, Na+-independent 
and selective carrier protein in several different cell types (Bisogno et a l, 2001, 
Bisogno et a l, 2005). However, thus far the protein remains uncharacterised at 
the molecular level. It has also been reported that AEA uptake may simply be 
due to diffusion which is facilitated by the intracellular breakdown of AEA by 
FAAH, one of the key enzymes involved in its metabolism, which shifts the 
AEA concentration gradient such that it favours diffusion into the cell without 
the involvement of a carrier protein (Glaser et a l, 2003). Furthermore, it has 
also been suggested that the two mechanisms may act in concert (Day et a l, 
2001, Deutsch et a l, 2001) and that FAAH alone is insufficient to cause 
accumulation, or that it may play no role at all (Bisogno et a l, 2005, Moore et 
al, 2005). It has also been proposed that AEA is sequestered either in a lipid
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compartment or by binding a specific protein once it enters the cell, hence 
lowering the concentration of free AEA to favour AEA accumulation into the 
cell (Hillard & Jarrahian, 2003). Finally, AEA uptake may take place via a 
caveolae-related endocytic process that targets AEA to intracellular 
compartments where it can then be metabolised (McFarland et al., 2004). Not all 
cells accumulate AEA to the same degree and therefore it is likely that the uptake 
mechanism is cell-type specific and that each process may play a role. Equally, 
studies have so far been inconclusive as to whether a 2-AG transporter exists and 
if it does, whether it is the same protein as the AMT (Di Marzo et al., 1999, 
Bisogno et al., 2001, Hajos et al., 2004, Hermann et al., 2006).
1.1.2.1.3 Inactivation
Once inside the cell both endocannabinoids are rapidly degraded and it is 
possible that some of the responses attributed to AEA and 2-AG may in fact be 
caused by their metabolites (Pertwee & Ross, 2002). The main metabolic 
pathways are summarised in Fig. 1.2. FAAH is the main enzyme involved in 
AEA degradation (Cravatt & Lichtman, 2002). This fairly widely expressed, 
membrane-bound, enzyme is capable of hydrolysing a wide range of NAEs to 
their fatty acids and belongs to the amidase signature family of enzymes (Cravatt 
& Lichtman, 2002). It is also capable of hydrolysing 2-AG (Goparaju et al., 
1998). AEA, but not 2-AG, is also hydrolysed by A-acylethanolamine- 
hydrolysing acid amidase (NAAA), although AEA is a poorer substrate than 
some other NAEs such as PEA (Ueda et al., 1999, Ueda et al., 2001). It belongs 
to the choloylglycine hydrolase family of enzymes and is closely related to acid 
ceramidase although it has no ceramidase activity (Tsuboi et al., 2005). It is 
widely expressed, although some differences between species have been noted 
(Sun et al., 2005). It has also been suggested that certain cytochrome P450s 
may metabolise AEA (Kozak & Mamett, 2002). Although the physiological 
relevance of this pathway is largely unknown it has been shown that AEA can 
indirectly activate TRPV4, a cation channel, via a mechanism involving its 
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Figure 1.2: AEA and 2-AG metabolism. An outline of som e of the pathways for AEA 
and 2-AG inactivation. These pathways may produce a range of metabolites that may 
have their own pharmacological effects. As well as  being hydrolysed both AEA and 2- 
AG can be metabolised by cyclooxygenase-2 (COX-2) and lipoxygenases and it has 
been shown, mainly through in vitro studies, that the resulting prostaglandin H2- 
ethanolamide (PGH2-EA) and-glycerol ester (PGH2-G) can then be converted into the 
corresponding prostaglandin-ethanolamides (prostamides) or -glycerol esters, 
thromboxane A2-ethanolamide (TxA2-EA) or -glycerol ester (TxA2-G), and 
hydroperoxyeicosatetraenoic acid related products. Abbreviations: HETEE, hydroxy- 
eicosatetraenoylethanolamide; HETE-G, hydroxy-eicosatetraenoyl-glycerol ester; 
HPETEE, hydroperoxyeicosatetraenoylethanolamide; HPETE-G, hydroperoxyeicosa- 
tetraenoyl-glycerol ester; MAGL, monoacylglycerol lipase
Both AEA and 2-AG are also substrates for COX-2 (Kozak et a l 2002a) and 
some lipoxygenases (Edgemond et a l. , 1998, Moody et a l., 2001, Kozak et a l , 
2002b), producing a number of novel prostanoid and hydroxyeicosatetraenoic 
acid related products (Fig. 1.2). It is largely unknown what physiological 
relevance these metabolites have and how they may act but a few studies have 
suggested that they could represent novel signalling molecules. For instance, 
undefined lipoxygenase AEA products may act via the vanilloid receptor 1 
(VR1) in the guinea pig bronchus (Craib et a l., 2001), 15-HETE-G can activate 
peroxisome proliferator-activated receptor (PPAR)-a (Kozak et a l., 2002b) and 
PGE2-G has been shown to mobilise calcium in the murine macrophage cell line,
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RAW264.7 (Nirodi et a l, 2004). It is important to note that the relevance of 
these metabolites may change in pathological states.
2-AG can also be hydrolysed by MAGL (Fig. 1.2). This widely expressed 
enzyme can degrade a range of unsaturated monoacylglycerols but not AEA 
(Dinh et al., 2002, Goparaju et a l, 1999, Karlsson et a l, 1997). In addition, 2- 
AG could enter a number of lipid metabolic pathways to produce DAG or 
phosphatidic acid (Schmid et a l, 2002) and it is rapidly converted to 1(3)-AG by 
acyl migration (Rouzer et a l, 2002).
1.1.2.1.4 Mechanism of action
AEA and 2-AG appear to be produced on demand rather than stored and are 
thought to act as autocrine or paracrine mediators (Giufffida et a l, 2001). They 
couple to number of intracellular pathways, such as activation of mitogen- 
activated protein kinases (MAPKs), inhibition of cyclic adenosine mono- 
phosphate (cAMP) accumulation and modulation of intracellular Ca 
concentrations to exert their various actions. They can bind to and activate two 
cannabinoid receptors, the CBiR and CB2R. Studies have shown that AEA is a 
partial agonist at both the CBiR and CB2R whilst 2-AG acts as a full agonist at 
both receptors (Sugiura et a l, 1999, Sugiura et a l, 2000, Howlett et a l, 2002). 
Several additional cannabinoid receptors have also been described as will be 
discussed later and may be involved in some of the actions of AEA and 2-AG 
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Figure 1.3: Schematic showing the various receptors and ion channels that the 
endocannabinoid AEA can interact with.
As shown in Fig. 1.3 there are also additional ways in which AEA can exert its 
actions. For instance, AEA has been shown to directly activate the VR1, a non- 
selective cation channel (Smart et al., 2000, Ross, 2003). It has low intrinsic 
efficacy at the VR1 and acts as a partial agonist in tissues with low receptor 
reserve and a full agonist in tissues with high receptor reserve (Ross, 2003). 2- 
AG has been shown to be a poor agonist for the VR1 (Zygmunt et al., 1999, 
Golech et al., 2004). AEA can also directly interact with a number of 
neurotransmitter-gated ion channels such as NMDA, 5-hydroxytryptamine (5- 
HT, serotonin) and a7-nicotinic acetylcholine-receptors in vitro, although the in 
vivo relevance of this is still not known (van der Stelt & Di Marzo, 2005). It has 
also been shown to bind the nuclear receptor PPAR-y and induce PPAR-y- 
dependent transcriptional activity (Bouaboula et al., 2005). Similarly, 2-AG has 
also been shown to activate PPAR-y (Bouaboula et al., 2005, Burstein, 2005, 
Rockwell et al., 2006). It is also possible that membrane perturbation, which 
was originally thought to be the mechanism of action of cannabinoids before the 
receptors were discovered, may still play a role in the actions of AEA and 2-AG
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(Bloom et al., 1997, Ambrosi et al., 2005). It was shown in one study that 
cannabinoids do alter membrane lipid ordering but it was not the primary 
mechanism of action as the pharmacological potency did not correlate well with 
their potency for membrane perturbation (Bloom et al., 1997). Recently, a role 
for lipid rafts in some AEA actions has also been suggested as membrane 
cholesterol depletion, which disrupts raft integrity, has been shown to affect 
CBiR binding and subsequently signal transduction as well as cannabinoid 
receptor and VR1-independent signalling (Sarker & Maruyama, 2003, Bari et al., 
2005a, Bari et al., 2005b). As already mentioned, it is also possible that some of 
the AEA and 2-AG actions are due to their metabolites having pharmacological 
actions (Craib et al., 2001, Kozak et a l , 2002b, Pertwee & Ross, 2002, Nirodi et 
al., 2004) and there may still exist more unidentified mechanisms by which AEA 










Figure 1.4: Structures of AA and some of the best characterised
endocannabinoids.
In addition to AEA and 2-AG there are numerous other endocannabinoids 
(Bradshaw & Walker, 2005) with varying affinities for the cannabinoid 
receptors. Of these, 2-arachidonoyl glycerol ether (noladin ether), O-
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arachidonoyl ethanolamide (virodhamine) and iV-arachidonoyl dopamine 
(NADA) are among the best characterised. Their structures, along with those of 
AEA and 2-AG, are shown in Fig. 1.4.
1.1.2.2.1 Noladin ether
Noladin ether was originally developed synthetically as a stable analogue of 2- 
AG (Sugiura et al., 1999). Its classification as an endocannabinoid is somewhat 
controversial as, although it has been shown to be naturally occurring in porcine 
(Hanus et al., 2001) and rat (Fezza et a l , 2002) brain, Oka et al (2003) failed to 
isolate appreciable amounts from rat, mouse, hamster, guinea pig and pig brain. 
Little is known about its biosynthesis and it is suggested that as its ether bond 
cannot be hydrolysed enzymatically, esterification is likely to be important in its 
inactivation (De Petrocellis et a l , 2004). It has been reported that, like AEA and 
2-AG, it is taken up into cells by a similar or perhaps identical membrane 
transporter, and that it is inactivated in a time, concentration and temperature- 
dependent manner (Hanus et a l , 2001). Initially, it was believed to be a CBiR- 
selective agonist (Hanus et a l, 2001) with a much higher affinity for the CBiR 
than CB2R. However, a recent report suggests that noladin ether does in fact act 
as a full agonist at the human CB2R with high nanomolar affinity (Shoemaker et 
a l, 2005a). It may also exert CBiR and CB2R-independent effects (Duncan et 
a l, 2004).
1.1.2.2.2 Virodhamine
Virodhamine, an ester-linked isomer of AEA, acts as a full agonist at the CB2R 
but is classified as a CBiR antagonist/inverse agonist (Porter et a l, 2002, 
Steffens et a l, 2005a). It was isolated from rat brain and human hippocampus at 
concentrations similar to AEA but was expressed at higher concentrations in rat 
peripheral tissues (Porter et a l, 2002). It is not yet fully known how 
virodhamine is produced, stored or degraded although it can inhibit AEA 
transport, suggesting that it has the same reuptake mechanism as AEA (Porter et 




NADA, like AEA, is both an endocannabinoid and an endovanilloid (Bisogno et 
al., 2000, Huang et a l , 2002). It has been found in rat and bovine nervous tissue 
(Huang et a l , 2002) and has been shown to be an agonist at both the CBiR 
(Bisogno et a l , 2000) and the VR1 (Huang et al, 2002, Toth et a l, 2003) 
although higher concentrations are required to activate the CBiR than the VR1. 
As for AEA, its activity at the VR1 is enhanced by protein kinase C (PKC) 
phosphorylation (Premkumar et a l, 2004). CBiR and VR1-independent effects 
have been reported, suggesting NADA may act on additional targets (Sancho et 
a l, 2004, Sancho et al, 2005). Currently very little is known about its 
biosynthesis or breakdown but it appears that there may be more than one route 
of synthesis (Huang et a l, 2002, De Petrocellis et a l, 2004).
1.1.2.3 Other cannabinergic ligands
As well as the endocannabinoids, there are numerous other cannabinergic ligands 
and it would simply not be possible to mention them all here. Table 1 lists a few 
of the commonly used cannabinoid receptor agonists and antagonists as well as 
their equilibrium dissociation constants at each receptor whilst Fig. 1.5 illustrates 
some of their structures. For more in depth reviews please refer to Howlett et al, 
2002 and Palmer et al, 2000.
Currently there are 70 known natural cannabinoids and A9-THC, cannabidiol and 
cannabinol are the most prevalent of these. They have also been the most widely 
studied. A9-THC is the most psychologically active constituent of cannabis and 
acts as a partial agonist at both the CBiR and CB2R (Elsohly & Slade, 2005). A9- 
tetrahydrocannabivarin is an example of a natural CBiR and CB2R antagonist 
(Thomas et a l, 2005). A wide variety of synthetic cannabinoid receptor agonists 
and antagonists have also been generated. One of the most commonly used is 
CP55,940, a non-specific, high affinity cannabinoid receptor agonist. Its tritiated 
analogue was used in the study that identified the existence of cannabinoid 
binding sites in rat brain (Devane et a l, 1988). Other non-selective, highly 
potent agonists include HU210 and WIN55,212-2. CBiR and CB2R-selective
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agonists have also been produced. For instance, arachidonoylcyclopropylamide 
(ACPA) and arachidonyl-2’-chloroethylamide (ACEA) are commonly used as 
CBiR-selective agonists whilst JWH-133 and JWH-015 are examples of CB2R- 
selective agonists. Methanandamide (met-AEA) has also been generated as a 
stable analogue of AEA and is somewhat selective for the CBiR. Sanofi created 
the two CBiR and CB2R antagonists SR141716A and SRI44528, respectively. 
In addition, AM251, a CBiR, and AM630, a CB2R-selective antagonist are also 
commonly used. Each of these has also been reported to behave as an inverse 




CB!R c b 2r
2-AG A A 472 1400
ACPA A 2.2 715
AEA PA PA 89 371
AM251 AN/LA 7.5 2290
AM630 AN/IA 5152 31.2
CP55,940 A A 0.58 0.69
HU210 A A 0.73 0.22
JWH-133 A 677 3.4
met-AEA A 17.9 868
SR141716A AN/IA 5.6 >1000
SR144528 AN/IA 437 0.60
WIN55,212-2 A A 1.89 0.28
Ay-THC PA PA 53.3 75.3
Table 1: Exam ples of ligands that interact w ith the C B ^  and CB2R. The Ki values 
of the ligands for the in vitro displacement of [3H]CP55,940, [3H]W IN55,212-2 or 
[3H]HU243 from the CBiR and CB2R are given as well as whether they have been found 
to act as an agonist (A), partial agonist (PA), antagonist (AN) or inverse agonist (IA) 
indicated. The Ki values quoted are taken from Howlett et al., 2002 and Palmer et al., 
2002.
The cannabinergic ligands also include inhibitors of FAAH and MAGL and the 
putative AMT. Phenylmethylsulphonyl fluoride (PMSF) was the first FAAH 
inhibitor but since then compounds with much greater potency have become 
available. For instance, methyl arachidonoyl fluorophosphonate (MAFP) is a
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potent, irreversible inhibitor of FAAH and can also inhibit MAGL (De 
Petrocellis et al., 1997, Goparaju et a l , 1999, Saario et a l , 2004). The most 
notable of the transport inhibitors is A-(4-hydroxyphenyl) arachidonylamide 
(AM404) which has been reported to inhibit AEA uptake and therefore also 
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Figure 1.5: Structures o f som e of the cannabinergic ligands.
The list of cannabinergic ligands continues to expand as more synthetic ligands 
are created in order to assess the role of the individual components of the 
cannabinoid system in some of the cannabinoid effects. In addition, it has also
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been recently reported that Echinacea alkylamides upregulate tumour necrosis 
factor a (TNFa) mRNA in primary human monocytes via the CB2R as this effect 
could be inhibited by SRI44528 (Gertsch et al., 2004). Although specific 
binding or interaction of these alkylamides with the CB2R has not been shown, it 
does suggest that additional natural cannabinergic ligands may exist.
1.1.3 Receptors
1.1.3.1 CB]R and CB2R
The CBiR was originally cloned from a rat cerebral cortex cDNA library 
(Matsuda et al., 1990) and cloning of the human CBjR soon followed (Gerard et 
al., 1991). The human CBiR is a 472 amino acid protein with a predicted 
molecular weight of 53kD (Gerard et al., 1991). Initially it was only detected in 
the brain, hence it was considered to be the ‘central’ cannabinoid receptor, but it 
is now know that it is also located in a number of peripheral tissues, including 
testes, heart, lung and bone marrow (Howlett et a l, 2002). CBiR mRNA has 
also been found in immune cells, albeit at much lower levels than in the brain 
(Bouaboula et al., 1993). It is believed to be involved in a number of 
cannabinoid actions such as the psychoactive effects (Iversen, 2003), gastric 
motitility (Izzo et al., 2001) and regulation of food intake (Di Marzo & Matias,
2005).
Soon after the initial discovery of the human CBiR (Gerard et al., 1991), the 
existence of an amino terminal splice variant of the human CBiR, termed CB1A 
was described (Shire et al., 1995). Although it is expressed in much lower 
amounts than the CBiR, CB1A mRNA expression pattern seems to mimic that of 
the CBiR. More recently, an additional human CBiR splice variant was 
described and termed CB1B (Ryberg et al., 2005). Again, the CB1B differs from 
the CBiR and CB1A in its amino terminal sequence and is expressed in a number 
of tissues. Both splice variants were found to exhibit altered ligand binding and 
activation properties compared to the CBjR when all three were transfected into 
HEK293 cells (Ryberg et a l , 2005).
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The CB2R was first called the ‘peripheral’ cannabioid receptor owing to its 
discovery in the human promyelocytic cell line HL-60 and macrophages (Munro 
et al., 1993). It shares 44% amino acid identity with the CBjR (Munro et al., 
1993) and is smaller in size as it has a predicted molecular mass of only 39kD. 
Its expression pattern in much more restricted than that of the CBiR, with its 
mRNA being found largely in a variety of immune subpopulations (Galiegue et 
al., 1995). However, more recently it has become apparent that it may also be 
expressed in the CNS, for instance, in oligodendrocytes, cerebellar neurons and 
the brainstem vagus nerve (Molina-Holgado et al., 2005, Van et al., 2005) as 
well as on cerebromicrovascular endothelial cells (Golech et al., 2004) and 
microglia (Carlisle et al., 2002). Its predominant location in cells of the immune 
system has led researchers to believe that it is mainly involved in the 
immunomodulatory actions of cannabinoids.
Both the CBiR and CB2R are class I G-protein-coupled receptors (GPCRs) and 
have the classic 7 transmembrane (TM) domain structure. The basic structures 
of the human CBiR and CB2R are shown in Fig. 1.6. The CBiR couples to Gi/o- 
proteins and it has been shown that multiple conformations of the receptor can be 
induced by ligands in order to regulate individual G-proteins (Glass & Northup, 
1999, Prather et al., 2000, Mukhopadhyay & Howlett, 2005) and that the CBiR 
can sequester Gi/o-proteins, making them unavailable to other GPCRs (Vasquez 
& Lewis, 1999). CBjR coupling to Gs (Glass & Felder, 1997, Bonhaus et al.,
1998, Jarrahian et al., 2004) and Gq-proteins (Lauckner et al., 2005) has also 
been noted. The CB2R couples to Gi-proteins but interacts less efficiently with 
Go-proteins (Glass & Northup, 1999). It has been demonstrated that both 
receptors are constitutively active (Bouaboula et a l , 1997, Bouaboula et al.,
1999, Portier et al., 1999) and they are capable of linking to a number of 
different signalling pathways, some of which will be discussed in further detail 
later, such as inhibition of cAMP production and activation of MAPKs such as 
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Figure 1.6: Basic structure of the human CBiR and CB2R. This cartoon symbolises 
the 7 TM topology of the CBiR and CB2R. The amino acid numbers that mark the 
beginning and end of each of the proposed TM domains are shown. Details of the 
amino acid sequence of both receptors can be found in Appendices.
It is believed that cannabinoid agonists bind the CBjR within the pore formed 
within the TM helical cluster (Mukhopadhyay et al., 2002, Murphy & Kendall,
2003) although certain portions of the extracellular loops may also play a role in 
ligand binding (Murphy & Kendall, 2003). AEA, for instance, is believed 
diffuse through the lipid bilayer and then interact with a groove in the sixth TM 
domain (Makriyannis et al., 2005). Similarly the TM domains of the CB2R have 
been shown to be important in ligand binding and specificity (Shire et al., 1999, 
Xie et al., 2003). The three cytosolic loops and the intracellular C-terminal 
domain of the CBiR all contribute to the activation of G-proteins 
(Mukhopadhyay et al., 2002). For example, the juxtamembrane C-terminal 
domain of the human CBiR is critical for G-protein coupling whilst the distal C- 
terminal domain is important for modulating the magnitude and kinetics of signal 
transduction (Nie & Lewis, 2001). In the CB2R the areas involved in G-protein
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coupling may be different as the juxtamembrane C-terminal domain of CB2R 
appears not to be involved in G-protein coupling (Mukhopadhyay & Howlett, 
2001). The CBiR also has an exceptionally long N-terminal domain which has 
been found to be involved in receptor stability and limits its expression at the 
plasma membrane (Andersson et al., 2003). It has also been recently discovered 
that the CBiR contains an allosteric binding site that can be recognised by a class 
of small synthetic ligands Org 27569, Org 27759 and Org 29647 although the 
implications of this are not yet known (Price et al., 2005).
Many GPCRs are known to form oligomers such as homodimers and 
heterodimers. It is a field that has gathered much interest as it has been shown 
that heterodimerisation can give rise to receptor complexes that bind ligands, 
signal and traffic differently from the component receptors (Maggio et al., 2005). 
There is evidence to suggest that the CBiR can exist as homodimers (Wager- 
Miller et al., 2002, Mackie, 2005, Xu et al., 2005) as well as form heterodimers 
with GPCRs such as the D2 receptor (Keam et al., 2005), lysophosphatidic acid 
(LPA) 1 receptor (LPA1, Edg2; Wright et al., 2005), orexin 1 receptor (Hilairet 
et al., 2003) and possibly opioid receptors (Rios et al., 2006). CB2R homodimers 
have also been suggested to exist (Filppula et al., 2004)
Exposure of GPCRs to agonists often results in rapid attenuation of receptor 
responsiveness, a process referred to as receptor desensitisation. This involves 
uncoupling of the receptor from its G-proteins in response to receptor 
phosphorylation, internalisation of cell surface receptors to intracellular 
compartments, and downregulation of the total receptor numbers (Fig. 1.7). 
However, the term desensitisation is often used just to refer to the process of G- 
protein uncoupling. The term homologous desensitisation denotes agonist- 
specific desensitisation whereby only the active receptor is regulated. This in 
contrast to heterologous desensitisation which is not agonist-specific and inactive 
receptors are regulated by other receptors coupling to the same or different 
signalling pathways. The extent of receptor desensitisation can vary between 
systems from complete termination of signalling to attenuation of agonist 
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Figure 1.7: Basic outline of homologous GPCR desensitisation and resensitisation.
The waning of GPCR responsiveness to agonist with time is important in protecting 
against receptor overstimulation and this desensitisation involves several mechanisms. 
1) Heterotrimeric G-protein uncoupling: G-protein uncoupling occurs in response to 
phosphorylation of the intracellular portions of the receptor (predominantly the third 
intracellular loop and C-terminal domain) by 2nd m essenger-dependent protein kinases 
such as cAMP-dependent protein kinase (PKA) and PKC, and G-protein-coupled 
receptor kinases (GRKs). GRKs selectively phosphorylate agonist-activated receptors 
and increase the affinity of (B-arrestin binding. (3-arrestins physically uncouple the G- 
protein from the receptor and also target GPCRs for internalisation via clathrin-coated 
vesicles. 2) Receptor internalisation: the rate of internalisation is receptor specific and it 
has been suggested that multiple endocytic mechanisms exist. Many GPCRs internalise 
in a (B-arrestin and clathrin-dependent manner as  depicted, but calveolae, which can 
contain proteins involved in vesicle formation, represent an alternative route for some. 
(3-arrestins target GPCRs to clathrin-coated pits by associating with a number of proteins 
involved in endocytosis such as the AP-2 adaptor complex which is involved in 
promoting clathrin coat assem bly and clathrin itself. 3) Receptor recycling versus 
downregulation: som e receptors are recycled back to the cell surface, once (3-arrestin is 
removed and they are dephosphorylated, thereby resensitising the cell to the agonist. 
However, other GPCRs are internalised and then retained in endosom es and/or targeted 
to lysosomes for degradation. The pathway followed by specific GPCRs is regulated by 
determinants in the C-terminus. Degradation of these internalised receptors, alongside 
a decrease in receptor mRNA and protein sysnthesis, constitutes receptor 
downregulation (Ferguson, 2001, Kristiansen, 2004).
Following cannabinoid exposure the CBjR has been demonstrated to desensitise 
in a GRK and p-arrestin-dependent manner (Jin et al., 1999). It has also been 
shown to internalise rapidly (Jin et al., 1999, Hsieh et al., 1999), via clathrin- 
coated pits (Hsieh et al., 1999) and caveolae (Keren & Same, 2003), and agonists 
vary in their potency with regard to stimulating internalisation (Hsieh et al.,
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1999). Following short-term cannabinoid treatment the CBiR can be recycled 
back to the cell surface (Hsieh et a l , 1999). Different sections of the C-terminal 
domain are thought to be involved in desensitisation and internalisation (Hsieh et 
a l , 1999, Jin et a l, 1999). The C-terminus is also thought to play an important 
role in CB2R desensitisation and internalisation (Bouaboula et a l, 1999). 
Chronic administration of cannabinoids in vivo induces downregulation of the 
CBiR in several brain areas (Martin et a l, 2004), suggesting that whereas short 
term agonist exposure appears to cause reversible internalisation of the CBiR, 
long term treatment leads to internalisation and receptor downregulation (Hsieh 
et a l, 1999).
Cannabinoid receptor expression is not only modulated by cannabinoid exposure 
but also by cellular activation and differentiation, as seen in immune cells. For 
example, it was found that CBiR mRNA expression increased when PBMCs 
were cultured for up to 24 hours in media and that this was counteracted if the 
cells were stimulated with the T lymphocyte mitogen phytohemagglutinin (PHA; 
Nong et a l, 2002). In addition, it has been shown that levels of both CB2R 
mRNA and protein are modulated during B cell differentiation from virgin B 
cells through to memory B cells (Carayon et a l, 1998, Marchand et a l, 1999).
1.1.3.2 Additional cannabinoid-like receptors
In addition to the CB]R and CB2R, other cannabinoid-like receptors have been 
suggested to exist (Howlett et a l, 2002, Wiley & Martin, 2002, Begg et al, 
2005, Demuth & Molleman, 2006). For example, an endothelial cannabinoid 
receptor has been proposed to exist based on the findings that AEA can cause 
vasodilatation in isolated mesenteric arterial beds that is dependent on the 
presence of endothelial cells, cannot be reproduced by synthetic non-selective 
cannabinoid agonists and is only inhibited by concentrations of the CBiR 
antagonist, SR141716A, above those needed to block the CB]R. Abnormal 
cannabidiol (abn-cannabidiol), a non-psychotropic cannabinoid, also stimulates 




Although non-classical, cannabinoid-like, receptors have been reported, a 
phylogenetic analysis of the cannabinoid receptors has revealed no additional 
cannabinoid receptor homologue (Anday & Mercier, 2005). One possibility is 
that some of the responses detected that do not conform to a typical CBiR or 
CB2R-mediated response are due to the formation of oligomers, either homo or 
heterodimers, between the cannabinoid receptors or with other GPCRs (Mackie,
2005). It is well documented that dimerisation can alter the pharmacology of 
GPCRs (Maggio et al., 2005) and CBiR homodimerisation as well as association 
with other GPCRs has already been reported as mentioned above (Keam et a l , 
2005, Mackie, 2005, Wright et al., 2005). Another possibility is that these 
responses are mediated by cannabinoid receptor splice variants. Thus far two 
splice variants of the CBiR with unique pharmacological profiles have been 
described (Ryberg et a l , 2005). There are also a number of additional receptors 
that the cannabinoids can couple to, as discussed below, and these may be 
involved in some of the effects seen, as may the endocannabinoid metabolites.
Furthermore, it is also possible that additional cannabinoid receptor subtypes do 
exist but that they exhibit little identity to the CBjR and CB2R. One recent paper 
has reported that two separate patents indicate that the orphan GPCR, GPR55, is 
a novel cannabinoid receptor (Baker et a l , 2006). Several cannabinoids, 
including CP55,940, AEA, 2-AG and AM251, were shown to bind GPR55, 
whilst others such as WIN55,212-2 did not. The receptor exhibits low identity 
(10-15%) to both the CBiR and CB2 R but there are certain conserved sequences 
between the putative TM domains of GPR55 and the CBiR and CB2R. In 
contrast to the CBiR and CB2R, GPR55 does not couple to Gi or Gs-proteins. It 
appears to be expressed in a number of human tissues, including certain brain 
regions and the spleen.
1.1.3.3 VR1
The VR1 (also known as TRPV1) is a non-selective cation channel that is 
expressed in sensory neurons in the peripheral nervous system and in various 
brain regions. It is a member of transient receptor potential channel superfamily. 
It is involved in nociception and responds to a number of different stimuli
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including several chemical stimuli such as capsaicin, AEA and other NAEs, 
NADA, resiniferatoxin, gingerols, and several lipoxygenase products (Smart et 
al, 2000, Caterina & Julius, 2001, Dedov et al., 2002, Huang et al., 2002, 
Hwang & Oh, 2002, Ross, 2003, Movahed et al., 2005). The lipid mediators all 
bind intracellularly. Activity at the VR1 by these ligands is reported to be 
regulated by several additional factors including phosphorylation of the VR1 by 
PKC (Ross, 2003) and acidic conditions (Caterina & Julius, 2001). VR1- 
dependent actions of AEA include induction of apoptosis in tumour cell lines 
(Maccarrone et al., 2000) and vasodilatation in isolated rat arteries (Zygmunt et 
a l , 1999).
1.1.3.4 Additional receptors cannabinoids may interact with
Cannabinoids have also been shown to interact with several receptors other than 
the cannabinoid receptors and the VR1 and it is likely that this list will continue 
to grow in the future. For instance, AEA can inhibit 5-HT-induced currents 
through the human 5 -HT3A receptor in a cannabinoid receptor-independent 
manner (Barann et al., 2002). It was suggested that AEA acts allosterically at a 
modulatory site on the 5 -HT3A receptor. Cannabidiol, one of the natural plant 
cannabinoids has also been shown to act as an agonist at the human 5-HTia 
receptor and it has been suggested that it is acting at the ligand-binding site of the 
receptor (Russo et al., 2005). Furthermore, it has been reported that AEA and 2- 
AG directly affect the functioning of inhibitory glycine receptor channels 
(Lozovaya et al., 2005) and that AEA can inhibit agonist binding to Mi 
muscarinic acetylcholine receptors (Lanzafame et al., 2004). Several 
cannabinoids have been shown to activate PPAR-y, including AEA and 2-AG as 
previously mentioned (Burstein, 2005). For example, ajulemic acid was found to 
bind to and activate the transcriptional activity of PPAR-y (Liu et al., 2003) and 
A9-THC was also shown to activate PPAR-y (O’Sullivan et al., 2005). 
Furthermore, 2-AG, ajulemic acid and A9-THC were all shown to stimulate 
adipocyte differentiation in cultured 3T3L1 cells, a well accepted property of 
PPAR-y ligands (Liu et al., 2003, Burstein, 2005, O'Sullivan et a l, 2005). In 
addition, PEA, another NAE, has recently been shown to activate PPAR-a (Lo 
Verme et a l, 2005a).
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1.1.4 Cannabinoids and cellular signal transduction
The cannabinoids have been linked to numerous downstream signalling 
pathways including ion channel activation, MAPK activation and regulation of 
cAMP production via the cannabinoid receptors. This is not meant to be an 
exhaustive review on cannabinoid signalling but rather an introduction to some 
of the downstream effectors that have been more widely studied. As well as 
cannabinoid receptor-mediated effects, there are also suggestions of receptor- 
independent effects. However, much of this data is largely based on the use of 
CBiR and CB2R antagonists such as SR141716A and SR144528. In light of the 
possible inverse agonism of these compounds (Bouaboula et al., 1999) and the 
suggested existence of additional cannabinoid receptors (Wiley & Martin, 2002, 
Begg et al., 2005) further work may be required to verify these claims.
The lipid bilayer appears to play an important role in cannabinoid signalling. 
Cholesterol enrichment of membranes has been shown to decrease CBiR binding 
and also decrease subsequent downstream signalling, whereas cholesterol 
depletion enhances binding and downstream signalling events, although actual 
levels of CBiR expression appeared to be unaffected (Bari et al., 2005a, Bari et 
al., 2005b). Other studies have shown that membrane cholesterol depletion can 
inhibit AEA or met-AEA-induced signalling that is independent of the 
cannabinoid receptors and VR1 (Sarker & Maruyama, 2003, Hinz et a l, 2004). 
Thus, a novel role for lipid rafts, which are highly dynamic and discreet 
membrane domains rich in sphingolipids and cholesterol (Rajendran & Simons,
2005), has been suggested in cannabinoid signalling. It may be that the lipid 
rafts play a role in determining whether receptor-dependent or independent 
events occur, alter AEA cellular accumulation or that they represent an additional 
mechanism of signal transduction.
1.1.4.1 MAPK activation
The MAPK family members, including ERK1/2 (p42/p44), p38 and c-Jun N- 
terminal kinase (JNK), play key roles in several cellular functions such as cell
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proliferation and differentiation. In resting cells the MAPKs largely reside in the 
cytoplasm but can enter the nucleus once activated to phosphorylate nuclear 
substrates such as transcription factors, protein kinases and cell cycle regulators. 
Each MAPK is activated through a cascade of successively activating protein 
kinases: MAPK kinase and MAPK kinase kinase. The basic outline of these 
pathways is shown in Fig. 1.8. There are multiple family members for each 
kinase, in particular there are many MAPK kinase kinases, and each is 
differentially regulated in part through interactions with G-proteins, scaffolds, 
chaperones, adaptors, kinases, phosphatases, substrates, regulatory proteins and 
lipids.
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Figure 1.8: Schematic representation of the structure of MAPK pathways. Briefly, 
the pathway consists of a cascade of three kinases: a MAPK kinase kinase (•) that 
phosphorylates and activates a MAPK kinase (•) which then activates the MAPK (•). 
The ERK1/2 activation pathway is shown in more detail a s  an example. Full activation 
of the Raf serine/threonine kinases (Raf-1, A-Raf and B-Raf) requires several steps, 
including several phosphorylations by upstream kinases. Once activated, Raf 
phosphorylates MAPK/ERK kinase-1/2 (MEK1/2) on serine residues and, in turn, this 
dual specificity kinase then activates ERK1/2 via phosphorylation of a Thr-Glu-Tyr motif 
in the activation loop. This phosphorylation can be detected, for instance by using 
antibodies that bind the phosphorylated form of the protein, and used as  a marker of 
activation. Once activated, ERK1/2 translocates to the nucleus and there regulates the 
activity of several transcription factors such as Elk-1 (Kolch, 2000, Pouyssegur et al., 
2002, Anderson, 2006). Abbreviations: MEKK, MEK kinase; MKK, mitogen-activated 
protein kinase kinase; MLK, mixed lineage kinase.
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Several studies have shown that cannabinoids can couple to these MAPKs and 
thereby have effects on a number of cellular activities or further signalling 
pathways. For example, MAPK has been shown to be involved in cannabinoid- 
induced glucose metabolism (Sanchez et a l , 1998), activation of the Na+/H+ 
exchanger NHE-1, which is involved in control of cell volume in CHO-CBiR 
cells (Howlett & Mukhopadhyay, 2000) and inducing expression of immediate 
early genes such as krox-24 (Bouaboula et a l, 1995a).
Wartmann et al (1995) were the first to report ERK activation by an 
endocannabinoid, namely AEA, and Bouaboula et al (1995b) were the first to 
demonstrate that the CBiR can couple positively to ERK 1/2 phosphorylation and 
activation via a pertussis toxin (PTX)-sensitive and cAMP-independent 
mechanism. Since then a number of in vitro studies have been done to show that 
ERK can be activated by cannabinoids in a CBiR and CB2R-dependent manner 
(Bouaboula et a l, 1996, Liu et a l, 2000, Kobayashi et a l, 2001, Galve-Roperh 
et al, 2002, Gomez et al, 2002, Samson et a l, 2003, Herrera et a l, 2005). In 
addition, the in vivo administration of A9-THC has been linked to the induction of 
ERK activation in murine dorsal striatum and nucleus accumbens (Valjent et al, 
2001), hippocampus (Derkinderen et a l, 2003) and rat cerebellum (Rubino et al,
2004). Cannabinoids have also been shown to couple negatively to ERK 
activation. For example, AEA has been reported to inhibit sustained ERK 
activation in PC 12 cells induced by nerve growth factor (Rueda et a l, 2002) and 
cannabinoids appear to inhibit phorbyl 13-myristate 1 2 -acetate 
(PMA)/Ionomycin-induced ERK activation in mouse splenocytes (Faubert & 
Kaminski, 2000, Faubert Kaplan & Kaminski, 2003).
As shown in Fig. 1.8 the basic pathway leading to ERK 1/2 activation involves 
the kinases Raf and MEK1/2 (Kolch, 2000, Pouyssegur et a l, 2002, Anderson,
2006). GPCRs can couple to this pathway in many different ways and the exact 
pathway involved in ERK 1/2 activation varies between receptor and cell types 
but some of the major pathways are outlined in Fig. 1.9. For example, activation 
of Gq-protein coupled receptors leads to ERK1/2 activation in either a PKC 
and/or Ras-dependent manner. PKC can both directly and indirectly enhance the 
activity of Raf-1 and Ras is a GTPase that binds Raf when active, thereby
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localising it to the plasma membrane, one of the steps in Raf activation. 
Activation of, for instance, Gi-protein-coupled receptors, and release of the Gpy- 
subunits, can also lead to ERK 1/2 activation via many different routes, including 
receptor transactivation. Transactivation occurs when activation of a GPCR 
leads to stimulation of a receptor tyrosine kinase (RTK), such as epidermal 
growth factor receptor (Marinissen & Gutkind, 2001, Werry et al., 2005). This 
creates docking sites for proteins that contain phosphotyrosine binding domains 
and leads to the assembly of complexes containing son of sevenless (SOS) which 
will in turn activate Ras. Activation of Gs-protein coupled receptors can lead to 
either inhibition or stimulation of ERK 1/2 activation via the generation of cAMP 
(Stork & Schmitt, 2002, Bos, 2003, Stork, 2003). In addition, there may also be 
a role for endocytosis, and proteins such as dynamin and arrestin which are 
involved in this process, in ERK 1/2 activation downstream of some, but not all, 
GPCRs (Werry et a l, 2005).
Current information on how the cannabinoid receptors couple to ERK 1/2 
activation indicates that the pathways may be cell specific, however, all the 
reports agree that a PTX-sensitive G-protein is involved. One of the ways in 
which the cannabinoid receptor could link to ERK activation is through the 
inhibition of cAMP as the possible links between cAMP and ERK 1/2 are 
numerous (Fig. 1.9; Stork & Schmitt, 2002, Bos, 2003, Stork, 2003). Whilst 
there are some studies that show that cannabinoid-induced ERK 1/2 activation is 
a cAMP-independent process (Bouaboula et al., 1995b, Bouaboula et a l, 1996, 
Sanchez et a l, 1998) other suggest that a decrease in cAMP levels, and 
subsequently PKA activity, may play a role in the stimulatory effects of 
cannabinoid receptor activation on ERK activation (Melck et a l, 1999, Davis et 
al, 2003, Derkinderen et a l, 2003). A link between the release of ceramide 
through sphingomyelin hydrolysis induced by cannabinoids acting through the 
CBiR and consequent activation of the Raf-l/ERKl/2 pathway has also been 
suggested (Sanchez et al, 1998). In accordance with a role for Raf in ERK 
activation there have been several reports indicating that cannabinoids can 
enhance Raf-1 translocation and activity (Sanchez et a l, 1998, Melck et al, 
1999, Galve-Roperh et a l, 2000, Galve-Roperh et a l, 2002, Sanchez et al,
2003).
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Figure 1.9: Schematic outlining some of the major pathways linking GPCRs to ERK1/2 activation. Notably many of the connections shown are 
not direct and involve additional scaffolding proteins and/or modulators. However, som e of the key regulators of ERK1/2 activation are shown and 
details of these pathways can be found in the following reviews; Kolch, 2000; Marinissen & Gutkind, 2001; Bos, 2003; Stork, 2003; Werry et al, 2006.
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Furthermore, both the CBiR and CB2R have also been shown to couple to 
ERK 1/2 via PKC (Bouaboula et a l, 1996, Liu et a l,  2000). A role for PI3K in 
cannabinoid-induced ERK activation has also been demonstrated in several 
different studies using the PI3K inhibitors LY294002 and wortmannin 
(Bouaboula et a l, 1997, Galve-Roperh et a l,  2002, Samson et a l,  2003, Sanchez 
et a l, 2003). It has also been suggested that the non-receptor tyrosine kinase, 
Src, may be required for maximal ERK activation as two studies have shown that 
Src inhibition decreased cannabinoid-induced ERK activation although the 
cannabinoids did not stimulate Src per se (Galve-Roperh et a l, 2002, Davis et 
a l, 2003). Similarly, another Src-family kinase, Fyn, was proposed to have a 
role in cannabinoid-induced ERK activation in two further studies (Derkinderen 
et a l, 2003, Zhao et a l, 2005). Some of the pathways currently thought to link 
the cannabinoid receptors and ERK 1/2 activation are briefly outlined in Fig. 
1. 10 .
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Figure 1.10: A schematic of some of the pathways currently thought to link the 
cannabinoid receptors to ERK1/2 activation. Many of the intermediary steps in these 
pathways have not yet been examined in the context of cannabinoid signalling and have 
therefore not been represented here. In addition, one study has shown that ERK 
activation occurred downstream of epidermal growth factor receptor transactivation in 
number of different cell lines, however, they did not investigate the role of the 
cannabinoid receptors in this response and it has therefore not been included on this 
diagram (Hart et al., 2004).
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Some studies have also reported receptor-independent activation of ERK by 
AEA. For instance, AEA-induced ERK activation in CB2R transfected CHO 
cells was only reduced by about 50% by the CE^R-selective antagonist 
SR144528 and also occurred in wild type CHO cells (Derocq et a l, 1998). The 
authors also showed that AA also stimulated ERK activation to a similar degree 
as AEA but did not further explore the receptor-independent mechanism of 
action. Similarly, AEA-induced ERK activation in ECV304 human umbilical 
vein endothelial cells was only partially inhibited by the CBiR-selective 
antagonist SR141716A or transfection with CBiR antisense oligonucleotides 
suggesting the involvement of additional pathways although again these were not 
further explored (Liu et al., 2000).
In addition to ERK1/2, cannabinoids have also been shown to activate JNK and 
p38. Both JNK1 and JNK2 were stimulated by cannabinoids in CBiR 
transfected CHOs, with data supporting the involvement of a Gi/o-protein, PI3K 
and Ras (Rueda et al., 2000). RTK transactivation was also though to play a role 
but not ceramide production. CBiR-dependent activation of JNK1 and JNK2 
was also detected in rat cortical neurons (Downer et al., 2003). Both JNK and 
p38 activation downstream of cannabinoids was also shown in several cell types 
such as ECV304 cells (Liu et al., 2000) and Jurkat human leukaemia cells 
(Herrera et al., 2005). In addition, cannabinoid receptor-dependent stimulation 
of p38 has been demonstrated in CBiR transfected CHO cells (Rueda et al., 
2000) and rat and murine hippocampal slices (Derkinderen et al., 2001a). In 
contrast, neither JNK, p38 nor ERK 1/2 was activated by cannabinoids in rat 
cortical neurons (Molina-Holgado et al., 2005) underlining the fact that although 
cannabinoids can couple to the MAPKs the responses are cell-type specific.
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1.1.4.2 Activation o f PI3K/PKB-dependent signalling
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Figure 1.11: In vitro lipid substrate specificity of the PI3K enzymes and their basic 
subunit components, tissue distribution and regulation. The PI3K family is divided 
into three classes based on their in vitro lipid substrate specificity, structure and likely 
modes of regulation. C lass I, which is further subdivided into two types, A and B, is the 
best characterised to date. Each class I PI3K is a heterodimer consisting of a catalytic 
subunit and an adaptor subunit. An interaction of the adaptor proteins with 
phosphotyrosines links the C lass IA PI3K isoforms with tyrosine kinase signalling 
pathways whilst the Class IB PI3K, p110y, couples to GPCRs signaling pathways 
through its adaptor proteins. In addition, p110p has also been shown to link to GPCR 
signalling and all the Class I isoforms can be regulated by Ras (Maier et al., 1999, Brock 
et al., 2003, Foster et al., 2003, Suire et al., 2005). Relatively little is known about the 
Class II and III PI3Ks although it is emerging that Class II PI3Ks may be activated 
downstream of several extracellular signals including integrin engagem ent, chemokines 
and growth factors, and that class III may be constitutively active and involved in 
intracellular trafficking events such a s  vesicular transport (Foster et al., 2003). 
Abbreviations: Ptdlns, phosphatidylinositol.
The PI3Ks are a family of kinases that phosphorylate PI lipids at the D-3 position 
to create a variety of lipid mediators and thereby regulate a multitude of 
biological functions (Foster et al., 2003). Their in vitro lipid substrate 
specificity, subunit composition, tissue distribution and regulation are outlined in 
Fig. 1.11. One of the downstream effectors of PI3K is PKB (also referred to as 
Akt), a serine/threonine protein kinase which is involved in many cellular 
functions including regulation of protein synthesis and cell survival pathways. 
There are three isoforms, a, p and y and their activation involves the 
phosphorylation of two residues, Ser473 and Thr308 (in PKBa; Vanhaesebroeck
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& Alessi, 2000, Song et al., 2005, Woodgett, 2005). The exact mechanism of 
activation has not yet been resolved but the events thought to occur are depicted 
in Fig. 1.12.
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Figure 1.12: The mechanism of activation of PKB. The production of Ptdlns(3,4,5)P3 
through the activation of class I PI3K is the first step in PKB activation by most stimuli. 
This lipid mediator recruits PKB to the plasma membrane through interaction with its N- 
terminal pleckstrin homology (PH) domain. It is thought that this interaction induces a 
conformation of PKB that is more accessible to 3’phosphoinositide-dependent kinase-1 
(PDK1) which phosphorylates PKB on Thr308 (of PKBa) in its kinase domain (KD). 
Constitutively active, PDK1 colocalises with PKB through interaction between its PH 
domain and Pis. An as  of yet unidentified kinase, generally referred to as PDK2, 
phosphorylates PKB on Ser473 (of PKBa) in the C-terminal hydrophobic motif. This 
phosphorylation may be important in PDK1-mediated phosphorylation of Thr308. 
Candidates for PDK2 include PKB itself, integrin-linked kinase, DNA-dependent protein 
kinase, PKCpll and a rictor-mammalian target of rapamycin complex. Both residues 
must be phosphorylated for full PKB activation. Once active, PKB dissociates from the 
membrane and translocates to its sites of action (Vanhaesebroeck & Alessi, 2000, 
Sarbassov et al., 2005, Song et al., 2005, Woodgett, 2005). PKB function is in part 
controlled by dephosphorylation of Ptdlns(3,4,5)P3, for instance by phosphatase and 
tensin homolog deleted on chromosome 10 (PTEN) as  well a s  a dephosphorylation of 
Ser473 by PH domain leucine-rich repeat protein phosphatase (Gao et al., 2005). Other 
PKB binding proteins also exist and could further modulate PKB activity (Anai et al., 
2005, Song etal., 2005).
Cannabinoid receptors appear to couple to PI3K (Bouaboula et al., 1997, Galve- 
Roperh et al., 2002) and thus it follows that PKB could be activated downstream 
of these receptors. Indeed, transient activation of PKB via the CBjR has been 
shown in several different cell types including U373 MG human astrocytoma 
cells and rat primary cortical neurons (Gomez et al., 2000, Galve-Roperh et al., 
2002, Molina-Holgado et al., 2002, Molina-Holgado et al., 2005) and is thought 
to be involved in the neuroprotective actions of cannabinoids. Initially it was
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suggested that the CB2R may not couple to PKB activation as cannabinoid- 
induced PKB activation was not detected in HL-60 cells which express the CB2R 
(Gomez et a l, 2000). However, subsequent data from rat primary cortical 
neurons demonstrated that HU210 elicited PKB phosphorylation, a critical step 
in activation. This response was downregulated by AM630, a CB2R-selective 
antagonist (Molina-Holgado et al., 2005). Furthermore, cannabinoid-induced 
PKB phosphorylation in PC-3 human prostate epithelial cells could be inhibited 
by SRI44528, another CB2R-selective antagonist (Sanchez et a l, 2003). In fact, 
in mast cells it was shown that the CB2R, but not the CBiR, couples to PKB 
phosphorylation (Samson et a l, 2003). This suggests that the CB2R may couple 
to PKB in some cell types. There has also been one recent study showing that in 
C6  glioma cells the non-selective agonist WIN55,212-2 downregulated PKB 
signalling over 48 hours (Ellert-Miklaszewska et al, 2005).
1.1.4.3 Activation of PKC
The PKC family of serine/threonine protein kinases is composes of at least 10 
isoforms which have distinct differences in structure, expression and activation 
requirements (Fig. 1.13). PKC is activated downstream of many different stimuli 
including those that activate GPCRs and are involved in a number of cellular 
functions such as cell migration and T lymphocyte activation and have a number 
of substrates including Raf. They are generally widely distributed in mammalian 
tissues although some isoforms are more restricted. For example, PKCy is 
mainly found in the CNS and spinal cord, PKC0 in skeletal muscle and 
haematopoietic cells and PKCp in pancreatic islet cells, monocytes, brain and 
retinal tissue. PKCs can interact with a myriad of different proteins some of 
which, such as receptors for activated PKCs (RACKs), target activate PKCs to 
specific membrane compartments and thereby play a role in determining 
isoform-specific functions (Way et a l, 2000, Tan & Parker, 2003, Parker & 
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Figure 1.13: The different PKC isoforms and how they are activated. Several PKC 
isoforms exist and they are divided into three groups based on their structure and 
requirements for activation. Inactive PKC resides in the cytosol and activation is 
multistep process which involves removing an inhibitory pseudosubstrate domain from 
the active site such that the enzyme can bind and phosphorylate its substrates. 
Conventional (c)PKCs are activated by the phospholipid phosphatidylserine (PS) in a 
Ca2+-dependent manner. In addition they bind DAG which not only increases their 
affinity for PS but also shifts the requirement for Ca2+ into the physiological range. 
cPKCs can also be activated by phorbol esters such a s  PMA. Conserved (C) domains, 
C1 and C2 in the regulatory region of the protein, are required for interaction with 
DAG/phorbol esters and PS and Ca2+, respectively. Although the novel (n)PKCs and 
atypical (a)PKCs have a C2-like domain, this region does not bind Ca2+ and thus these 
enzym es are Ca2+-insensitive. However, nPKCs are activated by DAG/phorbol esters in 
the presence of PS unlike the aPKCs. The C4 domain of PKC is the substrate binding 
site and lies within the C-terminal catalytic region. Conformational changes associated 
with PS binding displaces the pseudosubstrate domain out of the active site in the C4 
region but for optimum catalytic activity all PKC isoforms must also be phosphorylated in 
their activation loop by PDK1 (Thr500 in PKC(3II). Additional phosphorylation sites also 
exist for the cPKCs and nPKCs and these all act in concert to lock the kinase in its 
active form (Way etal., 2000, Parker & Murray-Rust, 2004).
PKC was shown to be involved in AEA-mediated ERK activation in ECV304 
cells and CP55,940-induced ERK activation in CB2R transfected CHO cells 
using the PKC-specific inhibitor GF 109203X (Bouaboula et al., 1996, Liu et al.,
2000). However, few studies have investigated cannabinoid-mediated effects on 
PKC directly. In one in vitro system the effects of PS, dioleylglycerol and AEA 
on Ca2+-induced rat brain PKC activity were examined. The authors reported a 
dual modulation of PKC activity. In the presence of AEA, the PS-induced 
activity of PKC was increased but DAG-mediated activation was inhibited (De 
Petrocellis et al., 1995). They suggested that AEA binds to the DAG site on 
PKC and therefore has a direct effect on PKC activity rather than a receptor- 
mediated one. However, in another study using human keratinocytes, AEA 
inhibited PMA and Ca2+-induced PKC activity in a concentration-dependent and 
SR141617A-sensitive manner when cells were treated with PMA, Ca2+ and AEA
48
Introduction
for 5 days (Maccarrone et al., 2003b). Thus cannabinoids may couple to both 
activation and inhibition of PKC although the mechanisms are still unclear.
1.1.4.4 Modulation of NFkB activity
The nuclear factor for immunoglobulin k chain in B cells (NFkB) family of 
transcription factors are essential for inflammation, immunity, cell proliferation 
and apoptosis. NFkB complexes are homo or heterodimers composed of 
subunits from the multigene family of RelA/p65, c-Rel, NFkB l(p50/p 105) and 
NFKB2(p52/pl00). The activation of this family of transcription factors is very 
complex and thus far three distinct NFxB-activating pathways have been 
described, all which are based around a cascade of sequentially activated kinases 
(Viatour et a l, 2005, Campbell & Perkins, 2006). The cannonical pathway, 
which activates NFkB complexes composed of RelA/p65, c-Rel and N FkB I, is 
outlined in Fig. 1.14. The interest in whether cannabinoids affect NFkB DNA- 
binding stems from the fact that this transcription factor is involved in interleukin 
(IL)-2 regulation, one of the factors expressed by activated T lymphocytes which 
plays a role in T lymphocyte growth and expansion (Nelson, 2004) and 
cannabinoids have been shown to differentially affect IL-2 production as 
discussed later (Condie et a l, 1996, Ouyang et a l, 1998, Jan & Kaminski, 2001, 
Jan et a l, 2002). Equally, both inhibition and activation of NFkB has been 
demonstrated.
Several studies have demonstrated that cannabinoids inhibit NFkB DNA binding 
and promotor activity in activated murine leukocytes (Jeon et a l, 1996, Ouyang 
et al, 1998, Herring & Kaminski, 1999, Herring et a l, 2001, Kaplan et al, 
2005b). The pathways involved in cannabinoid-induced inhibition of NFkB 
activity have not been extensively studied. However, one study showed that 
IkBoi degradation was inhibited (Herring & Kaminski, 1999) and a role for 
cAMP inhibition was demonstrated in RAW264.7 murine macrophages (Jeon et 
al, 1996) but not in murine thymocytes (Herring et a l, 2001). However, the role 
of the cannabinoid receptors was not examined in any of these studies. 
Cannabinoids were also shown to inhibit TNFa-induced transcriptional activity 
of NFkB in U373 MG human astrocytoma cells (Juttler et a l, 2004) and Jurkats
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(Sancho et a l 2003). These effects were suggested to be cannabinoid receptor- 
independent although the role of the CB2R in the Jurkats was not fully assessed. 
One recent study has indicated that 2-AG may be inhibiting NFkB transcriptional 
activity in a PPAR-y dependent manner (Rockwell et al., 2006).
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Figure 1.14: The canonical pathway of NFkB transcription factor activation. This 
pathway is activated downstream of pro-inflammatory cytokines such as  TNFa. In 
quiescent cells N F k B , for example p50-p65, is sequestered in the cytoplasm by 
inhibitory molecules, the inhibitor of N F k B  ( I k B ) proteins, of which kB a is one. Binding 
of TNFa to its receptor leads to the recruitment of several adaptor proteins to the 
membrane. One of these is TNF-receptor-associated factor 2 (TRAF2) which then 
recruits the I k B  kinase (IKK) complex which is com posed of IKKa, IKKp and N F k B  
essential modulator (NEMO) as  well as  additional adaptor proteins. Activation of the IKK 
complex leads to phosphorylation of the I k B o , targeting it for ubiquitination and 
subsequent degradation via the proteasome pathway. The p50-p65 heterodimer is thus 
released and translocates to the nucleus where it binds to appropriate k B  motifs in DNA 
(Viatour et al., 2005, Campbell & Perkins, 2006). Abbreviations: RIP, receptor- 




In contrast, CP55,940 stimulation of HL-60 cells and A9-THC stimulation of 
dendritic cells led to IkBo, degradation, NFkB translocation to the nucleus and 
upregulation of several genes controlled by NFkB (Derocq et al, 2000, Do et al,
2004). Again, the role of the cannabinoid receptors in NFkB activity specifically 
was not assessed in these studies.
1.1.4.5 Focal adhesion kinase (FAK) activation
The CBiR has also been shown to couple to another kinase, focal adhesion 
kinase (FAK). FAK can be activated by a number of cell surface receptors such 
as integrins and GPCRs and is found in focal contacts and adhesions as its name 
suggests. There it acts to regulate the cycle of focal contact formation and 
disassembly and is thereby involved in the control of cell shape, adhesion and 
motility, although it has also been linked to the control of cell survival and cell 
cycle progression (Schlaepfer et a l, 2004). The precise mechanism of FAK 
activation is not yet understood but tyrosine phosphorylation of FAK on various 
residues plays an important role in regulating the function of the enzyme 
(Schlaepfer et a l, 2004).
Cannabinoids were first linked to FAK activation in rat hippocampal slices 
(Derkinderen et a l, 1996) where cannabinoids stimulated tyrosine 
phosphorylation of a neuronal isoform of FAK, FAK+, in a PTX-sensitive 
manner via PKA inhibition. The authors suggested CBiR-dependent FAK+ 
activation could have a role in synaptic plasticity. A later study went on to 
demonstrate a role for both Fyn and other Src family kinases in the pathway 
between the CBiR and FAK+ (Derkinderen et a l, 2001b). Although CBiR- 
dependent FAK+ activation was also shown in another study using rat 
hippocampal slices (Karanian et a l, 2005), HU210, a non-selective cannabinoid 
agonist, failed to activate FAK+ in differentiated mouse neuroblastoma N1E-115 
cells (Zhou & Song, 2002). However, HU210 did stimulate tyrosine 
phosphorylation of focal adhesion kinase-related non-kinase (FRNK) in a CBjR- 
dependent manner via a reduction in intracellular cAMP (Zhou & Song, 2002). 
FRNK is the C-terminal non-catalytic domain of FAK that has been suggested to 
be an endogenous regulatory mechanism which negatively regulates the activity
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of FAK (Schlaepfer et a l , 2004). Furthermore, in a human breast cancer cell 
line, a stable anandamide analogue, 2 -methyl- 2  ’ -F-anandamide induced a 
decrease in FAK tyrosine phosphorylation in a CBiR-dependent manner 
(Grimaldi et al., 2006), indicating that the cannabinoids may have different 
effects on neuronal and non-neuronal isoforms of FAK.
1.1.4.6 Acute modulation of cAMP production
Production of cAMP through the activation of AC can influence a number of 
cellular functions such as metabolism, cell shape and gene transcription through 
interaction with a number of downstream molecules, the best known of which is 
PKA (Fig. 1.15; Kopperud et al., 2003). Inhibition of cAMP production is 
commonly associated with Gi/o-protein coupled GPCRs and was one of the first 
cannabinoid receptor-induced signalling pathways to be defined. For instance, 
Matsuda et al (1990) demonstrated that A9-THC and CP55,940 inhibited 
forskolin-induced cAMP accumulation in CHO cells transfected with the newly 
cloned CBiR in a PTX-sensitive manner. Since then both the cannabinoid 
receptors have been linked to inhibition of forskolin-induced cAMP production 
in a number of different cell types ranging from neuronal cells to leukocytes 
(Pertwee, 1997, Kaminski, 1998, Howlett et al., 2002, Demuth & Molleman,
2006).
As well as inhibiting forskolin-induced cAMP production, several reports have 
linked cannabinoids to increases in forskolin-induced (Glass & Felder, 1997, 
Felder et a l , 1998) and basal cAMP production (Maneuf & Brotchie, 1997, 
Steffens et a l , 2005a). For example, in rat striatum and CHO-CBiR cells, PTX 
pre-treatment unmasked a CBiR-mediated stimulatory effect on cAMP 
accumulation (Glass & Felder, 1997). It was suggested that this response was 
mediated through Gs-proteins. Since then there has been further evidence to 
suggest that the CBiR can couple to Gs-proteins under certain circumstances 
(Glass & Felder, 1997, Bonhaus et a l , 1998, Jarrahian et a l , 2004) and this 
could explain the increases in cAMP accumulation detected. However, the 
contrasting effects of cannabinoids on cAMP production could also be attributed 
to the specific AC isoforms present in different cellular preparations. Thus far
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nine distinct isozymes of membrane bound AC have been identified which are 
differentially regulated as outlined in Fig. 1.15. The effect of cannabinoids on 
individual AC isoforms has been investigated and showed that AC-I, III, V, VI 
and VIII where inhibited by, whereas AC-II, IV and VII were stimulated by, 
CBiR and CB2R activation (Rhee et al., 1998). AC-IX inhibition by 
cannabinoids was very modest.
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Figure 1.15: Basic outline of G-protein mediated activation of AC. AC is an integral 
membrane protein composed of 12 TM segm ents and 2 large cytoplasmic catalytic loops 
(C1 and C2). Nine membrane bound isoforms of mammalian AC exist and each is 
differentially regulated although all can be stimulated by forskolin. Generally AC activity 
is stimulated by G as and inhibited by Gai subunits whilst G(3y subunits regulate AC in an 
isoform-specific manner. AC activity can also be modulated by other factors such as 
phosphorylation by PKC and Ca2+ (Sunahara & Taussig, 2002). Activated AC generates 
cAMP which goes on to influence a number of different cellular functions, largely through 
the activation of PKA, although other cAMP effector mechanims do exist (Dremier et al., 




1.1.4.7 Modulation of intracellular Ca2+ concentration
• • • #Cannabinoids appear to stimulate an increase in intracellular Ca levels in a
number of different cell types via both cannabinoid receptor-dependent and 
independent mechanisms. For instance, in neuroblastoma x glioma hybrid 
NG108-15 cells 2-AG increased levels of intracellular Ca in a PTX-sensitive 
manner (Sugiura et a l, 1996). Further investigation showed that the response 
was CBiR-dependent and sensitive to a PLC inhibitor which suggested the 
involvement of inositol 1,4,5-triphosphate (IP3) controlled stores (Demuth & 
Molleman, 2006). However, the cannabinoid-induced increase in intracellular
7-1-Ca detected in CBiR transfected CHO cells was not receptor dependent as the 
same responses were also detected in wild type cells (Felder et a l , 1992)
AEA has also been linked to a rise in intracellular Ca in endothelial cells in 
both a CBiR-dependent and independent manner. For example, in human
7-1-arterial endothelial cells AEA increased intracellular Ca in a SR141716A- 
sensitive manner (Fimiani et al., 1999). In contrast, in human umbilical vein
7 .
endothelial cells AEA-induced a rise in intracellular Ca which was only partly 
blocked by SR141716A and insensitive to PTX (Mombouli et a l, 1999). In this
7-4-study it was suggested that the Ca was released from caffeine sensitive stores.
7_i
The mobilisation of cytosolic Ca in endothelial cells has been suggested to play 
a role in the endothelium-dependent and nitric oxide mediated vasodilator actions 
of AEA.
An early study using CB2R transfected CHO cells suggested that the receptor did
7 .
not couple to intracellular Ca mobilisation (Slipetz et al., 1995). However, the
7 .
CB2R has now been linked to a rise in intracellular Ca in calf pulmonary
71
endothelial cells where AEA induced an increase in intracellular Ca from IP3 - 
sensitive stores through the activation of PLC (Zoratti et al., 2003) and HL-60 
cells (Sugiura et a l, 2000).
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1.1.4.8 Ion channel effects
Cannabinioids can activate A-type and inwardly rectifying K+ channels and
^ I |
inhibit N-type and P/Q-type voltage gated Ca channels as well as D-type K 
channels downstream of the CBiR (Howlett et a l , 2002, Pertwee & Ross, 2002, 
van der Stelt & Di Marzo, 2005, Demuth & Molleman, 2006). The CB2R is not 
believed to modulate ion channel function.
In addition to CBiR-mediated effects, AEA has also been shown to directly 
interact with a number of neurotransmitter-gated ion channels such as NMDA, 5- 
HT3 and a7-nicotinic acetylcholine receptors. For instance, AEA augmented the 
NMDA-induced current and acetylcholine currents were inhibited (van der Stelt 
& Di Marzo, 2005). Several cannabinoid agonists such as AEA and WIN55,212- 
2 have been shown to inhibit 5-HT-induced currents through the 5 -HT3A 
receptor, a ligand-gated ion channel (Barann et a l , 2002) as mentioned earlier.
^  I
Furthermore, AEA can also directly inhibit T- and L-type Ca channels, Shaker- 
related K+ channels, the background K+ channel TASK-1 and voltage gated Na+ 
channels (van der Stelt & Di Marzo, 2005, Demuth & Molleman, 2006).
1.2 T lymphocytes
The immune system is divided into two branches: innate immunity and 
adaptative immunity. The innate immune response is the first response to any 
pathogen and defends against it in a non-specific manner. For instance, 
neutrophils and macrophages are part of the innate immune response. The 
adaptive immune response is the response of antigen-specific lymphocytes to 
antigen. T lymphocytes form a major part of the adaptive immune response and 
are especially important in developing immunological memory (Janeway et a l , 
1999).
1.2.1 The T cell antigen receptor (TCR)
In general T lymphocytes only recognise short peptide antigen bound to major 
histocompatability complex (MHC) molecules which is presented by cells known
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as antigen-presenting cells (APCs). There are two classes of MHC molecules. 
Class I molecules are found on virtually all cells and present peptides derived 
from intracellular pathogens such as viruses. In contrast, class II MHC molecule 
expression is restricted to macrophages, dendritic cells and B lymphocytes which 
are said to be professional APCs. This type of MHC molecule presents peptides 
derived from pathogens residing extracellularly which have been taken into cells 
via endocytosis. T lymphocytes are said to be MHC restricted because their 
receptors are specific for both a particular MHC allele and the antigen peptide it 
binds (Hennecke & Wiley, 2001).
It is the TCR on the T lymphocytes which recognises the peptide/MHC complex. 
The TCR is composed of two polypeptide chains which in most T lymphocytes 
are the a and p-chains. However, there is a subset of T lymphocytes which 
express a TCR composed of y and 8 -chains. These chains are composed of a N- 
terminal variable region, parts of which form the antigen binding site, and a C- 
terminal constant region which is attached to the TM region. It is differences in 
the amino acid sequence of the variable region that creates the enormous variety 
of binding sites that are specific for particular peptide/MHC molecule 
complexes. This diversity is generated by gene rearrangement in a process 
referred to as somatic recombination. The ap and y8  dimers are associated with 
cluster of differentiation (CD)3, a complex itself composed of y, 8  and ^-chains, 
and TCR ^-chains which are important in T lymphocyte activation as they relay 
signalling into the cell. All together these form the TCR complex. Activation of 
the TCR triggers a cascade of intracellular biochemical events which eventually 
lead to proliferation and effector functions which are discussed in further detail 
below (Janeway etal., 1999).
1.2.2 T lymphocyte subsets
T lymphocytes can be subdivided into two main classes. Cytotoxic T 
lymphocytes, which are distinguishable by the expression of the cell surface 
glycoprotein, CD8 , act to kill infected cells and thereby help to prevent the 
spread of infection. When exposed to infected cells, they release cytotoxins such 
as perforin, which form pores in the target cells’ plasma membrane eventually
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lysing it, and granzymes, proteases which activate apoptosis. They also express 
CD95L (also known as Fas ligand), which upon binding its receptor (CD95) on 
the target cell induces apoptosis (Janeway et al., 1999). CD8 + T lymphocytes 
recognise peptide presented by cells bearing MHC class I molecules. Helper T 
lymphocytes (Th), which express CD4, are involved in co-ordinating the immune 
response. The two main types of Th lymphocytes are Thl and Th2 which secrete 
different profiles of cytokines and have distinct functions, although additional 
subsets have been described. Thl cells secrete interferon (IFN)y and are thus 
involved in activating macrophages. Th2 cells secrete IL-4 and IL-5 which 
activate B lymphocytes and also IL-10 which inhibits macrophage function. 
CD4+ T lymphocytes recognise antigen when presented by MHC class II 
molecules (Janeway et al., 1999, Reinhardt et al., 2006).
In addition there are also regulatory T lymphocytes and natural killer T 
lymphocytes. Regulatory T lymphocytes, sometimes also referred to as 
suppressor T lymphocytes, actively suppress activation of the immune system 
and prevent pathological self-reactivity or autoimmune disease. Different 
subsets exist, including CD4+ cells that also express high levels of the IL-2 
receptor a-chain (CD25). The transcription factor forkhead box p3 is required 
for the development and function of these CD4+CD25+ regulatory T lymphocytes 
(Thompson & Powrie, 2004). Natural killer T lymphocytes are a heterogenous 
group of T lymphocytes that share properties of both T lymphocytes and natural 
killer (NK) cells. They are reactive to glycolipid when presented by CD Id, an 
atypcial MHC class I molecule, and are potent cytokine producers. They express 
an invariant TCR a-chain as well as NK cell markers and can be CD4+, CD8 + or 
CD4'CD8' (Godfrey et a l, 2004).
There is also a minor population of T lymphocytes which, unlike the vast 
majority of T lymphocytes, expresses a TCR composed of y and 8 -chains rather 
than a and P-chains. They can exert both cytotoxic effects as well as producing 
cytokines and are capable of regulating various responses of the innate immune 
system, some of which in turn affect adaptive immune responses. Thus they 
have been described as a bridge between the innate and adaptive immune 
responses. They are different from ap T lymphocytes in that they recognize
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soluble protein and non-protein antigens and that they are not MHC restricted. 
Most are CD4'CD8' and although they represent only 1-5% of T lymphocytes in 
peripheral lymphoid tissues, they can represent up to 50% of the T lymphocyte 
population of epithelial-rich tissues such as the intestine (Carding & Egan, 2002).
1.2.3 T lymphocyte development
T lymphocytes are derived from bone marrow haematopoietic stem cells that 
enter and populate the thymus. The specific identity of these progenitors is still 
unclear. Immature T lymphocytes (also called thymocytes) go through several 
distinct phenotypic stages before they leave the thymus as mature CD4+ or CD8 + 
T lymphocytes. These include the gene rearrangments that produce the TCR and 
positive and negative selection which determines the T lymphocyte repertoire 
(Fig. 1.16; Germain, 2002). These nai've T lymphocytes then leave the thymus 
and recirculate through the blood, homing to secondary lymphoid organs such as 
the lymph nodes. Inside these, the T lymphocytes screen APCs for peptide/MHC 
complexes and those that recognise peptide/MHC molecules are activated and 
will divide and differentiate into effector T lymphocytes. Each T lymphocyte 
that is activated by a particular antigen gives rise to a clonal population of cells 
all expressing the same TCR. This process is referred to as clonal selection. 
Activated T lymphocytes eventually leave the secondary lymphoid organs to 
accumulate at sites of inflammation or other effector sites (Stein & Nombela- 
Arrieta, 2005). Importantly, some T lymphocytes also become memory cells 
which are long-lived antigen-specific T lymphocytes that become activated 
during a secondary immune response to a pathogen already encountered. They 
retain the TCR affinity of the originally activated T lymphocyte and are used to 















Figure 1.16: Development of ap T lymphocytes in the thymus. Haematopoietic stem 
cells enter the thymus and interactions with the thymic stroma triggers differentiation and 
proliferation such that double negative (DN) thymocytes are generated. These cells are 
committed to the T lymphocyte lineage but still lack all the major markers of mature T 
lymphocyte, namely CD3, CD4 and CD8. These cells can still develop along the ap  or 
y5 pathway although the focus here is on ap T lymphocytes. These DN thymocytes 
cells at first express CD44, an adhesion molecule, but not CD25 and then differentiate to 
express CD25 as well. As they continue to mature they start to loose CD44 expression 
and it is in these CD44LOWCD25+ cells that rearrangem ent of the TCR p-chain gene 
occurs. The cells that successfully express a p-chain lose CD25 and the p-chain pairs 
with a surrogate a-chain which is referred to a s  the pre-T-cell a  (pTa) and low levels of 
CD3 molecules. Once this complex is expressed on the surface and the cell cycle is 
triggered causing the cells to proliferate, CD25 is lost, p-chain rearrangem ent is arrested 
and cells begin to express CD4 and CD8 thus becoming double positive (DP) 
thymocytes. Once these stop proliferating the TCR a-chain gene rearranges, producing 
the complete ap TCR although it is still only expressed at low levels. Cells then undergo 
negative and positive selection. Negative selection determines whether the T 
lymphocyte recognises self antigens with high affinity, and if they do, they receive 
signals to apoptose, thereby eliminating autoreactive T lymphocytes. Positive selection 
determines whether the T lymphocyte is able to recognise and bind self-MHC molecules 
and only those cells which bind the MHC complex with enough affinity receive survival 
signals. Those cells that survive then differentiate and mature into single positive, CD4+ 
or CD8+, lymphocytes which can exit the thymus (Germain, 2002).
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1.2.4 T lymphocyte activation
Naive T lymphocyte activation involves two signals. First the TCR interacts 
with specific MHC/peptide complex presented by APCs. It is largely the CD3 
and ^-chains within the TCR complex that are responsible for transducing signal 
into the cells via immunoreceptor tyrosine-based activation motifs (ITAMs). 
These conserved motifs act as tyrosine kinase substrates and once 
phosphorylated, as binding sites for other kinases. In this way the TCR complex 
is coupled to a wide range of kinases and adaptor proteins which intiate signals 
that bring about T lymphocyte activation. CD4 is important for stimulating 
molecular clustering at the immunological synapse and for stabilising cell-cell 
interactions such that the T lymphocyte can interact with the APC for a sufficient 
length of time for activation to occur. Further stabilisation occurs by adhesion 
molecules such as leukocyte function associated antigen-1 (LFA-1) which binds 
intracellular adhesion molecule-1 (ICAM-1) on the APC (Zhang & Samelson, 
2000, Samelson, 2002).
Stimulation of the TCR alone is not sufficient to induce activation. A second, 
co-stimulatory, signal is required to amplify signals from the TCR and prevent 
the T lymphocyte from becoming functionally inert or anergic. CD28 on the 
naive T lymphocyte interacts with B7 molecules on the APC and this is 
necessary to induce IL-2 transcription, CD25 expression, entry into the cell cycle 
and enhance cell survival (Kroczek et al., 2004). Activation is also negatively 
regulated in order to limit the T lymphocyte response. One of the main proteins 
involved is the co-stimulatory molecule, cytotoxic T lymphocyte antigen-4 
(CTLA-4). Unlike CD28, which is constitutively expressed, CTLA-4 is 
upregulated on activated T lymphocytes (Kroczek et al., 2004).
Once active, naive T lymphocytes differentiate into effector cells. CD4+ T 
lymphocytes differentiate into Thl or Th2 cells and this is dependent on the 
production of IL-12 (Thl) and IL-10 (Th2) by dendritic cells as well as the 
balance of other cytokines such as IL-4 and IFNy in the local environment. 
Activated CD8 + T lymphocytes differentiate into cytotoxic T lymphocytes. In
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both instances it is IL-2, which acts in an autocrine or paracrine fashion, which 
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Figure 1.17: Naive T lymphocyte activation involves two signals. First the TCR 
recognises antigen presented via an MHC molecule. In this example the cell is CD4" 
and therefore binds MHC class II molecules. This initiates the phosphorylation of ITAMs 
found within the CD3 subunits and £-chain of the TCR complex. Lymphocyte-specific 
protein tyrosine kinase (Lck) is the predominant kinase involved in this. Lck is a Src 
family kinase and interacts with the cytoplasmic tail of CD4 and CD8 such that when 
they bind MHC molecules Lck is brought into the proximity of the TCR complex, thereby 
facilitating ITAM phosphorylation. Phosphorylated ITAMs then provide docking sites for 
a 70kD TCR ^-chain-associated protein kinase (ZAP-70), a Syk family protein tyrosine 
kinase, via its SH2 domains. Upon recruitment, ZAP-70 is phosphorylated and activated 
by the already functional Lck. One of the downstream effectors of ZAP-70 is linker for 
activation of T cells (LAT). This adaptor protein can associate with a great number of 
proteins and connects several second m essenger pathways, as  shown above, to 
increased activity of transcription factors such as activator protein-1 (AP-1), nuclear 
factor of activated T cells (NFAT) and NFkB and thereby expression of new proteins 
such as CD25 and IL-2. A second signal is also required for T lymphocyte activation 
where CD28 interacts with CD80 (B7.1) or CD86 (B7.2) on professional APCs. One of 
the first events in CD28 activation is its phosphorylation by Lck, creating a SH2-binding 
motif for a number of proteins including the p85 adaptor subunit of class IB PI3Ks. PI3K, 
through its downstream effector PKB, plays an important role in the differentiation, 
survival, cell-cycle entry and growth stimulated by T lymphocyte activation (Zhang & 





1.2.5.1 Recruitment of T lymphocytes into secondary lymphoid 
organs and inflamed tissue
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Figure 1.18: Recruitment of effector T lymphocytes from blood into a site of 
inflammation. Firstly the effector T lymphocyte is tethered to the endothelium via 
adhesion molecules such as  selectins and low affinity integrins. In this example, P- 
selectin glycoprotein ligand-1 (PSGL-1) and CD44 binding to their respective ligands 
initialises tethering to the endothelium. Due to the shear flow in the vessel these initial 
interactions between the T lymphocytes and the endothelial cells are only transient and 
so the T lymphocyte appears to roll along the endothelium. Chemoattractants, such as 
chemokines, bound to the surface of the endothelium via glycosaminoglycans activate 
GPCRs on the T lymphocyte which in turn triggers increases in affinity and avidity of 
integrins, such as a LJ32 (also known as  LFA-1), thereby allowing the leukocytes to adhere 
more firmly to the endothelial cells. The T lymphocyte can then migrate through the 
vessel wall into the underlying tissue via a process known as  diapedesis. The main 
route of diapedesis noted in vitro and in vivo is paracellular and involves the transient 
disassembly of endothelial junctions followed by penetration through the underlying 
basem ent membrane. Although this process is essentially the sam e for all leukocytes, 
including the various subtypes of T lymphocytes, specificity is ensured such that the 
correct types of leukocytes are recruited under any given circumstances. This specificity 
is achieved by the selective expression of adhesion molecule pairs and 
chemoattractants and their receptors on leukocytes and endothelial cells, factors which 
can be influenced by cellular activation status and inflammatory mediators. Thus, for 
instance, naive T lymphocytes leaving the thymus express molecules which mean they 
respond poorly to inflammatory signals but will migrate efficiently to secondary lymph 
tissues where they transmigrate through specialized high endothelial venules and 
endothelial cells in peripheral tissues will permit little/no leukocyte binding unless 
exposed to inflammatory mediators (Johnston & Butcher, 2002, S teeber et al., 2005, 
Luster et al., 2005). Adapted from Steeber et al, 2005. Abbreviations: HA, hyaluronan.
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The migration of T lymphocytes is important in T lymphocyte development, 
immunosurveillance and the immune response. As already mentioned naive T 
lymphocytes circulate through the blood until they reach secondary lymph tissues 
where they will encounter antigen and are transformed into effector cells. These 
cells then recirculate through the blood until they reach the site of inflammation 
or non-lymphoid tissues such as skin or gut. The process by which leukocytes, 
including T lymphocytes, are recruited from the blood to lymphoid and 
peripheral tissues is outlined in Fig. 1.18. Briefly, interactions mediated by 
surface adhesion molecules cause leukocytes to tether to and then roll along the 
endothelium. Chemoattractants, such as chemokines presented on the 
endothelial cell surface, trigger increases in integrin affinity and avidity thereby 
inducing firmer adhesion of the leukocytes to the endothelial cells. The 
leukocytes can then transmigrate through the vascular wall into the extravascular 
tissue where they are then further guided by chemokines and other 
chemoattractants into specific tissue environments (Johnston & Butcher, 2002, 
Luster et al., 2005, Steeber et al., 2005).
1.2.5.2 Types of chemoattractants and modes of migration
The different types of chemoattractant agents known to date and various modes 
of migration are outlined in Fig. 1.19. Essentially the largest group of 
chemoattractants is that of the chemokines which are small peptides that signal 
through GPCRs. Some chemokines, such as CXCL12, are mainly homeostatic 
whilst others play more of a role in inflammation. However the division of the 
chemokines into homeostatic and inflammatory ones is not categorical. 
Chemoattractants provide directional cues for the movement of cells and abarrent 
recruitment of cells in inflammatory and autoimmune diseases can be associated 
with upregulation of chemoattractants and their receptors. Cells are capable of 
migrating in many different ways. The term chemotaxis refers to directed cell 
migration up a concentration gradient of a soluble chemoattractant, whereas 
chemofugetaxis is movement down a concentration gradient. In vivo chemokines 
exist not only as soluble peptides but can also be surface bound. Cell migration 
towards surface bound chemoattractants is referred to as haptotaxis and repulsion
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from them is haptorepulsion. Finally, chemokinesis refers to random cell 
movement in the absence of any chemoattractant gradient.
Chemoattractant
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Figure 1.19: Types of chemoattractants and the various types of immune cell 
migration. Adapted from Kim, 2005. Abbreviations: C5a, activated complement 
com ponent5; LTB«, leukotriene B4; S1P, sphingosine-1-phosphate.
1.2.5.3 Steps involved in directed cell migration
Migration of any cell is itself made up of several steps. The first response to a 
chemoattractant is for the cell to polarize and extent protrusions or pseudopodia 
in the direction of migration. A dominant pseudopod then adheres to the 
substratum, for instance the extracellular matrix, which stabilises it. These 
adhesions also serve as tractions sites for migration. Net forward movement of 
the cell is achieved when the cell body contracts and releases attachment sites at 
the rear. In slow moving cells such as fibroblasts these steps are very distinct but 
the stages are less obvious in faster moving cell types such as leukocytes (Ridley 
et al., 2003, Chodniewicz & Klemke, 2004).
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Figure 1.20: Basic outline of a migrating cell and some of the molecules involved 
in the different steps of directed migration. Directed cell migration can be thought of 
as  a cyclical process which starts with cell polarisation. Establishing and maintaining 
polarity in response to the external stimulus is mediated by several interlinked feeback 
loops. This is then followed by the extension of protrusions and adhesion formation at 
the front or leading edge of the cell and is completed when the rear of the cell detaches 
from the substratum and retracts. Many signalling molecules have been implicated in 
these various stages, som e of which are shown. For example, the Rho G TPase Cdc42 
is key in regulating polarity and is mainly active at the leading edge. It is involved in 
regulating where lamellipodia form and microtubule-organising centre (MTOC) and Golgi 
apparatus localisation. Where another member of the Rho GTPase family, Rac, is 
active in the cell is involved in defining where actin polymerisation occurs and thus is 
important in maintaing directional protrusion. Several feedback loops exist to help 
maintain active Rac at the leading edge. In contrast, a  third RhoA GTPase, Rho, is 
active at the rear of the cell and is involved in controlling rear retraction (Fukata et al., 
2003, Ridley et al., 2003). Adapted from Ridley et al, 2003. Abbreviations: Arp2/3, 
actin-related protein 2/3; WASP, Wiskott-Aldrich syndrome protein; WAVE, WASP-family 
verprolin homologuos protein.
1.2.5.3.1 Polarisation
The term polarisation refers to the fact that the molecular processes at the front 
and the rear of the cell are different and is induced by chemoattractants such as 
chemokines. Morphological polarity is characterised by the formation of a 
dominant pseudopod in the direction of migration. The front of the cells thus 
becomes the leading edge and the rear is the trailing edge, sometimes also 
referred to as the uropod. Notably, cell polarity is also defined in terms of the 
positioning of the nucleus and reorientation of the MTOC and Golgi apparatus 
towards the leading edge, although this is less important in fast moving cells such 
as leukocytes (Ridley et al., 2003, Vicente-Manzanares et al., 2005).
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Cells not only exhibit morphological polarity but also in terms of intracellular 
signalling molecules. For instance, it is important in directional sensing, which 
is the ability of the cell to detect even a very shallow chemoattractant gradient 
and generate an internal amplied response. One of the first polarised responses 
in many leukocytes is the accumulation of the PtdIns(3 ,4 ,5 )P3 , at the leading 
edge. This is caused by the activation of PI3K at the leading edge and feedback 
loops that amplify PtdIns(3 ,4 ,5 )P3 synthesis at the front of the cell and control its 
degradation at the sides and back of the cell. PtdIns(3 ,4 ,5 )P3 itself is involved in 
protrusion formation and when a new pseudopod is formed this occurs 
preferentially at a site with elevated levels of PtdIns(3 ,4 ,5 )P3 (Ridley et al, 
2003, Van Haastert & Devreotes, 2004, Procko & McColl, 2005).
1.2.5.3.2 Protrusion and adhesion formation
Cells can extend different types of pseudopods. For instance, lamellipodia are 
large, broad protrusions that may serve as the main basis for directional 
migration whereas filopodia are spike-like protrusions which may instead act as 
sensors which explore the extracellular environment. Indeed, in the absence of a 
directional cue cells can move randomly, sending out pseudopodia in several 
directions. When they encounter a chemoattractant gradient one dominant 
pseudopod is extended at what becomes the leading edge of the cell.
These protrusions are driven by actin polymerisation. Actin is a structural 
protein which exists as monomers known as globular actin (G-actin) and 
polymerises into filaments when it is known as filamentous actin (F-actin). 
Actin filaments are intrinsically polarized with fast-growing ‘barbed’ ends and 
slow-growing ‘pointed’ ends (Fig. 1.21). In lamellipodia the actin exists as a 
branched network of short filaments and its polymerisation is mediated by the 
Arp2/3 complex which binds the sides or tip of a pre-existing actin filament and 
promotes the extension of a new filament. The Arp2/3 complex is localised by 
WASP/WAVE family members which are in turn activated by Cdc42 and Rac. 
In contrast, the actin in filopodia is organised in long parallel bundles. 
Enabled/vasodilator-stimulated phosphoprotein (Ena/VASP) proteins are found 
in the tip of filopodia and are involved in catalysing elongation of newly formed
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filaments (Ridley et al., 2003, Revenu et al., 2004, Vicente-Manzanares et a l, 
2005).
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Figure 1.21: Structure and dynamics of actin filaments. G-actin monomers can 
associate to form helical filaments which consist of a fast-growing barbed and a slow- 
growing pointed end. When the concentrations of G-actin and F-actin are at equilibrium, 
there is a loss of actin monomers from the pointed end and an equal addition of 
monomers at the barbed end such that there is a flow of actin subunits through the 
filament. This is often referred to as  treadmilling. Actin monomers can bind either ADP 
or ATP and the addition of ATP-actin monomers is favoured at the barbed end. As the 
ATP is hydrolysed to ADP, ADP-actin monomers are released from the pointed end. 
Several proteins can regulate the rate and organisation of actin polymerisation. 
Bundling proteins are implicated in the organisation of actin filaments into bundles in 
structures such as  filopodia. For example, in filopodia, fascin is found along the length 
of the protrusion wheras a-actinin is found at the rear of the protrusion. Capping 
proteins, such as gelsolin, block actin polymerisation at the barbed ends, terminating 
filament elongation and are important in maintaining filament length in branched 
networks such as  lamellipodia. Sequestering proteins can control the availability of 
activated actin monomers. Profilin not only binds actin monmers but also catalyses the 
exchange of ADP for ATP. Members of the actin-depolymerising factor (ADF)/cofilin 
family of proteins not only act a s  severing proteins, creating free barbed ends, but also 
promote depolymerisation of free filament pointed ends and thus play an important role 
in controlling the turnover of actin filaments. Finally, actin bundles and branched 
networks are also linked to the plasma membrane via actin-membrane-protein linkers 
such as  members of the ezrin/radixin/moesin family and this link is important in the 
formation and maintenance of protrusions. All of these actin-binding proteins 
them selves are also under regulation by different proteins. (Ridley et al., 2003, Revenu 
et al., 2004, Vicente-M anzanares et al., 2005). Adapted from Revenu et al, 2004.
Although the protrusion of the leading pseudopod is key in migration additional 
steps are involved in achieving cell migration. The adhesion of the leading 
pseudopod to the underlying substratum is very important and it has been shown 
that pseudopodia that do not establish adhesive contacts retract back into the cell
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body. TM receptors of the integrin family are key in the formation of adhesion 
complexes. They are heterodimeric receptors composed of non-covalently 
associated a and P subunits and the group includes 014 integrins such as (X4 P1 (also 
known as very late antigen-4) and P2 integrins such as ciLp2 - Integrins are largely 
maintained in a low affinity conformational state but, as mentioned earlier, 
chemoattractants can signal to activate or functionally upregulate integrins 
(Ridley et al., 2003, Laudanna & Alon, 2006). Activated integrins preferentially 
localise at the leading edge of cells. Binding of ligands to the large extracellular 
binding domain of the integrins induces conformational changes and clustering 
which initiates intracellular signalling, the effects of which include regulation of 
adhesion site formation and strengthening. Just as cells are capable of producing 
different types of protrusions, different types of adhesions also exist and although 
integrins are an integral part of these adhesions they also contain many other 
proteins including structural and signalling components. In non-migratory and 
very slow moving cells large integrin clusters called focal adhesions are formed 
and tightly adhere the cells to the substratum. In other cells smaller adhesions, 
known as focal complexes form at the leading edge. However, many rapidly 
migrating cells such as leukocytes have very few integrin clusters and therefore 
appear to glide over the substratum (Ridley et al., 2003).
1.2.5.3.3 Achieving net forward movement of the cell
Formation of adhesive contact is necessary not only to stabilise the pseudopod 
but also to generate the contractile force to pull the cell forward. Myosin II has 
been shown to link these adhesion complexes with actin filaments to produce the 
contractile force used to move the cell forward. Myosin II activity is controlled 
by phosphorylation of myosin light-chain (MLC). Phosphorylation of MCL is 
caused by MLC kinase (MLCK), which is regulated by Ca and several kinases, 
and Rho kinase (ROCK), which as its name suggests is regulated by RhoA, and 
phosphorylation leads to increased contractility (Ridley et al., 2003, 
Chodniewicz & Klemke, 2004, Vicente-Manzanares et a l , 2005).
In order for the rear of the cell to retract and the cell to move forward adhesions 
at the trailing edge must disassemble. Currently it is still unclear exactly how
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adhesion disassembly occurs but several mechanisms have been implicated. For 
example, the high tension exerted on the rear adhesions may contribute to 
detachment. Equally, modulation of integrin affinity and the cytosolic 
components of adhesion has been suggested to play a role. For instance, these 
could be cleaved by the protease calpain. The tyrosine kinases Src and FAK as 
well as intracellular Ca levels have also been associated with disassembly of 
rear end adhesions (Ridley et al., 2003, Kirfel et al., 2004, Vicente-Manzanares 
et al., 2005).
1.3 Cannabinoid functions in the immune system
One of the first reports of cannabinoids having any effect on the immune system 
came from the 1970s when it was suggested that cannabis use was associated 
with an increased incidence of viral infection (Cabral & Dove Pettit, 1998). 
Although many studies have shown that cannabinoids are immunosuppressive, 
data also suggests that cannabinoids can exert pro as well as anti-inflammatory 
actions and may be important in the control of immune reactions (Croxford & 
Yamamura, 2005). It is also noteworthy that often the inhibitory effects of 
cannabinoids occur in the micromolar range which may not be physiological 
(Croxford & Yamamura, 2005). However, the potential therapeutic use of 
cannabinoids in inflammatory diseases continues to be studied (Di Marzo et al., 
2004, Klein, 2005). Thus, whilst the exact role of the cannabinoids in the 
immune system remains unclear they are currently described as 
immunomodulatory.
Just as cannabinoids affect a number of intracellular signalling pathways, they 
also affect a number of different immune cell functions such as cytokine 
production and migration as indicated in Fig. 1.22. Only some of these will be 
discussed here with emphasis on those relevant to T lymphocyte function. The 
CB2R is generally considered the ‘immune’ cannabinoid receptor and is 
suggested to be involved in some of the immunumodulatory functions of the 
cannabinoids, although cannabinoid receptor-independent effects have also been 
noted. A CB2R knockout mouse has been generated and is helping to establish
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the role of the receptor in cannabinoid-induced immune system modulation 
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Figure 1.22: Schematic diagram to represent the effects of cannabinoids on 
different immune subpopulations. Adapted from Croxford & Yamamura, 2005. 
Abbreviations: TGF, transforming growth factor.
1.3.1 Modulation o f cell migration
Cannabinoids have been reported to affect immune cell migration, although it is 
noteworthy that they also affect migration of non-immune cells. Firstly, they 
have been shown to affect spontaneous migration and several studies have 
suggested that 2-AG acts as a chemoattractant for immune cells including HL-60 
cells differentiated into macrophage-like cells (Kishimoto et al., 2003), CB2R- 
expressing myeloid precursor cells (Jorda et al., 2003), B lymphocytes (Jorda et 
al., 2002, Rayman et al., 2004) and eosinophils (Oka et al., 2004). When 
receptor involvement was studied in immune cell migration it was shown that 
CB2R was involved (Jorda et al., 2003, Oka et al., 2004, Rayman et al., 2004). 
Although 2-AG is generally considered to induce migration, results using other 
cannabinoids have been mixed. Cannabinoids may also alter ligand-induced 
migration, although again the effects may be ligand and cell-type specific. For
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instance, CP55,940 inhibited formyl-metionyl-leucine-phenylalanine (fMLP)- 
induced rat peritoneal macrophage migration (Sacerdote et al., 2000), yet AEA 
did not alter fMLP-induced migration of human neutrophil granulocytes (Joseph 
et al., 2004). Thus, cannabinoid effects on both basal and ligand-induced 
migration appear to be both ligand and cell-type specific. Examples of how 
cannabinoids affect immune cell migration are outlined in Table 2.
Cell type Migrationstudied Cannabinoid Effect References
Murine B 
lymphocytes basal 2-AG induced




Jorda eta l., 2002, 
Jorda et al., 2003, 










Derocq et al., 
2000
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Sacerdote et al., 
2005
Human monocytes basal 2-AG induced





induced AEA no effect Joseph et al., 
2004
basal AEA no effect
Human neutrophils basal 2-AG no effect Oka etal., 2004
Human eosinophils basal
2-AG, noladin 









Franklin et al., 
2003, Walter et 
al., 2003, Franklin 
& Stella, 2003
Table 2: Cannabinoid effects on immune cell migration. Examples of how 
cannabinoids affect migration in a number of different immune cell types.
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In vivo, cannabinoids may also be able to affect cell migration indirectly by 
altering the production of chemokines or chemokine receptor expression. For 
example, in mice treated with thioglycollate broth to induce peritonitis it was 
found that two synthetic cannabinoids HU210 and WIN55,212-2 blocked the 
migration of neutrophils into the peritoneal cavity and that this effect was caused 
by a delay in the production of the chemokines CXCL1 and CXCL2/3 (Smith et 
al., 2001). It has also been shown in vitro that A9-THC can inhibit TNFa- 
induced increases in CCR2 mRNA expression in mouse splenocytes (Steffens et 
al, 2005b). Cannabinoid effects on cytokine and chemokine production will be 
further discussed below.
1.3.2 Modulation of cytokine and chemokine production
1.3.2.1 General
The first evidence that cannabinoid could modulate cytokine production came 
came from experiments carried out in the 1980s (Klein, 2005). Murine 
splencoytes treated with A9-THC produced less IFN when subsequently 
stimulated with PHA, concanavalin A or lipopolysaccharide (LPS) compared to 
controls (Blanchard et a l, 1986). Mice which were chronically exposed to A9- 
THC in vivo also demonstrated suppressed IFN response to these mitogens in 
vitro (Blanchard et a l, 1986).
Cannabinoids have been shown to suppress the production of a number of 
cytokines and chemokines. Since those early studies, decreases in levels of IFNy 
production have also been described in studies in concanavalin A stimulated 
splenocytes of mice treated with A9-THC (Massi et a l , 1998), PMA/Ionomycin- 
stimulated mouse splenocytes treated with 2-AG (Kaplan et a l, 2005a) and 
human T lymphocytes stimulated with allogeneic dendritic cells and A9-THC 
(Yuan et a l , 2002). One study on human subjects showed that macrophages 
from marijuana smokers were compromised in their ability to produce TNFa, 
granulocyte macrophage-colony stimulating factor (GM-CSF) and IL- 6  in 
response to LPS stimulation (Klein, 2005). LPS-induced TNFa release was also 
inhibited by AEA, 2-AG, WIN55,212-2, CP55,940 and HU210 in primary
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cultures of rat cortical microglial cells (Facchinetti et a l, 2003) and in the 
macrophage cell line RAW264.7, the decrease in supernatant TNFa levels 
elicited by A9-THC treatment was due to an inhibition of the conversion of the 
pro-peptide to the secreted protein (Klein et al., 1998b). Furthermore, A9-THC 
and AEA decreased levels of LPS-induced IL-la and p and IL- 6  mRNA 
expression in rat microglial cells (Puffenbarger et al., 2000). A9-THC also 
inhibited CCL3 and CCL4, CCL5, TNFa, GM-CSF and IFNy production in a 
NK cell line stimulated with PMA, IL-10 in HUT-78 HTVL-1 positive T 
lymphocyte cell line and CCL4 in a HTVL-1 positive B lymphocyte cell line 
(Srivastava et a l, 1998).
However, cannabinoids have also been shown to increase the production of 
cytokines in certain studies. One early study showed that TNF and IL- 6  were 
found to be increased in serum collected from mice which were treated with A9- 
THC before and after infection with Legionella pneumophila. The second 
injection of A9-THC led to acute collapse and death and this was attributed to the 
increased mobilisation of these acute phase cytokines (Klein et a l, 1998a). 
Another showed A9-THC treatment of endotoxin stimulated cultured mouse 
peritoneal macrophages increases the amount of IL-la and p bioactivity in 
supernatants compared to endotoxin treatment alone. A9-THC was found to 
affect processing and release of IL-1 rather than increase protein production 
(Klein et al., 1998a). More recently, other papers have also shown that these and 
other cytokines and chemokines can be upregulated by cannabinoids (Croxford 
& Yamamura, 2005, Klein, 2005). For instance, A9-THC increased TGFp 
production in human, anti-CD3 stimulated peripheral blood lymphocytes in a 
CB2R-dependent manner (Gardner et al., 2002) and CP55,940, a synthetic 
cannabinoid, was shown to increase CXCL8 , CCL2, CCL4 and TNFa mRNA 
and protein production in wild type and CB2R overexpressing HL-60 cells (Jbilo 
et al, 1999, Derocq et a l, 2000). The effects on CXCL8  and CCL2 were shown 
to be CB2R-dependent (Jbilo et al, 1999).
Thus, whilst it is clear that cannabinoids can modulate cytokine and chemokine 
production it is not clear whether in this capacity they are pro or anti­
inflammatory. They can enhance and suppress production of both pro and anti­
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inflammatory cytokines in a cell-type and cannabinoid specific manner 
(Srivastava et al., 1998). Furthermore, one study has shown that cannabinoid 
concentration can play a role in deciding whether cytokines are up or 
downregulated. In LPS-stimulated human PBMCs 3nM A9-THC inhibited 
TNFa, IL- 6  and CXCL8  release whilst 3pM stimulated their release (Berdyshev 
et a l , 1997). Whilst some of the responses seen have been attributed to specific 
cannabinoid receptors, some cannabinoid receptor-independent effects have also 
been described (Puffenbarger et a l, 2000, Facchinetti et a l, 2003, Kaplan et a l, 
2005a, Klein, 2005). Thus, in vivo, many factors are likely to decide whether 
cannabinoids are pro or anti-inflammatory with respect to cytokine production.
1.3.2.2 Modulation of Thl/Th2 cytokine balance
Naive CD4+ T lymphocytes can differentiate into Thl or Th2 cells depending on 
the local environment and thereby help regulate cell-mediated (Thl) and humoral 
(Th2) immune responses. A shift towards Thl has been associated with disease 
progression whereas a shift towards Th2 can be associated with therapeutic 
benefits (Croxford & Yamamura, 2005). Initially it was shown that A9-THC 
suppressed cell-mediated immunity to Legionella pneumophila infection when 
injected into mice before infection (Klein et a l, 2000). It also appeared to cause 
an increase in Th2 activity, shifting the normal Thl/Th2 balance to favour a Th2- 
mediated response. Further studies have gone on to show that A9-THC 
suppresses the Thl responses by inhibiting the production of IFNy and IL-12, as 
well as expression of IL-12 receptor 02 mRNA, and biases it towards Th2 by 
increasing the production of IL-4 (Klein et a l, 2000). Both the CBiR and CB2R 
have been implicated in the Th biasing response in the mouse Legionella 
infection model (Klein et a l, 2000) with the CBiR being important in the 
inhibition of IL-12 receptor expression (Klein et a l, 2004). Other laboratories 
have also reported similar biasing to a Th2-mediated response (Roth et a l, 2002, 
Klein et a l, 2003, Klein, 2005). For instance, A9-THC inhibited IFNy mRNA 
expression and increased IL-4 mRNA expression in human peripheral blood 
lymphocytes activated using allogeneic dendritic cells (Yuan et a l, 2002) and it 
depressed cell-mediated immunity and increased production of IL-10 in mice 
injected with tumour cells (Yuan et a l, 2002). These effects were CB2R
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mediated (Yuan et a l, 2002). In contrast, one study, in which mice were injected 
with 2-AG, a foreign soluble protein and toll-like receptor agonist during primary 
immunization, showed that 2-AG shifted the response to a Thl phenotype via 
activation of CB2R in dendritic cells (Maestroni, 2004).
1.3.2.3 Modulation of IL-2 production
Cannabinoids have been reported to both positively (Nakano et a l, 1993, Jan & 
Kaminski, 2001, Jan et a l, 2002) and negatively (Condie et a l, 1996, Massi et 
al, 1998, Ouyang et a l, 1998, Herring et a l, 2001, Ihenetu et a l, 2003a, 
Rockwell & Kaminski, 2004) modulate IL-2 expression by T lymphocytes. The 
magnitude of T lymphocyte activation appears to be the principal factor that 
governs the differential regulation of IL-2 by one of the natural cannabinoids, 
cannabinol (Jan & Kaminski, 2001). In primary mouse splenocytes and EL4.IL- 
2 murine thymoma cells, it was shown that suboptimal activation of T 
lymphocytes in the presence of cannabinol resulted in a stimulation of IL-2 
production, whilst maximal activation resulted in suppression of IL-2 production 
by cannabinol.
Currently relatively little is known about how cannabinoids modulate IL-2 
production. Initially, inhibition of cAMP was thought to be involved in 
cannabinoid-induced negative modulation of IL-2 expression (Condie et al,
1996) and there is evidence to suggest that suppression of cAMP can lead to 
suppression of IL-2 (Kaplan et a l, 2005b). However, several papers have 
suggested that inhibition of cAMP does not seem to be the primary mechanism 
involved in modulation of IL-2 by cannabinoids. Instead, inhibition of NFkB 
and NFAT DNA binding activity may be involved (Ouyang et a l, 1998, Herring 
& Kaminski, 1999, Kaplan et a l, 2005b). An attentuation of ERK signalling has 
been associated with cannabinoid-induced suppression of IL-2 production 
(Herring et a l, 2001) whilst stimulation of ERK has been associated with 
cannabinoid-induced stimulation of IL-2 production (Jan & Kaminski, 2001). 
The role of the cannabinoid receptors in the modulation of IL-2 production has 
not been extensively studied although several papers have suggested that the 
effects are cannabinoid receptor-independent (Jan et a l, 2002, Kaplan et a l,
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2003, Rockwell & Kaminski, 2004). Interestingly, one study has shown that 
AEA-induced suppression of IL-2 production in primary mouse splenocytes may 
be mediated by one of the COX-2 metabolites of AEA activating PPAR-y 
(Rockwell & Kaminski, 2004).
1.3.3 Modulation of cell number
Initial experiments in the 1970s examined the proliferative ability of peripheral 
blood lymphocytes isolated from marijuana smokers and some found that 
proliferation was inhibited whilst others saw no effect (Klein et al., 1998a, 
Croxford & Yamamura, 2005). Since then no clear consensus on how 
cannabinoids affect cell number has been reached as they have been shown to 
both enhance and suppress immune cell numbers.
It has been demonstrated that in mice treated with A9-THC for 14 days there is a 
20% reduction in the number of T lymphocytes and a 26% rise in the number of 
B lymphocytes in the splenocyte population (Massi et a l, 1998). In contrast, it 
was found that after 24 hour treatment with A9-THC there was a general decrease 
in splenocyte cell number rather than a specific effect on T or B lymphocytes 
(McKallip et a l, 2002b). Similarly, it was determined that in human subjects 
who ingested bhang for 6-36 months there was a reduction in the number of all 
the various immune subpopulations (EL-Gohary & Eid, 2004).
Studies have shown that, in vitro, splenocytes from mice treated with A9-THC for 
two weeks have a reduced proliferative response to mitogens such as 
concanavalin A (Massi et a l, 1998, Steffens et a l, 2005b). This was also 
apparent when mice were treated with A9-THC for only 6  hours (McKallip et al, 
2002b). Similarly, murine splenocytes treated with A9-THC in vitro also showed 
decreased proliferative responses to mitogens (Pross et a l, 1990, Schatz et al, 
1993, McKallip et a l, 2002b). A9-THC also suppressed human T lymphocyte 
proliferation stimulated by allogeneic dendritic cells (Yuan et a l, 2002), 
WIN55,212-2 inhibited the growth of Rec-1 mantle cell lymphoma cells in 
culture (Flygare et a l, 2005) and AEA inhibited mitogen-induced proliferation of 
human peripheral blood mononuclear cells (PBMCs; Schwarz et a l, 1994).
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Apoptosis has been suggested to account for at least some of the cannabinoid- 
induced decrease in cell number detected in some studies (Schwarz et al., 1994, 
Flygare et a l, 2005). A9-THC and AEA have been demonstrated to induce 
apoptosis in several immune cell lines including Jurkat (McKallip et a l, 2002a, 
Sarker & Maruyama, 2003, Herrera et al, 2005, Lombard et a l, 2005), MOLT-4 
(McKallip et a l, 2002a), HL-60 (Sarker & Maruyama, 2003, Powles et al, 
2005), CEM (Powles et a l, 2005) and U937 human lymphoma cells (Maccarrone 
et al, 2000). A9-THC has also been shown to induce apoptosis of murine bone 
marrow derived dendritic cells (Do et a l, 2004), murine peritoneal macrophages 
and splenocytes (Zhu et a l, 1998), primary human acute lymphoblastic 
leukaemia cells (McKallip et a l, 2002a) and human PBMCs (Powles et al, 
2005).
Not many studies have looked at the mechanisms of cannabinoid-induced 
apoptosis in immune cells compared to other cell types. One noteworthy aspect 
is that generally high concentrations are required to induce apoptosis (Schwarz et 
al, 1994, McKallip et a l, 2002a, Powles et al., 2005). Both cannabinoid 
receptor-dependent (McKallip et a l, 2002a, Do et a l, 2004, Herrera et a l, 2005) 
and -independent apoptosis has been described (Sarker & Maruyama, 2003, 
Powles et al., 2005). The VR1 has also been implicated in AEA-induced 
apoptosis of human lymphoma U937 cells (Maccarrone et a l, 2000) and a role 
for lipid rafts in AEA-induced apoptosis of Jurkats and HL-60 cells was also 
demonstrated (Sarker & Maruyama, 2003). The MAPK p38 was shown to play a 
role in A9-THC induced apoptosis of Jurkats (Herrera et a l, 2005). Activation of 
NFkB and caspase-2, -8 , -9 and -10, cleavage of Bid, decrease in Bcl-2, 
decreased mitochondrial membrane potential and cytochrome c release have also 
been implicated in cannabinoid-induced apoptosis of immune cells (Zhu et a l , 
1998, Do et a l, 2004, Lombard et a l, 2005).
Cannabinoids have also been reported to increase proliferation of immune cells. 
A9-THC, CP55,940 and WIN55,212-2 increased proliferation of activated human 
B lymphocytes in a PTX-sensitive manner. It was suggested that the CB2R was 
involved in this response (Derocq et a l, 1995). 2-AG, but not AEA, was also
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shown to enhance proliferation of a M-CSF-dependent rat microglial cell line in 
the presence of M-CSF. This response was mimicked by the CB2R-selective 
agonist JWH-133 and blocked by the CB2R antagonist SR144528 (Carrier et al.,
2004). However, AEA did enhance growth factor-dependent proliferation of a 
number of haematopoietic growth factor-dependent murine cell lines (Valk et al,
1997) and cytokine-dependent proliferation of the murine IL-6 -dependent 
lymphoid cell line B9 and IL-3-dependent myeloblastic cell line FDC-P1 
(Derocq et al., 1998). In the latter study the AEA effect was shown to be 
cannabinoid receptor-independent (Derocq et al., 1998). In all of these studies 
the cannabinoids on their own had no effect on proliferation, their effect was on 
stimulated proliferation.
It has been suggested that cannabinoid effects on lymphocyte proliferation may 
be concentration-dependent (Luo et al., 1992). A9-THC increased PHA or 
concanavalin A-stimulated proliferation of human peripheral blood lymphocytes 
and murine splencoytes at low concentrations but suppressed proliferation at high 
concentrations (Luo et al., 1992). Equally, whilst nanomolar concentrations of 
CP55,940 enhanced proliferation of activated human B lymphocytes, high 
micromolar concentrations inhibited proliferation (Derocq et al., 1995). Thus, 
the effects of cannabinoids on immune cell number may be concentration- 
dependent in certain circumstances and studies using high concentrations may 
need to be reviewed with this data in mind.
1.3.4 Antibody production
Several early reports have shown that cannabinoids suppress serum 
immunoglobulin (Ig) levels and antibody formation. Several in vivo and in vitro 
studies have demonstrated that cannabinoids generally inhibit antibody 
formation. In humans and primates it has been shown that either marijuana 
smoking or ingestion of bhang decreases serum levels of IgG although the effects 
on other Ig types was more variable (Klein et a l, 1998a, EL-Gohary & Eid, 
2004, Croxford & Yamamura, 2005). The duration of exposure and dose 
affected the extent to which IgG levels were decreased. Studies in mice, both in 
vivo and in vitro, using isolated splenocytes have also shown that A9-THC
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suppresses the antibody forming response (Klein et al., 1998a). As antibody 
formation requires co-ordinated interaction between T lymphocytes, 
macrophages and B lymphocytes for maximal response, suppression of any or all 
of these cell types might reduce the type and amount of antibody produced. 
Although it is still not clear exactly what mechanisms are involved in the 
cannabinoid suppression of antibody production, one study has suggested that it 
is T lymphocyte-dependent (Schatz et al., 1993). A9-THC administered to mice 
or to murine splenocytes suppressed the antibody response to sheep red blood 
cells which is a T lymphocyte-dependent response, but not to DNP-Ficoll which 
is a T lymphocyte-independent response (Schatz et al., 1993). Another study 
also implicated cannabinoid suppression of cAMP signalling in the inhibition of 
antibody production (Klein et al., 1998a, Berdyshev, 2000).
1.4 Aims of the Project
The initial aim of the study was to further work carried out in the colonic 
epithelial cell line, HT-29, that showed ERK 1/2 activation downstream of 
cannabinoids. This was to be done by first repeating data already collected 
within the group and extending it to additional cell lines and other signalling 
pathways in order to develop our understanding of cannabinoid receptor 
signalling in colonic epithelial cells. This idea stemmed from work being done 
in the group which showed that whilst only the CBiR was present on normal 
colonic epithelial cells, the CB2R could be detected in the epithelium of colonic 
sections taken from patients with inflammatory bowel disease (IBD) indicating 
an immunomodulatory role for the cannabinoids in mucosal tissue (Wright et al.,
2005). However, problems were encountered in that the cell lines used expressed 
moderate to high basal levels of phosphorylated ERK1/2 and these were 
significantly augmented when cells were treated with vehicle, making data with 
the cannabinoids both inconsistent and difficult to interpret.
Therefore, the focus of the project shifted towards the effects of cannabinoid on 
T lymphocyte function. T lymphocytes were chosen as they play an important 
role in inflammatory diseases such as IBD (MacDonald & Monteleone, 2005) 
and although the effects of cannabinoids on T lymphocytes have begun to be
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explored much of the data available is contradictory and studies have not always 
used human cells.
Thus the aims of the project were as follows:
• To investigate the expression of cannabinoid receptor protein in activated 
human T lymphocytes and determine whether this differs from naive T 
lymphocytes.
• To determine whether cannabinoids couple to intracellular signalling 
pathways in activated T lymphocytes and whether the effects detected are 
receptor mediated or not.
• To explore the effects of cannabinoids on migration of activated T 
lymphocytes.
• To explore the effects of cannabinoids on proliferation of activated T 
lymphocytes.
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2.1.1 Cell culture materials
Cell culture media, foetal bovine serum, penicillin and streptomycin, trypan blue,
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trypsin-EDTA and PBS (without Ca and Mg ) were purchased from Gibco® 
(Invitrogen, Paisley, UK). Lymphoprep (Ficoll-paque 1.077g/ml density) was 
purchased from Axis-Shield (Oslo, Norway). Staphylococcal enterotoxin B was 
purchased from Sigma-Aldrich (Gillingham, UK) and Dynabeads® CD3/CD28 T 
cell expander beads from Dynal Biotech (UK). IL-2 was purchased from 
Chemicon (Hampshire, UK). All plastics were obtained from Nunc (UK), except 
cryotubes which were purchased from Fisher Scientific (Loughborough, UK).
2.1.2 Antibodies
2.1.2.1 For immunoblotting
Rabbit polyclonal anti-CBiR antibodies were purchased from Affinity 
Bioreagents (Cambridge Bioscience, Cambridge, U K ; catalogue no. PA-743), 
Cayman Chemicals (Michigan, USA; catalogue no. 101500) and Santa Cruz 
Biotechnologies (California, USA ; catalogue no. sc-20754). Rabbit polyclonal 
anti-CB2R antibodies were obtained from Cayman Chemicals (Michigan, USA ; 
catalogue no. 101550) and Santa Cruz Biotechnologies (California, USA; 
catalogue no. sc-25494). CBjR and CB2R blocking peptides were also purchased 
from Cayman Chemicals (Michigan, USA). A rabbit polyclonal anti-FAAH 
antibody was purchased from Alpha Diagnostics International (Texas, USA; 
catalogue no. 11-A) and a rabbit polyclonal anti-MAGL antibody was obtained 
from Cayman Chemicals (Michigan, USA; catalogue no. 100035). Rabbit 
polyclonal anti-phospho ERKl/2T hr202/T yr204 (catalogue no. 9101) and anti- 
phospho PKBSer473 (catalogue no. 9271) were purchased from Cell Signalling 
Technologies (UK). Rabbit polyclonal pan ERK (catalogue no. sc-93) and anti- 
IicBa (catalogue no. sc-371) and goat polyclonal pan PKB (catalogue no. sc- 
1618) antibodies were obtained from Santa Cruz Biotechnologies (California,
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USA). HRP conjugated anti-goat and anti-rabbit immunoglobin were purchased 
from Dako (Glostrup, Denmark).
2.1.2.2 For flow cytometry
A mouse monoclonal anti-CD3 (clone UCHT1) antibody was obtained from 
Doreen Cantrell (School of Life Sciences, Dundee, UK) and a mouse monoclonal 
anti-CD28 (clone 9.3) was obtained from Carl June (University of Pennsylvania, 
USA). Mouse monoclonal R-PE-conjugated anti-human CD3 (catalogue no. 
555340), FITC-conjugated anti-human CD8  (catalogue no. 555366) and R-PE- 
conjugated IgGl and IgG2 were purchased from BD Biosciences (Oxford, UK).
2.1.3 Other
2-AG, ACPA, AEA, AM251, AM630, JWH-133, MAFP, (R)-(+)-
methanandamide, and LY294002 were purchased from Tocris Cookson 
(Avonmouth, UK). G66976, PD98059, Ro-32-0432, rottlerin, PMA and 
tunicamycin (source Streptomyces lysosuperflcus) were purchased from 
Calbiochem (Nottingham, UK). FITC-conjugated phalloidin was obtained from 
Alexis Biochemical (Axxora Ltd, Nottingham, UK). Acrylamide/bis acrylamide 
and molecular weight protein markers were purchased from Bio-rad (UK). 
Versene was purchased from Gibco® (Invitrogen, Paisley, UK). Bromophenol 
blue, nitrocellulose and hydrochloric acid were obtained from BDH (Poole, UK). 
Cell Titer 96® Aqueous One Solution Cell Proliferation Assay was purchased 
from Promega UK (Southampton, UK). The Cyclic AMP (low pH) 
Immunoassay and recombinant human CXCL12 were obtained from R&D 
Systems (Abingdon, UK). The pan T cell isolation kit II was purchased from 
Miltenyi Biotec (California, USA). The Enhanced chemiluminescence detection 
kit and X-OMAT film were purchased from Amersham Intemationl (UK). 
Ethanol, methanol and isoton II were obtained from Fisher Scientific 
(Loughborough, UK). The filter paper used in immunoblotting was purchased 
from Whatman (Maidstone, UK). Marvel was purchased from the local 
supermarket. All general plastic ware was obtained from Greiner-Bioone 
(Germany), including the 96-well plates used in the in vitro cell migration assay.
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All other reagents, including pertussis toxin (source Bordella pertussis) were 
purchased from Sigma-Aldrich (Gillingham, UK).
2.2 Cell types and culture conditions
2.2.1 General
All cells were routinely maintained in their respective media supplemented with 
penicillin (lOOU/ml), streptomycin (lOOpg/ml) and 10% (v/v) foetal bovine 
serum (FBS, referred to as complete media). The medium was changed every 2 
to 3 days and cultures were maintained at 37°C in an atmosphere of 5% CO2 . 
Prior to each experiment cells were counted and cell viability checked by trypan 
blue exclusion. 40pl of cell suspension was mixed with 40pl of trypan blue and 
cells counted using a Neubauer haemocytometer. Cell viability was always 
greater than 95%.
2.2.2 Jurkat cells
The human leukaemic T lymphocyte cell line Jurkat was obtained from the 
Imperial Cancer Research Fund. Jurkats were cultured in complete RPMI 1640 
medium in 175cm tissue culture flasks and split into additional flasks when 
confluent.
2.2.3 CEM cells
The human Caucasian acute T lymphoblastoid leukaemia cell line CEM was 
obtained from Dr. Z. Brown (Novartis, Horsham, UK). CEMs were cultured in 
complete RPMI 1640 medium in 175cm tissue culture flasks and split into 
additional flasks when confluent.
2.2.4 HT-29 cells
The human colonic epithelial cell line HT-29 was obtained from the European 
Collection of Animal Cell Cultures. HT-29 cells are human colon
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adenocarcinoma cells isolated from a primary tumour in a 44 year old Caucasian 
female. HT-29s were cultured as monolayers in complete McCoy’s 5A medium
•y
in 80cm tissue culture flasks. Confluent monolayers were subcultured as 
follows. The medium was removed from the flask and the monolayer washed
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twice with phosphate-buffered saline (PBS, without Ca and Mg ) before being 
washed with 3ml of a Trypsin-EDTA (0.05% (w/v) Trypsin and 0.02% (w/v) 
EDTA). The excess Trypsin-EDTA was removed and cells incubated at 37°C in 
an atmosphere of 5% CO2 for up to 5 minutes to allow the HT-29s to detach from 
the tissue culture flask. The action of the Trypsin-EDTA was stopped by adding 
approximately 20ml of complete medium. The cells were spun down at 
l,500rpm for 5 minutes and the media removed to wash out the Trypsin-EDTA. 
The pellet was resuspended in fresh complete media before being counted and 
viability checked as described above. Cells were then seeded into a tissue culture 
flask and/or into a variety of dishes as required for experiments.
2.2.5 Activated peripheral blood-derived T lymphocytes (PBLs)
Activated human PBLs were generated from PBMCs as described below and 
then maintained in complete RPMI 1640 medium supplemented with 50U/ml of
9 9IL-2 in 80cm or 175cm tissue culture flasks. When confluent, these were split 
into additional or larger flasks.
2.2.6 Freezing and thawing of cells
The cell lines were stored frozen in liquid nitrogen tanks to provide a stock of 
cells of a particular age and to minimise the transformation of cell lines that may 
occur with long-term cell culture. Growing cells were resuspended at 2- 
10xl06cells/ml in ‘freeze media’ (90% (v/v) FBS, 10% (v/v) dimethylsulphoxide 
(DMSO)) and quickly transferred to cryotubes at 1 ml/tube. These tubes were 
then slowly frozen at a rate of 1 °C/min to reduce to the occurrence of artefacts 
prior to being stored in liquid nitrogen tanks. When cells were thawed the 
cryotube was held in a 37°C water bath to rapidly defrost the cell suspension. 
Once thawed the cells were quickly resuspended in their respective complete 
media and spun down at l,500rpm for 5 minutes. The cells were resuspended in
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fresh complete media, seeded into a 80cm tissue culture flask and maintained as 
described above.
2.3 Generation of activated PBLs in vitro
2.3.1 Overview
In this study, activated human PBLs were cultured in order to investigate the 
expression and role of the cannabinoid receptors in activated T lymphocytes. 
These cells are T lymphocytes that have been activated in vitro and clonally 
expanded using IL-2. Briefly, PBMCs are isolated as described below and the T 
lymphocytes present in the population activated using the superantigen 
Staphylococcal enterotoxin B (SEB) or CD3/CD28-coated beads. SEB acts by 
binding to the class II MHC molecules expressed on professional APCs, such as 
the B lymphocytes found in the PBMC population, and then sequentially binding 
the TCR, bringing them together to induce T lymphocyte activation (Proft & 
Fraser, 2003). In contrast, the CD3/CD28-coated beads mimic the stimulation of 
T lymphocytes by APCs by binding both CD3 and CD28.
2.3.2 Isolation of PBMCs by density gradient centrifugation
Blood (50-100ml) was collected from healthy volunteers in heparinised syringes 
(500U/50ml syringe) and diluted 1:1 with RPMI 1640 medium. 35ml of the 
blood/RPMI mix was then carefully layered over 15ml of lymphoprep in a 50ml 
falcon tube before being centrifuged at l,500rpm at room temperature for 30 
minutes with the brake off. After centrifugation, the milky layer of PBMCs, 
shown in Fig. 2.1, containing the lymphocytes and monocytes was swiftly 
removed into a fresh tube. This fraction was diluted 1:1 with RPMI 1640 and the 
cells washed 3 times to remove any lymphoprep collected during the isolation. 
After the final wash the cells were resuspended in complete RPMI 1640 at a 











Figure 2.1: Schematic showing the falcon tube containing blood and lymphoprep 
before and after centrifugation.
2.3.3 A ctivation of T  lym phocytes using SEB
The PBMCs were placed in a 175cm2 tissue culture flask and lpg/ml of SEB was 
added to activate the T lymphocytes. After 72 hours the cells were washed three 
times in RPMI 1640 and then placed into a new 175cm2 tissue culture flask at a 
density of lx l0 6cells/ml in complete RPMI 1640 and IL-2 added as described 
above to clonally expand the activated T lymphocytes. These activated PBLs 
were thus further maintained until they were set up for experiments. Cells were 
cultured for a total of 2 weeks.
Day 0
PBMCs isolated from blood and 
resuspended in complete media
▼ Non-adherent cell population washed 
Day 3 & resuspended in complete media
with 50U/ml IL-2
1pg/ml SEB added 
T lymphocyte activation 
and induction of IL-2 
receptor expression
IL-2 and media added every 2-3 
days a s  needed
Maintenance of IL-2- 
y  dependent growth
▼
Day 14
Figure 2.2: A summary of the preparation of SEB-activated PBLs.
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2.3.4 Activation of T lymphocytes using CD3/CD28-coated beads
7 7Approximately 2x10 cells in complete RPMI 1640 were placed in a 80cm 
tissue culture flask and incubated for up to 3 hours to allow the monocytes to 
adhere to the plastic. The remaining cells were then counted as described above 
and resuspended in complete RPMI 1640 at lx l06cells/ml. Dynal® CD3/CD28 T 
cell expander beads were then added at 2 beads/cell and the complete media 
supplemented with 50U/ml of IL-2. Subsequently these activated PBLs were 
maintained as described above under the cell culture conditions for a total of 3 
weeks.
2.4 Purification of naive human peripheral T lymphocytes
2.4.1 Isolation of naive T lymphocytes
Naive human T lymphocytes were purified from freshly isolated PBMCs using a 
human Pan T Cell Isolation Kit (Miltenyi Biotec). The system works by 
indirectly magnetically labelling all of the non-T lymphocytes in the PBMC 
population by using a cocktail of biotin-labelled monoclonal antibodies (against 
CD 14, CD 16, CD 19, CD36, CD56, CD124 and glycophorin A) and then adding 
in anti-biotin microbeads. By retaining the magnetically labelled cells in a 
column, a pure population of T lymphocytes can be isolated.
The protocol was followed as per the manufacturers instructions. Briefly, 
PBMCs were isolated from human blood as described above being especially 
careful to avoid collecting any erythrocytes and lymphoprep as far as possible as 
these will affect the purity of the population. Cells were resuspended in PBS 
(without Ca2+ and Mg2+) containing with 2mM EDTA and 0.5% bovine serum 
albumin (BSA; referred to as buffer A) and centrifuged at l,500rpm for 15 
minutes in a 50ml falcon tube. The buffer was removed and the pellet 
resuspended in 10ml of buffer A and transferred to a 15ml falcon tube. The cells 
were washed twice in buffer A and as many platelets removed as possible. The 
remaining cells were resuspended in buffer A at a density of 40pl of 
bufferA/lxlO7 cells. To this, 10pl of Pan T cell Biotin-Antibody Cocktail
n
(human) was added per 1x10 cells. This was left to incubate on ice for 15
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minutes. The cells were then washed to remove excess unbound antibody and 
resuspended in buffer A at a density of 30pl bufferA/lxlO7 cells. 20pl of Anti- 
Biotin MicroBeads/lxlO7 cells were then added and the cells again incubated on 
ice for 15 minutes. After this the cells were washed in buffer A. During this 
time the MACS column was prepared by slowly running 3ml of buffer A through 
the column. The cells were resuspended in 500pl of buffer A and run through 
the column. The cells that have bound antibody bind to the column, so the T 
lymphocytes could be collected as they ran through. 1ml of buffer A was 
subsequently run through the column in order to ensure that as many T 
lymphocytes were collected as possible. At this stage cells were removed from 
the population to be evaluated for purity and kept on ice in buffer A. The 
remaining cells were spun down and stored at -80°C for later use or used 
immediately in stimulations as described below.
2.4.2 Evaluation of T lymphocyte population purity
In order to verify that the purification procedure was successful flow cytometry 
analysis of the percentage of cells expressing CD3 and CD28 was carried out as 
described later on. Briefly, the cells were analysed for autofluorescence, the 
expression of CD3 using an anti-CD3 antibody (clone UCHT1, lpg/ml) and the 
expression of CD28 using and anti-CD28 antibody (clone 9.3, lpg/ml). An 















Figure 2.3: Evaluation of T lymphocyte population purity. Naive T lymphocytes were 
purifed from human PBMCs as  described above and flow cytometry was used to 
determine the percentage purity of the population isolated. The expression of CD3 and 
CD28 was verified by staining the cells with anti-CD28 antibody (— dark blue line), anti- 
CD3 antibody (— green line) and isotype control (— purple line) followed by flow 
cytometric analysis. Some cells were also left unstained (light blue histogram) to 
ascertain autofluorescence. Purity was always >93%. Data are representative of three 
separate experiments.
2.5 S tim ulations in suspension cells
The day prior to the experiment, activated PBLs were washed three times in 
RPMI 1640 to remove IL-2 and resuspended in complete media overnight. On 
the day of the experiment, all suspension cells were washed three times in RPMI 
1640 and counted as described above. They were then resuspended at a density 
of 2-10xl06cell/ml and 500pl of cell suspension used per stimulation. Cells were 
placed in 1.5ml plastic tubes and allowed to rest in a 37°C water bath for 1 hour. 
During this hour any pre-treatments necessary were added to the cells. To start 
the stimulation the appropriate cannabinoid, vehicle or other ligand was added to 
the cells and the cells returned to the water bath. To terminate the stimulation 
and generate whole cell lysates (WCLs) the cells were rapidly centrifuged at 
10,000rpm, the media removed, ice cold lysis buffer added to solubilise the cells 
and the tube vortexed. lOOpl of lysis buffer was used per lxlO6 Jurkats and 
2xl06 activated PBLs or naive T lymphocytes. The samples were kept on ice 
until all stimulations were completed. Once they were all completed the samples
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were rotated for 10 minutes at 4°C and then centrifuged at 14,000rpm for 10 
minutes at 4°C to remove any insoluble material. The protein containing 
supernatant was transferred to fresh 1.5ml plastic tubes. These WCLs could be 
frozen and stored at -80°C at this point.
2.6 Immunoblotting
2.6.1 Overview
Immunoblotting or Western blotting is a technique that allows visualisation of 
the relative amounts of specific proteins within cells. The cells are lysed and the 
whole proteins are extracted. These WCLs are then run in a current through a 
polyacrylamide gel to separate the proteins according to their molecular weight. 
The now separated proteins are then transferred to a membrane which can be 
probed for specific proteins using antibodies. Once this primary antibody has 
bound the protein of interest a secondary antibody, which has a horseradish 
peroxidase tag, is applied. The horseradish peroxidase tag on the secondary 
antibody catalyses a reaction which can then be visualised and represents a way 
of detecting the protein.
The primary antibodies that are used can be specific to a certain conformation of 
the protein of interest. For instance, they can be generated to bind the 
phosphorylated form of a protein. This type of primary antibody can be used to 
assess relative changes in amounts of phosphorylated protein, which may occur, 
for example, when the cells are stimulated by different ligands. In order to verify 
that the total amount of protein is unchanged, results from these phosphorylation 
site antibodies are compared to results using an antibody against all forms of the 
protein, usually referred to as a pan antibody.
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2.6.2 Generating samples 
2.6.2.1 General
Once lysates were generated and transferred to clean tubes, 5x sample buffer (see 
recipe in Appendices) was added and the samples boiled for 5 minutes. The 
sodium dodecyl sulphate (SDS) in the buffer acts to denature the proteins and the 
2-mercaptoethanol reduces the disulphide bridges. In addition, the SDS binds to 
the polypeptides and gives them a negative charge in such a way that all of the 
SDS-polypeptide complexes have essentially the same negative charge and shape 
such that they migrate through the gel according to molecular size only.
2.6.2.2 Stimulated cells
Cells were stimulated as described above and WCL samples prepared by adding 
5x sample buffer. Samples were always prepared such that the they represented 
8,000 cells/pl sample for T lymphocytes cell lines and 16,000 cells/pl sample for 
activated PBLs and naive T lymphocytes.
2.6.2.3 Unstimulated cells
In order to look at certain parameters, for instance receptor expression during the 
course of PBL culture, WCLs of cells on different days of culture were 
generated. In order to do this, l-2xl06 cells were removed from culture, spun 
down, the medium removed and the cells placed in a -80°C freezer for storage. 
In the case of the CD3/CD28-activated PBLs, care was taken to first remove the 
beads. Once the time course was completed all the samples were lysed in lysis 
buffer to generate the WCLs. Freshly isolated and purified T lymphocytes were 
also lysed to generate WCLs. The lysates were transferred to clean 1.5ml plastic 
tubes and a protein assay completed as described below and then 5x sample 
buffer added and the samples boiled. In this instance, each sample contained a 
different concentration of protein and different volumes of each sample were 
loaded onto gels in order to ensure equal loading.
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Again, in order to verify receptor expression in the various cell lines used in this 
study, samples were also taken of these at intervals throughout culture and lysed 
to generate WCLs. For the HT-29s these were seeded into 6cm dishes at 0.8x106 
cells/dish and allowed to grow to approximately 80% confluency, before being 
solubilised by adding lysis buffer and using a cell scraper. For CEMs and 
Jurkats, approximately 5x106 cells were removed from culture, spun down and 
the medium removed. The cells were then solubilised in lysis buffer to generate 
WCLs. Samples were transferred to clean plastic tubes and a protein assay 
carried out as described below. In this instance, each sample contained a 
different concentration of protein and different volumes of each sample were 
loaded onto gels in order to ensure equal loading.
2.6.2.4 Subcellular fractionations
In order to determine where in the cells certain proteins were located subcellular 
fractions were carried out to separate the cytosolic and membranous proteins. 
Alongside this protocol WCLs of each cell type were also prepared as described 
above as a control. Jurkats were washed three times in RPMI 1640 and then 
resuspended in ice cold hypotonic lysis buffer (see recipe in Appendices) at a 
density of 2xl07 cells/ml. HT-29s were seeded onto 10cm dishes 2-3 days in 
advance and grown to approximately 80% confluency. They were then 
solubilised by adding hypotonic lysis buffer and a cell scraper used to remove the 
cells from the dish.
The cells were left in the hypotonic lysis buffer on ice for 10 minutes to swell 
before being disrupted by sonication. The cells were disrupted using 3 x 2  
second pulses at 20 second intervals and kept on ice. Before continuing, it was 
ensured that at least 80% of the cells were disrupted by looking at them under the 
microscope. The nuclei and any remaining intact cells were removed by 
centrifuging the cells at 13,000rpm at 4°C for 15-30 seconds. The supernatant 
was then centrifuged at 39,000rpm for 20 minutes at 4°C. The supernatant, 
which is the cytosolic fraction, was carefully removed, placed in clean tubes and 
kept on ice. The pellet was carefully rinsed in 500pl of hypotonic lysis buffer to 
ensure that all of the cytosolic fraction was removed so it would not contaminate
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the membranous fraction. The pellet was then solubilised in 150pl of hypotonic 
lysis buffer containing 1% (v/v) Nonidet P-40, centrifuged at 13,000rpm for 5 
minutes at 4°C to remove any remaining insoluble material and transferred to 
clean 1.5ml plastic tubes. Samples could be stored at -80°C at this point. 
Before 5x sample buffer was added a protein assay was carried out as described 
below such that they could be equally loaded onto SDS-PAGE gels according to 
protein content rather than on an equivalent cell basis.
2.6.2.5 Immunoprecipitations (IPs)
HT-29s were grown on 10cm dishes until they reached approximately 80% 
confluency. They were then solubilised by adding 1ml of lysis buffer and using 
a cell scraper. The samples were then centrifuged at 14,000rpm for 10 minutes at 
4°C to remove any insoluble material and the supernatants were transferred to 
clean plastic tubes. Protein G sepharose beads (20pl of a 50% slurry with lysis 
buffer) was added to each sample and the samples rotated at 4°C for 30 minutes 
to preclear the samples and minimise non-specific binding. The beads were then 
removed from the samples and 5 pi of antibody was added to each sample and the 
samples rotated at 4°C for 1 hour. 30pl of protein G sepharose beads (50% slury 
with lysis buffer) were then added to each sample and the sample rotated for 
another hour at 4°C. The samples were then centrifuged at 13,000rpm for 1 
minute at 4°C and the supernatant removed. Fresh lysis buffer was added to 
wash the beads which now had the protein of interest attached to them. This 
process was repeated 3 times. After the final wash the supernatant was carefully 
removed and 15pi of 2x sample buffer was added (5x sample buffer diluted with 
MilliQ). The samples were boiled for 5 minutes as for other samples. The entire 
sample was loaded onto gels. Alongside the IPs, WCLs of unstimulated HT-29s 
were also generated as described above to run as comparison.
2.6.3 Protein assay
In certain cases a protein assay was carried out in order to determine the 
concentrations of protein within samples generated such that equal quantities 
could be loaded onto SDS-PAGE gels. Total protein per lysate was estimated
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using the Bio-Rad Protein assay. Bradford solution was diluted in MilliQ water 
to 20%. For each sample, 5 pi of cell lysate was added to 1ml of diluted Bradford 
reagent and vortexed. lOOpl of this Bradford sample was then transferred to a 96 
well plate in duplicate. A standard curve was also generated using known 
concentrations of BSA and added to the plate. The plate was then read at 595nm 
on a VersaMax platereader. The protein concentrations were calculated by linear 
regression from the standard curve.
2.6.4 Separation of cellular proteins by electrophoresis
Proteins were analysed by one dimensional gel electrophoresis, which under 
reducing conditions separates proteins based on molecule size. Sodium Dodecyl 
Sulphate -  Polyacrylamide Gel Electrophoresis (SDS-PAGE) was carried out 
using the Bio-Rad Mini Protean II system (Biorad Labs, Hemel Hemptstead, 
UK).
Minigels were prepared following the recipes described in the appendix (10% 
resolving gels were prepared unless otherwise stated). The resolving gel was 
poured into the gel equipment and overlaid with MilliQ water to create a uniform 
surface. After approximately 30 minutes, once the gel had set, the water was 
removed, the stacking gel poured on top and combs inserted to create wells. 
After another 10 minutes, once the stacking gel had set, the combs were removed 
and the wells were thoroughly cleaned with MilliQ water before being filled with 
running buffer (see recipe in Appendices). The samples were then loaded, 
typically 30pg of protein or the equivalent of 1.6xl06 Jurkats or 3.2x106 
activated PBLs. In one of the wells 5 pi molecular weight markers were loaded 
for ease of protein band identification later on. The gels were then run at room 
temperature at 80 volts until the bromophenol blue tracking dye in the samples 
entered the resolving gel. The voltage was then increased up to 180 volts. Gels 
were run until the bromophenol blue dye reached the bottom of the resolving gel. 
Gels were then placed into semi-dry transfer buffer (see recipe in Appendices).
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2.6.5 Semi-dry transfer of proteins to nitrocellulose
Once the proteins were separated according to size they were transferred onto 
nitrocellulose membrane. Firstly the graphite electrodes of the transfer apparatus 
(Pharmacia-Biotech Multiphor II) were dampened with semi-dry transfer buffer. 
Four pieces of 3MM Whatman paper, cut to the same size as the gel, soaked in 
semi-dry transfer buffer were placed on the bottom electrode and rolled to gently 
expel any airbubbles. On top of this a piece of nitrocellulose membrane, again 
cut to be the same size as the gel, also soaked in semi-dry transfer buffer, was 
placed. The gel was then placed on top of this before another 4 wet pieces of 
3MM Whatman paper were placed on top. Once this ‘sandwhich’ was 
assembled it was again gently rolled to expel airbubbles. The transfer was run 
for 1 hour at 0.8mA/cm of membrane (approximately 40mA per gel). Once the 
transfer was finished the membrane was stained using Ponceau S to verify 
whether the transfer had occurred evenly. The stain was removed by briefly 
washing the membranes in MilliQ water before washing them for up to 10 
minutes in Tris-buffered saline (TBS, see recipe in Appendices).
2.6.6 Immunoblotting of nitrocellulose bound protein
Once the Ponceau S stain was completely removed, non-specific binding sites on 
the nitrocellulose were blocked by incubating the membranes with the 
appropriate blocking buffer (see conditions for each antibody in the Appendices) 
for 1 hour at room temperature. After this time the blocking buffer was removed 
and the membrane washed briefly in TBS-Tween (TBST, see recipe in 
Appendices) to remove excess blocking buffer. The membranes were then 
incubated in primary antibody, which was diluted in TBS (as stated in the 
Appendices), overnight at room temperature. After this the primary antibody was 
removed and the membranes were then washed 3 times for 10 minutes in TBST 
to remove any excess antibody before the secondary antibody (diluted in TBST 
as mentioned in the Appendices) and was added to the membranes. The 
secondary antibody was left on the membranes for 1-3 hours and the membranes 
then again washed 3 times for 10 minutes in TBST. The membranes were then 
finally washed for 5 minutes in TBS. 5ml of Enhanced Chemiluminescent
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Lumigen reagent was added for 1 minute and the membranes were then exposed 
to X-ray film for 2 seconds -  2 hours and the film developed using an RGII Fuji 
X-ray film developer. During this incubation periods and the washes the 
membranes were rocked on a moving platform to ensure even distribution of the 
blocking buffer and antibody or to ensure even washing of the membrane 
surface.
2.6.7 Membrane stripping and reprobing
In order to verify whether the samples were equally loaded the nitrocellulose 
membranes were stripped free of antibody and reprobed with a pan antibody. 
Firstly, membranes were rehydrated in TBS. Each membrane was then placed in 
a sealed container with approximately 25ml of stripping buffer (see recipe in 
Appendices), and the container placed in a water bath, which was preheated to 
60°C, for 30 minutes. During this time the container was frequently shaken to 
ensure the blot was properly stripped. After the half hour the stripping buffer 
was disposed of, the blots moved to clean containers and washed three times in 
TBST for 10 minutes each time. After a final fourth wash in TBS the membranes 
were then again blocked as before and a new pan primary antibody placed on 
them, also as before. The rest of the procedure is identical to normal 
immunoblotting.
2.6.8 Densitometric analysis
Densitometric analysis was carried on some blots. Optical densitometry was 
measured using the GeneTools software from SynGene and values were 
expressed as fold change over vehicle.
2.7 In vitro cell migration assay
An assay based on the Boyden Chamber system was used to examine cell 
migration in vitro. In this assay a 96-well plate is set up with appropriate ligands 
and placed in the bottom of the chamber. A filter is then applied through which 
the cells will migrate. The chamber is then closed and in the top wells, which
97
Materials & Methods
form part of the chamber structure and coincide with the bottom 96-well plate, 
cells are placed and they are allowed to migrate.
Specifically, a 96-well chemotaxis chamber from NeuroProbe (Fig. 2.4; 
Gaithersburg, MD) was used. The day prior to the experiment, activated PBLs 
were washed three times in RPMI 1640 medium to remove IL-2 and resuspended 
in complete media overnight. On the day of the experiment, all suspension cells 
were washed three times in RPMI 1640 and counted as described above. They 
were then resuspended at a density of lx l06cell/ml in RPMI 1640 supplemented 
with 0.1% BSA and allowed to rest in a 37°C water bath for 1 hour, during 
which time any appropriate pre-incubations were carried out. A clear bottom 96- 
well plate was set up with 395pi of agonist or vehicle controls, diluted to the 
appropriate concentration in RPMI 1640 supplemented with 0.1% BSA, per well. 
This was then placed in the lower part of the chamber. A polyvinylpyrrolidine- 
free polycarbonate filter (5pm pore size) was carefully placed on top. The 
chamber was closed and 200pl of cell suspension added to each well of the upper 
chamber. A minimum of triplicates was set up for each condition tested. The 
chamber was then incubated for 3 hours if activated PBLs were being used or 90 
minutes for Jurkats and CEMs in at 37°C in an atmosphere of 5% CO2 . After 
this time the suspension from the top wells of the chamber was removed and 
200pl of versene placed in each well to dissociate cells adhering to the filter for 
20 minutes. The versene was removed and the filter covered 96-well plate was 
centrifuged at l,500rpm for 10 minutes. The media was then carefully removed 
and the cells in each well resuspended in lOOpl of fresh RPMI 1640 
supplemented with 0.1% BSA. The number of cells migrated across the filter to 
the lower chamber was determined by adding 20pl of Cell Titer 96 Aqueous One 
solution to each well of the plate as well as the standard curve. Cell Titer reagent 
works by viable cells bioreducing the 3-(4,5-dimethylthiazol-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium compound in the Cell 
Titer 96 Aqueous One solution leading to a colour change. Once the colour 
change had sufficiently developed the plates were then read at 490nm on a 
VersaMax platereader. Data was represented as a chemotactic index which is 
the number of cells migrated towards the ligand divided by the number of cells 
migrated towards vehicle. Basal migration is denoted by an index of 1.
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Figure 2.4: Neuroprobe chemotaxis chamber. Photo of the cham ber obtained from 
the Neuroprobe website (www.neuroprobe.com).
2.8 Flow cytom etry
2.8.1 S taining of cells w ith antibodies
Cells were washed twice in PBS and resuspended in ice cold PBS containing 
20% (v/v) FBS (PBS/FBS). Primary antibody, diluted in PBS/FBS, was added to 
a total of lxlO6 cells/sample and the cells then rotated at 4°C. The final 
concentration of primary antibody depended on the individual antibody but was 
typically between l-10pg/ml. After a 30 minute incubation period the cells were 
washed twice in ice cold PBS. The following stages were carried out in the dark. 
Secondary antibody was diluted in PBS/FBS to give a final concentration of 
1:250 and added to the cells. Again the samples were rotated for 30 minutes at 
4°C. They were then again washed twice in PBS and transferred to FACS tubes 
ready to be read. If pre-conjugated antibodies were used typically 20pl of 
antibody were added to lxlO6 cells in the dark as per manufacturers instructions 
and the cells allowed to rotate in the dark at 4°C. After a 30 minute incubation 
the cells were washed twice in ice cold PBS and put into FACS tubes. Whenever 
possible an isotype control was also set up to match the primary antibody. lxlO6 
cells were also left untreated to give a measure of the cells’ autofluorescence. 
All samples were read on a FACS Vantage (BD Biosciences, San Jose, CA) and 
analysed using the CellQuest programme.
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2.8.2 Staining with phalloidin
Activated PBLs were set up as for stimulations, except always at a density of 
2xl06 cells. In order to terminate the stimulations, rather than use lysis buffer to 
solubilise the cells, 3.7% formaldehyde was added to fix the cells. They were 
incubated in formaldehyde for 5 minutes at room temperature. The cells were 
then washed 2 times in PBS before being incubated in 0.1% (w/v) triton 
containing 0.1% (w/v) BSA to permeabilise the cells for 5 minutes at room 
temperature. The cells were then again washed twice in PBS to remove any 
traces of triton. The following steps were carried out in the dark. The cells were 
then incubated for 30 minutes with 0.6pM FITC-conjugated phalloidin and then 
washed 2 times in PBS. After the final wash, they were resuspended in 200pl of 
PBS and transferred to FACS tubes.
One set of unstimulated cells were always fixed and permeabilised as described 
above but not stained with phalloidin. These were used to set up the machine 
and determine the autofluorescence of the cells. All samples were read on a 
FACS Vantage (BD Biosciences, San Jose, CA) and analysed using the 
CellQuest programme. The median fluorescence intensity value for each sample 
was used in further data analysis.
2.9 Cell proliferation assays
2.9.1 XTT assay
Cell proliferation can be measured in a number of ways, including using XTT 
assays. The assay is set up such that cells are allowed to grow in a 96-well plate 
and at the end of the assay XTT, which is a yellow tetrazolium salt, is added to 
the cells. The assay works on the principle that the tetrazolium salt will be 
converted to an orange formazan dye by part of the respiratory chain of 
mitochondria and thus only in metabolically active cells. In this way a colour 
change can be measured and the optical densitometry will reflect the number of 
cells present in the wells. Thus the assay can be used to compare how different 
conditions affect cell number.
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Activated PBLs were washed free of exogenous IL-2 the day prior to setting up 
the experiment but maintained in complete RPMI 1640. On the day the 
experiment was set up, cells were plated in 96-well tissue culture plates at a 
density of 5x104 cells/well in complete RPMI 1640 and the appropriate 
concentration of cannabinoid and/or IL-2 added to the wells. After the
incubation period, typically 48 or 72 hours, at 37°C in 5% CO2 , 25pi of PMS-
XTT solution (1 mg/ml XTT in RPMI 1640, containing 5pl/ml XTT in a solution 
of phenazine methosulfate which was made up in PBS at 1.53mg/ml) was added 
to each well and the plate returned to the incubator for a period of 2-6 hours to 
allow the plate to develop. The plate was then read on a VersaMax platereader at 
450nm.
2.9.2 Counting cells using a Coulter counter
Activated PBLs were washed free of exogenous IL-2 the day prior to setting up 
the experiment but maintained in complete RPMI 1640. On the day the 
experiment was set up, cells were counted and placed in a 24 well plate at a 
density of lx l05 cells/well in complete RPMI 1640 and the appropriate 
concentration of cannabinoid and/or IL-2 added to each well. After the
incubation period, typically 72 hours, at 37°C in 5% CO2 , each sample was
removed from the well and placed in isoton. The well was then washed out with 
an additional 500pl of media and this too was added to the isoton. The sample 
was then read twice on a Coulter Multisizer II (Beckman Coulter) in order to 
determine the number of cells in the sample.
2.10 Treatment of HT-29s with tunicamycin
Tunicamycin is a nucleoside antibiotic that prevents A-glycosylation from 
occurring in the endoplasmic reticulum and in this study was used to investigate 
whether the CBiR is iV-glycosylated.
HT-29s were set up in 6-well plates at a density of 0.3x106 cells/well in 1.9ml 
complete McCoy’s 5A and allowed to adhere overnight. The following day 
lOOpl of tunicamycin or DMSO as vehicle control was added to each well to
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obtain the appropriate final concentration. The cells were maintained at 37°C in 
an atmosphere of 5% CO2 for the up to 48 hours, after which they were lysed in 
lOOpl of lysis buffer/well. Samples were assayed for protein content and 
immunoblotted with the CBiR antibody as described above.
2.11 Determination of intracellular cAMP
Intracellular cAMP content of activated PBLs was determined using a cAMP 
immunoassay (R&D Research). The assay functions by the cAMP present in the 
sample competing with a fixed amount of alkaline phosphatase-labeled cAMP 
for sites on a rabbit polyclonal antibody. This rabbit antibody is allowed to bind 
a goat anti-rabbit antibody which is coated on the plates provided in the kit. 
After removing excess conjugate and unbound sample, a substrate solution is 
added to each well to determine the bound enzyme activity. A change in colour 
occurs and the intensity of the colour is inversely proportional to the 
concentration of cAMP in the sample.
The protocol was followed as per manufacturers instructions. Briefly, activated 
PBLs were set up as for other stimulations at a total of 2xl06 per sample and 
allowed to rest in a 37°C water bath for 1 hour. The cells were then stimulated 
with cannabinoids and/or forskolin for the appropriate length of time. The 
reaction was terminated by rapidly spinning down the cells at 10,000rpm, 
removing the media and adding 255pl of 0.1N HCl/0.2% triton as provided in the 
kit. After a 20 minute incubation the samples were centrifuged and supernatants 
transferred to clean tubes. The reagents and standards were prepared and the 
plate set up as per the manufacturers instructions. The plates were read on a 
VersaMax platereader at 405nm.
2.12 Statistical analysis
Statistical analysis was performed where appropriate using One way analysis of 
variance (ANOVA) with Bonferroni correction where necessary or Student’s t 
test. These were carried out using the GraphPad Prism version 3.0 software.
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Results I -  Cannabinoid receptor protein expression in T lymphocytes
3.1 Background
It has been established that mRNA for both the CBiR and CB2R is expressed in a 
variety of immune cells (Bouaboula et a l, 1993, Galiegue et al., 1995). Initially 
it was believed that the CBiR was expressed only in neuronal tissue but the 
development of more sensitive RT-PCR techniques revealed that CBiR mRNA 
was expressed, albeit at much lower levels than in the brain, in several immune 
subpopulations, including T lymphocytes (Bouaboula et a l , 1993, Galiegue et 
a l , 1995). The CB2R is classically considered to be the ‘immune’ cannabinoid 
receptor and CB2R mRNA has been previously detected in human T 
lymphocytes, although at lower levels than in other immune subpopulations: B 
lymphocytes > NK cells > monocytes > polymorphonuclear neutrophils > T 
lymphocytes (Galiegue et a l , 1995). However, data published concerning CB2R 
protein expression in T lymphocytes is contradictory. Staining of human tonsil 
sections revealed CB2R expression in B lymphocyte, but not T lymphocyte, 
enriched areas of the mantle of the secondary lymphoid follicles (Galiegue et a l , 
1995) and binding assays showed that specific binding was absent from T 
lymphocyte-enriched areas such as the thymus (Lynn & Herkenham, 1994). 
However, the CB2R has been detected on human T lymphocytes using flow 
cytometry (Carayon et a l , 1998) and on T lymphocytes in mouse atherosclerotic 
lesions by immunoflourescent staining (Steffens et a l , 2005b). This part of the 
current study aimed to gain more definitive insight into the expression of the 
cannabinoid receptor proteins in T lymphocytes and hopefully dispel confusion 
from previous studies. Thus, using immunoblotting, a survey of CBiR and CB2R 
expression in normal human T lymphocytes and leukaemic T lymphocyte cell 
lines was carried out.
3.2 CBjR and CB2R protein expression in T cell lines
The CBiR is only weakly expressed in immune cells (Galiegue et a l , 1995), 
thus it was necessary to establish which cell type could be used as a positive 
control for CBiR protein expression before investigating its presence in T 
lymphocytes. Work carried out within the group (Wright et a l , 2005) showed 
that the colonic epithelial cell line, HT-29s, expressed the CBiR, and therefore
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they were, given that they were readily available to use, used as a control for 
CBiR expression.
The predicted weight of the CBiR is 53kD based on its amino acid sequence 
(Gerard et al., 1991) and using the Cayman Chemicals CBjR antibody a band of 
approximately this molecular weight was detected in WCLs of HT-29s (Fig. 
3.L4) corroborating previous data (Wright et a l, 2005). In addition to the strong 
band at 53kD, a lighter band could sometimes also be detected just below, as in 
Fig. 3.L4. The antibody also recognised an 83kD band, which is generally 
presumed to be a modified form of the receptor resulting from post-translational 
modifications (Song & Howlett, 1995, Daaka et a l, 1996, Pettit et a l, 1998, 
Matias et a l, 2002) and which will be discussed in further detail below. In order 
to verify the specificity of the Cayman Chemicals CBjR antibody in detecting 
these bands the appropriate blocking peptide was used. As the 53kD band was 
completely abolished and the 83kD band significantly reduced with the use of the 
blocking peptide (Fig. 3.1C) it suggests that both are forms of the CBiR. In the 
HT-29 sample in Fig. 3.L4 an additional faint band at approximately 60kD was 
also detected. This signal was not consistently detected in HT-29s but may also 
represent another post-translationally modified protein (Song & Howlett, 1995). 
No other immunoreactive bands were ever detected. Using the Cayman 
Chemicals CBjR antibody only the 83kD band was detected in Jurkats and 
another leukaemic T lymphocyte cell line, CEMs (Fig. 3.L4).
The CB2R is a 39kD protein and using the Cayman Chemicals CB2R antibody an 
immunoreactive band of this approximate size was detected in Jurkat and also 
CEM WCLs (Fig. 3.IB). Previous studies have shown that Jurkats express CB2R 
mRNA (Schatz et a l, 1997, McKallip et a l, 2002a) and thus it was not 
surprising to find that the Jurkats used in this investigation express CB2R protein. 
Again, the use of a blocking peptide confirmed the specificity of the antibody in 
detecting this band (Fig. 3.1Z>). Having established that Jurkats express the 
CB2R protein, WCLs were used as positive controls for CB2R protein expression 
in the majority of subsequent experiments.
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Figure 3.1: CBiR and CB2R protein expression in HT-29s, Jurkats and OEMs.
Immunoblotting was used to determine the presence of CBiR and CB2R protein in the 
colonic epithelial cell line, HT-29s, and two leukaemic T lymphocyte cell lines, Jurkats 
and CEMs. A and B) WCLs were generated and proteins quantified by Bradford assay, 
boiled with 5x sample buffer, resolved by SDS-PAGE (30pg of protein was loaded), 
transferred to nitrocellulose m em branes and immunoblotted, as  described in Materials 
and Methods, with a polyclonal antibody raised against the N-terminus of the human 
CBtR (A; Cayman Chemicals) or CB2R (B; Cayman Chemicals). C and D) In order to 
verify the specificity of the antibodies, duplicate WCL sam ples of HT-29s (C) and Jurkats 
(D) were resolved by SDS-PAGE (30pg of protein was loaded) and the proteins 
transferred to nitrocellulose membranes. After the blocking stage these were cut in half 
and one half treated with the C B ^  (C) and the CB2R (D) antibody as  normal and the 
other half treated with antibody that had been incubated with the appropriate blocking 
peptide (BP; 1:9 for CBtR and 1:4 for CB2R). They were then further immunoblotted as 
described in Materials and Methods. Data are representative of at least three different 
sets of cells. E) Schematic representation of the CBiR and CB2R indicating which 
sections of the receptor the Cayman Chemicals antibodies were raised against.
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3.3 Evidence suggesting the 83kD protein detected is a modified
form of the CBtR protein
Although the 83kD band detected by the Cayman Chemicals CBjR antibody in 
HT-29s appears not to be due to non-specific interactions as preadsorbing of the 
antibody with its blocking peptide eliminated most of the signal, it is not clear 
exactly what this band represents. In the literature it is generally assumed to be a 
post-translationally modified form of the CBiR (Pettit et al., 1998, Wright et al,
2005). However, as the 83kD band was also detected in Jurkats (Fig. 1A), which 
have previously been shown to not express CBiR mRNA (Bouaboula et al., 
1993, Daaka et a l, 1996, Schatz et al., 1997, McKallip et a l, 2002a) this 83kD 
protein was further investigated.
First, a negative control was carried out whereby membrane was probed only 
with the secondary antibody (data not shown). No bands were detected 
indicating that the 83kD band is not simply due to non-specific binding of the 
secondary antibody. A BLAST network search was also performed using the 
ExPASy Proteomics Server of the Swiss Institute of Bioinformatics to investigate 
whether the Cayman Chemicals CBiR antibody could be cross-reacting with any 
other known proteins. The results indicate that it would only potentially cross- 
react with other CBiR orthologues and the CB1B splice variant which is a 
truncated form of the receptor (Ryberg et al, 2005), therefore suggesting that the 
83kD protein detected is a form of the CBiR.
Next, it was determined whether the CBiR could be detected in Jurkats using 
other CBiR-specific antibodies. If it was, this would further imply that the 83kD 
protein detected is indeed a form of the CBiR protein. Both the Affinity 
Bioreagents and Santa Cruz antibodies used are, like the Cayman Chemicals 
antibody, raised against the N-terminus of the human CBjR (see Appendices for 
more details on all three antibodies). The Affinity Bioreagents CBiR antibody 
detected both a 53kD and higher, approximately 75kD, band in HT-29s (Fig. 
3.2A), although the signal with this antibody was much weaker than that with the 
Cayman Chemicals antibody. Only the 75kD band was detected in Jurkats and
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CEMs (Fig. 3.2A). The Santa Cruz CBiR antibody detected a band at 
approximately 60kD in both HT-29s and Jurkats (Fig. 3.2B). These results 
further indicate that the Jurkats used in this study do express CBiR protein and 
hence that the 83kD protein detected by the Cayman Chemicals antibody 
represents a form of the receptor rather than an artefact.
One of the questions raised is whether the 83kD protein is expressed at the cell 
surface. Although immunoblotting of WCLs is an indication that a protein is 
expressed in the cell it does not determine its intracellular localisation. Cytosolic 
and membrane fractions of Jurkats and HT-29s were generated and protein 
expression examined using the Cayman Chemicals receptor antibodies in order to 
investigate where the 83kD protein is expressed. Both fractions of the HT-29s 
express the 53kD and 83kD proteins (Fig. 3.3A). Unfortunately, as the samples 
were loaded according to equal quantities of protein rather than equal cell 
number it cannot be concluded which fraction contained more or less of each 
protein. Equally, the CB2R is also expressed in both fractions of Jurkats, as is the 
83kD form of the CBiR (Fig 3.35). In each instance samples were also blotted 
for IicBa, a cytosolic protein involved in sequestering NFkB proteins in the 
cytoplasm, preventing their activation (Viatour et al., 2005, Campbell & Perkins,
2006), in order to verify the purity of the fractions (Fig. 3.3). In each sample the 
IicBa protein was only detected in the cytosolic fraction and weakly in the WCL 
but not in the membrane fractions indicating that the fractions were pure. Thus 
the 83kD protein can be membrane localised indicating that it is likely to be 
expressed at the cell surface.
Given its molecular weight, the 83kD protein is presumably a post-translationally 
modified form of the CBiR. Indeed, this is what is generally stated in papers 
(Song & Howlett, 1995, Daaka et ah, 1996, Pettit et al., 1998, Matias et ah, 
2002). The rat brain CBiR protein was found to be A-glycosylated at two out of 
three potential sites at the N-terminus to produce 59kD and 64kD proteins (Song 
& Howlett, 1995). Thus, the question raised is whether the 83kD protein 
represents a more heavily A-glycosylated form of the CBjR. Tunicamycin, 
which is a nucleoside antibiotic that prevents A-glycosylation from occurring in 
the endoplasmic reticulum, was used to investigate this. HT-29s were treated
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with tunicamycin or an equivalent concentration of vehicle for up to 48 hours. 
There was no noticeable change in expression of the 83kD band over the time 
course or with varying concentrations of tunicamycin (Fig. 3.4A and B). 
However, the 53kD band was decreased in both a time and concentration- 
dependent manner (Fig. 3.4/4 and B). The intensity of the 53kD band began to 
decrease after 8 hours of treatment and although the effect was strongest at 
lOpg/ml, lpg/ml also decreased levels of the 53kD protein.
This decrease in the level of the 53kD protein was unexpected given that 53kD is 
the calculated molecular weight of the protein based solely on its amino acid 
sequence and it raised the question of whether the 53kD band that is detected by 
the Cayman Chemicals antibody is actually a 53kD protein. In some blots, such 
as Fig. 3.1/4, it is possible to detect an additional band just below the supposed 
53kD band and it is likely that this lower band is usually masked by the stronger 
signal of the band above. It is possible that it is this lower band is actually the 
53kD protein and that the higher band referred to up until now as being 53kD is 
actually 55-56kD and represents a TV-glycosylated CBiR. Unfortunately in the 
blots relating to the tunicamycin experiments it was not possible to clearly detect 
both bands and confirm this. To test whether the two bands would be easier to 
distinguish on a 12% SDS-PAGE gel compared to the 10% gels normally used, 
WCLs of untreated HT-29s were resolved on 12% gels. Fig. 3.4C shows that on 
12% gels the two bands are easier to distinguish and thus these could be used to 
investigate whether tunicamycin only affects the expression of the higher band or 
not. As the nature of these two bands has not been concretely resolved the strong 
signal that is detected at approximately 53kD will continue to be referred to as 
the 53kD band throughout the rest of this study.
Collectively, these results suggest that the 83kD protein detected by the Cayman 
Chemicals antibody is a modified form of the CBiR and that it can be expressed 
at the cell surface alongside the 53kD CBiR protein. Results indicate that the 
83kD protein in not TV-glycosylated and further investigation is needed to 
elucidate exactly how it is modified. Furthermore, it was established that the 
Jurkats used in this study also express a form of the CBjR.
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Figure 3.2: Detection of the C B ^  protein using alternative antibodies. Two
additional, commercially available, CBtR antibodies were used to investigate whether 
the 83kD protein detected using the Cayman Chemicals antibody is a modified form of 
the receptor. WCLs of the various cell types were generated as described in Materials 
and Methods. The proteins were quantified by Bradford assay, sam ples boiled with 5x 
sample buffer, resolved by SDS-PAGE (30pg of protein was loaded), transferred to 
nitrocellulose mem branes and immunoblotted with antibodies raised against the human 
CBtR. A) Affinity Bioreagents, representative of a single experiment, B) Santa Cruz, 
representative of two different sets of cells. Schematic representations of the CBtR 
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Figure 3.3: Localisation of the C B ^  and CB2R within cells. HT-29s {A) and Jurkats 
(B) were lysed as described in Materials and Methods to generate cytosolic (C) and 
membrane (M) fractions and WCLs. Samples were assayed for protein content by 
Bradford assay, boiled with 5x sam ple buffer, resolved by SDS-PAGE (30pg of protein 
was loaded), transferred to nitrocellolose membrane and immunoblotted, as  described in 
Materials and Methods, with antibodies against the CB^R or CB2R (Cayman Chemicals). 
Sam ples were also immunoblotted with an antibody to IkB o  in order to verify the purity of 
the fractions. Data are representative of two different se ts  of cells.
111
Results I -  Cannabinoid receptor protein expression in T lymphocytes
A)


















Figure 3 4: The effect of tunicamycin on C B ^  protein expression in HT-29s. A and
B) HT-29s were set up in 6-well plates as described in Materials and Methods and 
treated either with 1pg/ml tunicamycin (+) or vehicle (-; DMSO) for increasing lengths of 
time (A) or with (O-IOpg/ml) or vehicle (V; DMSO equivalent to 10|jg/ml tunicamycin) for 
48 hours (B). At the end of the incubation period WCLs were generated and proteins 
quantified by Bradford assay, boiled with 5x sample buffer, resolved by SDS-PAGE 
(30pg of protein was loaded), transferred to nitrocellulose m em branes and 
immunoblotted, as  described in Materials and Methods, with an antibody raised against 
the human CB^R (Cayman Chemicals). Data are representative of three different sets of 
cells. C) WCLs of HT-29s were generated and resolved on 12% SDS-PAGE gels (30pg 
of protein was loaded), transferred to nitrocellulose m em branes and immunoblotted, as 
described in Materials and Methods, with an antibody raised against the human CBtR 
(Cayman Chemicals). Data are representative of two different sets of cells.
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3.4 CBiR and CB2R protein expression in naive T lymphocytes 
and PBLs
T lymphocytes express both CBiR and CB2R mRNA (Galiegue et al., 1995) and 
although one study has indicated murine T lymphocytes express CBiR protein 
(Klein et al., 2003) data regarding CB2R protein expression is contradictory 
(Lynn & Herkenham, 1994, Galiegue et a l, 1995, Carayon et a l, 1998, Steffens 
et a l, 2005b). One of the main aims of this project was to establish which 
cannabinoid receptors are expressed in human T lymphocytes, starting with naive 
peripheral T lymphocytes. Cells were isolated from whole human blood as 
described in Materials and Methods and WCLs generated. Using the Cayman 
Chemicals CBjR antibody only the 83kD form of the CBiR was detected in 
naive human T lymphocytes (Fig. 3.5A). The CB2R protein was not detected in 
these cells (Fig. 3.5B).
Previous studies have reported that cannabinoid receptor expression can be 
upregulated or downregulated by a variety of factors such as differentiation as in 
the case of B lymphocytes (Carayon et a l, 1998, Marchand et a l, 1999). 
However, these investigations have focused on the changes in receptor mRNA 
expression over 24 or 48 hours and have not examined the long-term effects on 
protein levels. In order to explore the long-term changes elicited by activation on 
cannabinoid receptor expression in T lymphocytes, PBLs were generated. PBLs 
are T lymphocytes that have been activated in vitro, for instance by the 
superantigen SEB, and clonally expanded using IL-2. Cells were removed from 
culture at day 5 and 12 after initial PBMC isolation and stained for CD3, CD4 
and CD8 as described in Materials and Methods in order to verify that a mainly 
T lymphocyte population was generated and that there was no or little 
contamination from B lymphocytes or monocytes. The results confirm that the 
method of PBL generation used yielded an almost pure T lymphocyte population, 
as measured by CD3 expression, which was approximately 80% CD4+ (Table 3).
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Day 5 97.38 (±2.99)







Table 3: Characterisation of activated PBLs. Cells were removed from culture at days 
5 and 12 after initial PBMC isolation and stained using fluorescently labelled CD3, CD4 
and CD8 antibodies as described in Materials and Methods. Fluorescence was detected 
using flow cytometry and data are represented as the percentage of the population 
expressing each marker. Data are stated as mean ±S.E.M, n=3.
The CB2R was not detected in the freshly isolated PBMCs used to generate the 
PBLs, however, expression of the CB2R protein was upregulated following T 
lymphocyte activation with SEB (Fig. 3.67?). This upregulation was transient, 
with receptor expression typically being downregulated around day 7-8. 
Expression consistently peaked at around day 5 of culture. WCLs of day 5 
PBLs, when CB2R expression was high, and day 12 PBLs, when expression was 
downmodulated, were also probed with an additional CB2R antibody to verify 
that these differences in expression could be detected by more than one antibody. 
The Santa Cruz CB2R antibody, which is raised against the C-terminus of the 
CB2R (further details on both antibodies can be found in Appendices), detected 
an approximately 60kD band in Jurkats and CEMs as well as in day 5 PBLs (Fig. 
3.67?). Expression was much lower in day 12 PBLs as seen with the Cayman 
Chemicals antibody. Only the 83kD form of the CBiR protein was detected in 
both PBMCs and PBLs and its expression remained constant throughout the 
culture period (Fig. 3.6/4).
In addition to activating T lymphocytes using the superantigen SEB, PBMCs 
were also activated using CD3/CD28-coated beads in order to study the effect of 
different types of stimulus on cannabinoid receptor protein expression. Again, 
only the modified 83kD CBiR protein was detected and its expression was not 
altered during the course of the culture (Fig. 3.67T). However, the CB2R was 
again upregulated following T lymphocyte activation and the elevated levels of 
expression induced were maintained for the duration of the culture period (Fig. 
3.6F). Interestingly, in the cultures used for these experiments, some CB2R was 
detected in the PBMC population contrary to those used in the SEB-activated 
PBL experiments.
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Figure 3.5: CBiR and CB2R protein expression in primary naive T lymphocytes.
Immunoblotting was used to determine the presence of the CBiR and CB2R in naive T 
lymphocytes. These were purified from human PBMCs as described in Materials and 
Methods and WCLs generated. Proteins were quantified by Bradford assay, boiled with 
5x sample buffer, resolved by SDS-PAGE (30pg of protein was loaded), transferred to 
nitrocellulose m em branes and immunoblotted, as  described in Materials and Methods, 
with antibody raised against the human CBiR (A; Cayman Chemicals) or CB2R (B; 
Cayman Chemicals). HT-29 and Jurkat WCLs were used as positive controls for CBiR 
and CB2R protein expression, respectively. Data is representative of three different sets 
of cells.
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Figure 3.6: CBiR and CB2R protein expression in activated PBLs. Immunoblotting 
was used to determine the presence of CBiR and CB2R protein in PBLs throughout the 
culture period. PBMCs were isolated from human blood and the T lymphocytes 
activated using SEB (A-C) or CD3/CD28-coated beads (E, F) as  described in Materials 
and Methods. Sam ples of cells were removed from culture on different days post­
isolation and WCLs generated. Protein levels were quantified by Bradford assay, 
sam ples boiled with 5x sam ple buffer, resolved by SDS-PAGE (30pg of protein was 
loaded), transferred to nitrocellulose m em branes and immunoblotted, as  described in 
Materials and Methods, with antibody raised against the human CBiR (A, E; Cayman 
Chemicals) and CB2R (B, F, Cayman Chemicals; C, Santa Cruz). HT-29 and Jurkat 
WCLs were used as  positive controls for CBiR and CB2R protein respectively. Data are 
representative of at least three (A and B) or two (C, E, F) different sets of cells. D) 
Schematic representation of the CB2R showing which sections of the receptor the 
antibodies are raised against.
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3.5 Potential heterodimerisation between the CB]R and CB2R
Although the existence of CBiR homodimers has been suggested in several 
papers (Wager-Miller et al., 2002, Mackie, 2005, Xu et a l , 2005), thus far no 
one has reported whether the CBiR and CB2R dimerise. As the CBiR has been 
shown to dimerise with several GPCRs including the LPA1 receptor (Wright et 
a l , 2005) and D2 dopamine receptor (Keam et al, 2005) it would not be 
surprising to find that the CBjR and CB2R could form heterooligomers in cells 
where they are both expressed. Given the impact that dimerisation is able to 
have on, for instance, receptor pharmacology (Maggio et a l, 2005), and that 
activated PBLs appear to express both the CB2R and a form of the CBiR, the 
possibility of CB1R-CB2R dimerisation was investigated in some preliminary 
experiments.
As HT-29s have been shown to express both the 53kD form of the CBiR and 
also the CB2R (Ihenetu et a l, 2003b, Wright et a l, 2005) dimerisation was 
investigated in this cell line. Preliminary data collected suggests that these two 
receptors can indeed associate (Fig. 3.7). Anti-CBiR IPs were generated using 
the Santa Cruz CBjR antibody and resolved by SDS-PAGE and membranes 
probed with the Cayman Chemicals CB2R antibody. The CB2R was detected in 
the HT-29 WCL sample as well as in the IP sample, suggesting an association 
between the two receptors. It remains to be seen whether the 83kD protein and 
the CB2R could also dimerise.
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Figure 3.7: Preliminary evidence suggesting CB1R-CB2R dimerisation in HT-29s.
HT-29s were grown on 10cm dishes, lysed and immunoprecipitated using C B ^  
antibody (Santa Cruz) as  described in Materials and Methods. WCLs of HT-29s and 
Jurkats were also generated at the sam e time. Sam ples were boiled with sam ple buffer, 
resolved on 12% SDS-PAGE gels (30pg of protein was loaded except for the IP sample 
which was loaded in its entirety), transferred to nitrocellulose membrane and 
immunoblotted as  described in Materials and Methods, with antibody against the CB2R 
(Cayman Chemicals). Data is representative of 2 separate experiments.
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3.6 Expression of FAAH and MAGL in T lymphocytes
As well as the receptors and the endogenous ligands, the cannabinoid system also 
comprises the enzymes involved in metabolising the endocannabinoids. These 
include FAAH, which primarily breaks down AEA but can also act on 2-AG 
(Goparaju et al., 1998, Cravatt & Lichtman, 2002), and MAGL, which 
metabolises 2-AG (Dinh et a l , 2002). It is possible that some of the effects 
contributed to the endocannabinoids may in part be due to their metabolites 
(Pertwee & Ross, 2002) and thus it is important to establish whether these two 
enzymes involved in endocannabinoid metabolism are expressed in the primary 
T lymphocytes and leukaemic T lymphocyte cell lines used in this study.
FAAH is a 63kD protein and has previously been detected in human T 
lymphocytes (Maccarrone et a l , 2003c). Immunoblotting with an antibody 
raised against human FAAH detected the expression of FAAH protein in day 5 
activated PBLs as well as the Jurkats and CEMs used in this study (Fig. 3.8). 
Interestingly, FAAH appeared as a doublet and ran at a slightly higher weight in 
the Jurkats and CEMs than in the PBLs, suggesting that in these cell lines FAAH 
may undergo some post-translational modifications. MAGL, a 33kD protein 
(Dinh et a l , 2002), was also detected also in CEMs, Jurkats and day 5 activated 
PBLs (Fig. 3.8). Notably, these blots only confirm the expression of these 
proteins, they cannot be used to compare amounts of enzyme expressed in each 
cell type as different amounts of protein were loaded per well.
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Figure 3.8: FAAH and MAGL expression in HT-29s, CEMs, Jurkats and PBLs.
Immunoblotting was used to determine the presence of FAAH and MAGL in several 
different cell types including day 5 activated PBLs. WCLs were generated and proteins 
were quantified by Bradford assay, boiled with 5x sample buffer, resolved by SDS-PAGE 
(20-30pg of protein was loaded per well), transferred to nitrocellulose m em branes and 
immunoblotted, as  described in Materials and Methods, with antibodies raised against 
human FAAH and MAGL. Data are representative of two separate experiments.
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3.7 Summary
• Using in vitro activated human T lymphocytes or PBLs this study has 
shown that the CB2R protein is upregulated following T lymphocyte 
activation. The mode of activation appears to influence how long the 
CB2R is upregulated for.
• In addition, a 83kD form of the CBiR is also expressed in T lymphocytes 
although it is not influenced by cellular activation. The exact nature of 
this 83kD protein remains unknown.
• Preliminary data suggests that the two cannabinoid receptors may be able 
to dimerise in cells where they are both expressed.
• It was also found that T lymphocytes express both FAAH and MAGL, 
two of the enzymes involved in the breakdown of the endocannabinoids 
AEA and 2-AG.
3.8 Discussion
One of the main aims of this part of the study was to gain insight into the 
expression of the cannabinoid receptor proteins in T lymphocytes. This involved 
not only investigating CBiR and CB2R protein expression in naive peripheral T 
lymphocytes but also in activated T lymphocytes. However, before this was 
work was carried out, expression in T lymphocyte cell lines was determined as a 
comparison.
3.8.1 CBiR protein expression in leukaemic T lymphocyte cell 
lines
3.8.1.1 The 53kD CBiR is not detected in Jurkats or CEMs
Using the Cayman Chemicals CBiR antibody, which is raised against the N- 
terminus of the human CBiR, a strong immunoreactive band of approximately 
53kD was detected in HT-29s, a colonic epithelial cell line. This corresponds to 
the calculated molecular weight of the CBiR based on its amino acid sequence 
and confirms previous data generated in the lab (Wright et al., 2005). The
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specificity of the antibody in detecting this band was confirmed through use of 
the appropriate blocking peptide. Having established that HT-29s express the 
53kD CBiR protein they were used as positive controls for the CBjR protein in 
further experiments. This 53kD band was not detected in Jurkats, nor in CEMs, 
another leukaemic T lymphocyte cell line.
In addition to the 53kD band, an approximately 60kD band was also sometimes 
detected in HT-29s using the Cayman Chemicals CBiR antibody. The rat CBjR 
was shown to be A-glycosylated at two out of three potential sites in the N- 
terminus generating 59kD and 64kD proteins (Song & Howlett, 1995). The 
human CBiR also has three potential A-glycosylation sites (Gerard et al., 1991) 
and thus this band is presumably an equivalent A-glycosylated form. It is likely 
that the lack of reliability in detecting this band in HT-29s is related to low 
expression and hence whether it is detected depends on the sensitivity of the 
antibody in any given experiment. It was also not detected in either Jurkats or 
CEMs. Although the Cayman Chemicals antibody would be able to detect the 
CB1B which is a truncated splice variant of the CBiR (Ryberg et a l , 2005) no 
appropriately sized bands were detected in HT-29s or any of the other cell types 
used in this investigation.
Several papers have also reported the detection of larger proteins using 
immunoblotting and suggest that these indicate that the CBiR can form 
homodimers or larger oligomers (Pettit et a l , 1998, Wager-Miller et a l, 2002, 
Mackie, 2005, Xu et a l, 2005). For instance, Wager-Miller et al have detected 
CBiR homodimers or larger oligomers using a C-terminal CBiR antibody which 
they say preferentially recognises the dimerised form of the receptor (Wager- 
Miller et a l, 2002, Mackie, 2005). Using this antibody a 160-200kD band was 
detected in rat membranes (Wager-Miller et a l, 2002, Mackie, 2005) which was 
suggested to be either SDS-resistant CBiR homodimers migrating anomalously 
or larger aggregates. The antibody labelled the same rat brain areas as the N- 
terminal CBiR antibodies and failed to label any areas in CBiR knockout 
animals, suggesting that it is indeed CBiR specific (Hajos et a l, 2000, Katona et 
al, 2001). The authors also say that they have shown CBiR dimer formation
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using immunoprecipitation but this data has not yet been published (Mackie, 
2005).
Further suggestion that the CBiR exists as homodimers has come from a study 
investigating human CBjR protein purified from a baculovirus expression system 
(Xu et a l, 2005). As well as a monomeric CBiR protein, a larger 120kD band 
was also detected by immunoblotting using an N-terminal CBiR antibody and 
was found to consist of CBiR monomers, thus confirming the existence of SDS- 
resistant CBiR homodimers in this expression system. Other papers using N- 
terminal CBiR antibodies have also detected proteins of approximately 116- 
120kD, for example in rat brain (Pettit et al., 1998), DLD-1 human colonic 
epithelial cells (Ligresti et a l, 2003) and mouse small intestine (Casu et al,
2003) and 160-200kD, for instance in rat brain membrane (Mukhopadhyay et al, 
2000). Again, these would suggest the existence of SDS-resistant CBjR 
homodimers or larger oligomers in tissues, rather than just in an expression 
system.
However, in the current study, using three different N-terminal CBiR antibodies, 
bands of either 116-120kD or 160-200kD were not detected in HT-29s. This 
indicates that any CBiR dimers in these cells are SDS-sensitive, in contrast to the 
SDS-resistant dimers suggested to exist by others. Although it is certainly likely 
that the CBiR does form homodimers given that it is suspected that all GPCRs 
can dimerise (Hansen & Sheikh, 2004, Maggio et a l, 2005), further investigation 
is needed. Techniques such as size exclusion chromatography would allow a 
more accurate molecular weight of the 120kD/160-200kD complexes to be 
determined whilst, for example, purifying and sequencing the bands would 
resolve what the components are. Creating truncated receptors would also 
establish which parts of the receptor are involved in dimer formation and confirm 
whether the C-terminus is indeed involved as suggested by the CBiR C-terminal 
antibody (Wager-Miller et a l, 2002).
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3.8.1.2 An 83kD protein is detected in Jurkats and CEMs
Although CBiR homodimers were not detected using the Cayman Chemicals 
CBiR antibody, as well as the 53kD band, a strong band of approximately 83kD 
was detected. In the literature it is generally stated to be a post-translationally 
modified form of the receptor (Song & Howlett, 1995, Daaka et al., 1996, Pettit 
et al., 1998, Matias et a l , 2002) and there are several lines of evidence to support 
this notion which will be discussed below.
3.8.1.2.1 Evidence that the 83kD protein is a modified CBiR
Firstly, use of the blocking peptide to preadsorb the antibody eliminated most of 
the signal, indicating that it is not simply non-specific binding and suggesting it 
is an additional form of the receptor. In addition, the 83kD band was not 
detected when a negative control was carried out by probing the membrane with 
only the secondary antibody, again confirming it is not due to non-specific 
binding. Recently, Klein et al (2003) reported that using commercial polyclonal 
antisera generated against CBiR peptides they detected major bands of either 
65kD or 75kD in splenocytes derived from wild type and CBiR knockout mice, 
thus calling into question the specificity of the available CBiR antibodies. 
Notably, they failed to specify which antibodies they used and also did not test 
one they generated against the 14 amino acids of the N-terminus of the CBiR, 
like the Cayman Chemicals antibody, on samples from knockout mice. They 
suggest that one explanation is that the antibodies are detecting other proteins 
that share epitopes with the CBiR. Therefore, a BLAST network search was 
carried out to verify whether the Cayman Chemicals antibody can react with any 
other know proteins. The search revealed that the antibody would only react 
with other CBiR orthologues and the CB1B. Thus, it is likely that the 83kD 
band represents an additional form of the CBiR protein rather than non-specific 
binding or another protein.
Secondly, only this 83kD protein was detected in Jurkat and other CBiR 
antibodies were used to verify the presence of the receptor in these cells. 
Although the CBiR has been suggested to be expressed on CEMs (Powles et al.,
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2005), several reports have stated that Jurkats express either no (Bouaboula et 
al., 1993, Schatz et al., 1997, McKallip et al., 2002a) or very little (Daaka et al., 
1996) CBiR mRNA and no protein (Daaka et al., 1996). Thus, initially it raised 
the possibility that either the 83kD band is in fact not a CBiR or the Jurkats used 
in this study do express a CBiR. Therefore, additional commercially available 
CBiR antibodies were used in order to address this issue. Although the Affinity 
Bioreagents antibody appeared not to be as sensitive as the Cayman Chemicals 
antibody it also detected a 53kD band in HT-29s, but not Jurkats or CEMs, and a 
higher band in all three cell lines. The higher band ran at approximately 75kD on 
the gel rather than 83kD as seen with the Cayman Chemicals antibody but this 
may simply be an anomaly of the experiment. The Santa Cruz CBjR antibody 
also detected a 60kD band although several additional smeared bands were also 
visible. The 60kD band was also detected in Jurkats, suggesting that the cells 
used in this study do express the CBiR protein and hence that the 83kD band 
detected with the Cayman Chemicals antibody is a form of the receptor. One 
important point to make is that all three of the antibodies used were raised 
against the N-terminus of the CBiR and therefore the band detected in Jurkats 
may simply be a result of all three antibodies detecting the same alternative 
protein. However, given that the BLAST search results revealed no such 
alternative protein it is very unlikely that this is the case. One way of confirming 
this would be to use the new commercially available CBiR antibody which has 
been generated against amino acids 461-472 at the C-terminus of the receptor.
Daaka et al (1996) have shown that in Jurkats that express almost negligible 
amounts of CBiR mRNA and no protein, receptor expression both at an mRNA 
and protein level can be upregulated by mitogen stimulation. In fact, the 
antibody used in this study detected several bands including ones at 45kD, 60kD 
and 87kD in N18TG2 mouse neuroblastoma cells which were used as a positive 
control and the 87kD band was amongst those upregulated upon mitogen 
stimulation. Thus it is possible that the Jurkats used in the current study have 
undergone some transformation to now consistently and strongly express the 
CBiR. This data does underline the need to be careful when interpreting data 
from cell lines and to ensure that characteristics such as receptor expression are 
monitored.
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Having determined that the 83kD protein detected by the Cayman Chemicals 
CBiR antibody is a form of the receptor, one question raised is whether or not 
this protein is expressed at the cell surface. The CBiR has previously been 
shown to be expressed at the plasma membrane and associates with lipid rafts 
(Samataro et a l , 2005). It has also been shown to be expressed in lysosomes 
(Samataro et a l , 2005) and can constitutively cycle between the plasma 
membrane and endosomes (Leterrier et al., 2004). This, together with the fact 
that its long N-terminal tail cannot be efficiently translocated across the ER 
membrane (Andersson et al., 2003), leads to low expression at the plasma 
membrane. Results obtained from generating cytosolic and membrane fractions 
of HT-29s and Jurkats indicate that the 83kD protein is membrane localised in 
both cell types, as well as being in the cytosol. Similarly, the 53kD CBiR and 
the CB2R were also detected in cytosolic and membrane fractions of HT-29s and 
Jurkats respectively, suggesting that they too are expressed at the cell surface.
Although the 83kD CBjR protein is generally stated to be a post-translationally 
modified form of the receptor in the literature, to the best of my knowledge the 
nature of this modification has not been investigated. The human CBiR has three 
potential A-glycosylation sites within in the N-terminus of the protein (Gerard et 
al., 1991). An early study looking at rat CBiR 7V-glycosylation only detected a 
59kD and 64kD glycosylated form of the receptor suggesting that only two out of 
the three potential sites are actually A-glycosylated (Song & Howlett, 1995). 
Using the inhibitor tunicamycin it was investigated whether the 83kD protein 
detected using the Cayman Chemicals antibody is TV-glycosylated. The 83kD 
protein was unaffected by tunicamycin treatment, even at high concentrations, 
indicating it is not TV-glycosylated.
Surprisingly, the 53kD band in HT-29s was nearly abolished by tunicamycin 
treatment. This was unexpected as the 53kD band is expected to represent the 
unmodified CBjR. However, in HT-29s the 53kD band is sometimes 
accompanied by an additional lower band as in Fig. 3.L4 which is not always 
detected and may be masked by the intensity of the 53kD band as it runs very 
close to it. This slightly lower band may in fact represent the 53kD protein,
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meaning that the slightly higher band is a A-glycosylated protein which is 
actually 55-56kD. The added weight may only be about 2kD suggesting a small 
oligosaccharide addition, which would not be surprising given that the three 
potential A-glycosylation sites are all very close together at residues 77, 83 and 
112 (of the human CBjR) and thus steric hindrance may prevent the addition of a 
large carbohydrate moiety at each of these sites. If this lower band is indeed the 
true, unglycosylated, 53kD protein it should not be affected by tunicamycin 
treatment. Unfortunately, it was not possible to clearly identify the lower band in 
any of the blots obtained from experiments were tunicamycin was used thus this 
could not be confirmed. However, results indicate that the two bands are easier 
to distinguish when HT-29 WCLs were resolved on 12% SDS-PAGE gels rather 
than the 10% gels routinely used. Thus, these higher percentage SDS-PAGE gels 
could be used to investigate whether or not tunicamycin only affects expression 
of the higher band. As for now it is not clear whether there are two bands or not 
the strong signal detected at approximately 53kD will continue to be referred to 
as the 53kD form of the CBiR protein.
The data suggests that the 83kD protein is not A-glycosylated. There are many 
more types of post-translational modifications, however, given the size of the 
modification it is most likely that 0-glycosylation would account for this large 
CBiR protein. Although there is no specific consensus sequence for O- 
glycosylation as there is for A-glycosylation, there are many serine and threonine 
residues in the N-terminal domain (Gerard et al., 1991) suggesting that the CBiR 
could be O-glycosylated.
3.8.1.2.2 What else could the 83kD protein represent?
As the data collected did not determine what the post-translational modification 
is, one cannot exclude the possibility that the protein detected is not strictly a 
single, modified, CBiR. When the human CBiR was purified and expressed 
using a baculovirus expression system an 80kD protein was detected and it was 
shown that this protein consisted of two truncated CBiRs (Xu et al., 2005). 
Therefore, the 83kD protein detected in this study may consist of two truncated 
CBiR proteins. The receptors would have to be truncated at the C-terminus as
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otherwise the Cayman Chemicals antibody, which is raised against the first 14 
amino acids of the N-terminus, would not detect the complex. The complex 
would also have to be SDS-resistant. The protein is too small to be a CBiR or 
CB1B homodimer and it is also too small to be a dimer of the CBiR with one of 
the CBiR splice variants, CB1A or CB1B (Shire et al., 1995, Ryberg et al., 
2005). However, it may be complexed with other proteins. For instance, two 
cannabinoid receptor interacting proteins (CRIPs), CRIP la and CRIP lb, have 
recently been identified (Niehaus et a l, 2004). These proteins bind to the C- 
terminal tail of the CBjR and CRIP la binding has been proposed to decrease the 
receptors’ constitutive activity (Niehaus et a l, 2004). Although these proteins 
are likely too small to account for the 83kD band detected, being only 164 
(CRIPla) and 128 (CRIPlb) amino acids in size, their existence raises the 
possibility that other proteins that specifically interact with the cannabinoid 
receptors may be present in cells. The receptor may also be able to interact with 
other, non-cannabinoid receptor related proteins. For example, although receptor 
activity-modifying proteins were initially found to be associated with class II 
GPCRs it is now becoming apparent that they may associate with all types of 
GPCRs (Hay et a l, 2006).
This 83kD form may also be one of the cannabinoid receptor-like receptors. 
Given that it is detected by N-terminal antibodies raised against the classical 
CBiR it would have to be identical in these regions but that would not prevent it 
having a different pharmacological profile as ligand binding has been shown to 
occur in the pore created by the TM domains (Mukhopadhyay et a l, 2002, 
Murphy & Kendall, 2003). Given that it is still not certain what this 83kD 
protein is, but the data suggests it is a form of the receptor, it will be referred to 
as a modified CBiR protein throughout the rest of this study.
3.8.2 CB2R protein expression in leukaemic T lymphocyte cell 
lines
The CB2R is a much smaller protein than the CBiR and its predicted molecular 
weights is 39kD based on its amino acid sequence. Using the Cayman
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Chemicals CB2R antibody a band of this approximate size was detected in both 
Jurkats and CEMs. This was expected as Jurkats have previously been shown to 
express CB2R mRNA (Schatz et al., 1997, McKallip et a l , 2002a) and CEMs 
have previously been shown to express low levels of CB2R by comparing 
binding of biotinylated A9-THC to cells in the presence and absence of CBiR and 
CB2R antagonists (Powles et al., 2005). Although the CB2R does have one 
potential A-glycosylation site and a 46kD glycosylated form of the receptor has 
been detected in other studies (Carayon et al., 1998, Ligresti et al., 2003, 
Filppula et al., 2004, Wright et al., 2005) only one band was ever detected in the 
cells used in this study. This suggests that in these cells the receptor may not be 
A-glycosylated or that very low levels are expressed and not detected by the 
antibody. It is unlikely that the Cayman Chemicals antibody is not able to detect 
the 46kD form as it has previously done so in other studies (Ligresti et al., 2003, 
Wright et al., 2005). Thus, Jurkats and CEMs express both the CB2R and at least 
one form of the CBiR, making them suitable for use in the second part of this 
study which focuses on the role of cannabinoids in T lymphocyte function.
3.8.3 Which cannabinoid receptors are expressed in naive
peripheral T lymphocytes?
Although it has been well established that primary T lymphocytes express CB2R 
mRNA (Galiegue et al., 1995), data published concerning CB2R protein 
expression is contradictory as already mentioned. It is know that CB2R mRNA 
expression in T lymphocytes is low compared to other immune subpopulations 
(Galiegue et al., 1995), therefore it is possible that these differences may be due 
to sensitivity of the techniques used in these studies. Using the Cayman 
Chemicals CB2R antibody the CB2R protein was not detected in WCLs of human 
naive peripheral T lymphocytes. It is possible that the level of CB2R protein fell 
below the detection limit of the antibody or that under basal conditions the 
mRNA is simply not translated into protein. For example, it was recently 
published that even though polymorphonuclear cells had been shown to express 
CB2R mRNA no functional protein could be detected (Deusch et al., 2003). 
Only the 83kD, modified, CBiR was detected in these nai've T lymphocytes.
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Similarly, some but not all PBMC populations appeared to express the CB2R 
protein although CB2R mRNA (Nong et al., 2002) and low levels of protein 
(Gardner et a l , 2002) have previously been detected in human PBMCs. Again, 
it may simply be that in certain instances the level of CB2R protein fell below the 
detection limit of the antibody. This could be due to either subtle differences in 
antibody specificity between batches and/or dilutions of the antibody or donor 
variation. It is currently not clear whether cannabinoid receptor expression 
varies among the population. One study has shown that CBiR expression in 
humans is dependent on gender and ethnic background although the blots they 
present are not particularly clear (Onaivi et a l, 1999). Receptor mRNA levels 
have also been shown to differ between individual donors in one study although 
they did not investigate whether this correlated with any differences in age or 
gender (Schwarz et a l, 1994). Another study has shown that neither age, gender 
nor ethnic origin affected the expression of CBiR and CB2R mRNA in human 
PBMCs (Nong et a l, 2002).
Oddly, the CB2R was never detected in the PBMC population whilst the effects 
of SEB-induced activation on receptor expression in T lymphocytes were being 
investigated, but was detected in samples collected to examine the effects of 
CD3/CD28-induced activation. Again, this suggests that the difference is likely 
to be due to differences in batches of antibody as these experiments were carried 
out at different times. However, it is important to note that the PBMCs were not 
treated in quite the same manner. The PBMCs used in the SEB-activation 
experiments are freshly isolated whereas those used in the CD3/CD28-induced 
activation experiments are monocyte depleted. It is possible that by removing 
the monocytes from the culture and thereby increasing the density of 
lymphocytes, this increases the relative concentration of CB2R protein. Further 
investigation is needed to verify whether this is possible. For instance, by 
characterising the PBMC population before and after monocyte depletion both in 
terms of cannabinoid receptor expression and also in terms of which cells are 
present in the population. Again, only the modified form of the CBjR was 
detected in all of the PBMCs.
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3.8.4 What is the effect of activation on cannabinoid receptor
expression in T lymphocytes?
CB2R, but not CBiR, protein expression was significantly upregulated when the 
T lymphocytes in the PBMC population were activated using the superantigen 
SEB and clonally expanded to generate PBLs. This method of generating and 
culturing PBLs yielded an almost pure T lymphocyte population indicating that 
the increase in CB2R protein was not due to contamination from other cell types. 
The increase in CB2R protein expression detected was transient as after several 
days the receptor levels were again downmodulated. Expression peaked around 
day 5 after initial PBMC isolation. The difference in CB2R protein expression 
between day 5 PBLs, when expression was high, and day 12 PBLs, when 
expression had been downregulated, was also detected using a second CB2R- 
specific antibody. That CB2R expression was modulated following activation 
was not surprising as previous studies have reported that cannabinoid receptor 
expression in immune cells can be upregulated or downregulated by a variety of 
factors (Table 4). Many of these investigations have focused on the changes in 
receptor mRNA expression over 24 or 48 hours elicited by cellular activation and 
not the long-term effects on protein expression. However, there are exceptions. 
For instance, CB2R mRNA and protein levels were shown to change as B 
lymphocytes differentiate from virgin to memory B lymphocytes (Carayon et al., 
1998) and the CB2R was found to be differentially expressed in relation to 
cellular activation of rat peritoneal macrophages at both the mRNA and protein 
level (Carlisle et a l , 2002). The importance of examining not just mRNA but 
also protein levels is highlighted by a report which showed that expression of 
CB2R mRNA but not protein was higher in immature compared to mature murine 
dendritic cells (Maestroni, 2004).
The results from the current study also raised the question of whether the mode 
of cellular activation would affect CB2R protein upregulation. CD3/CD28- 
coated beads were used to activate the T lymphocytes in the PBMC population. 
Again, the expression of the 83kD form of the CBiR remained constant 
throughout the culture period. However, CB2R upregulation was maintained for 
longer than when the T lymphocytes were activated using the superantigen SEB.
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SEB acts by binding, as an intact molecule, to the class II MHC complex 
expressed on professional APCs, such as the B lymphocytes found in the PBMC 
population, and then sequentially binding the TCR, bringing them together to 
induce T lymphocyte activation (Prof! & Fraser, 2003). Whether co-stimulation 
of CD28 is required for activation by superantigens remains controversial 
(Damle et al., 1993, Muraille et al., 1995, Krummel et a l, 1996, Rajagopalan et 
a l , 2002). The beads are coated in CD3 and CD28 antibodies and thereby mimic 
the in vivo stimulation of T lymphocytes by APCs by binding not only the CD3 
but also inducing co-stimulatory signals by binding CD28. Thus there may be 
differences in the pathways activated by these two methods of T lymphocyte 
activation. Unfortunately, to the best of my knowledge, nothing is currently 
known about what promoter the cannabinoid receptors are under control of and 
hence it is not possible to speculate how the two methods of cellular activation 
would act differently in this respect. However, as well as possibly activating the 
T lymphocytes in slightly different ways there is another key difference in how 
these two types of PBLs are cultured. Whereas SEB is only added to the cells 
once, the CD3/CD28-coated beads remain in the tissue culture flasks throughout 
the culture. It is possible that as the CD3/CD28-activated PBLs are expanding, 
the beads are again activating the new cells and hence this is why the levels of 
CB2R protein expression do not return towards basal as in the SEB-activated 
PBLs. One way of testing this would be to grow two cultures up from the same 
source of PBMCs, one which continues to have the CD3/CD28-coated beads in 
the culture, the other where they are removed on, for example, day 7 and then 
compare the levels of CB2R expression.
That the CB2R but not the CBiR is upregulated is likely to reflect a difference in 
promoters for these two receptors. However, this finding was somewhat 
unexpected as CBiR mRNA expression has been shown to be regulated in 
immune cells by a number of mitogens including the T lymphocyte mitogen 
PHA (Table 4). Nonetheless, in light of these findings it is clear that the role or 
effect of cannabinoids may change throughout the course of the T lymphocyte 
response to inflammation and that the circumstances under which the T 
lymphocytes are activated could influence cannabinoid effects on the cells.
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Stimulus Cell type References
CB,R t PHA Jurkats Daaka et al., 1996
mRNA
Anti-CD40 antibody mouse splenocytes Noe et al., 2000
LPS mouse macrophages Klein et al., 2003
Marijuana use human PBMCs Nong et al., 2002
t PHA Jurkats Daaka etal., 1996
protein
1 PHA human PBMCs Nong et al., 2002
mRNA
Anti-CD3 antibody mouse splenocytes Noe et al., 2000
PMA/Ionomycin mouse splenocytes Noe et al., 2000
c b 2r  t Anti-CD40 antibody mouse splenocytes Lee et al., 2001
mRNA
Marijuana use human PBMCs Nong et al., 2002
IFNy rat peritoneal 
macrophages
Carlisle et al., 2002
IFNy + GM-CSF mouse microglial cells Maresz et al., 2005
T Anti-CD3 antibody human lymphocytes Gardner et al., 2002
protein
IFNy rat peritoneal 
macrophages




1 Differentiation B lymphocytes Carayon et al., 1998
mRNA
LPS mouse splenocytes Lee et al., 2001, 
McKallip et al., 
2002b
Concanavalin A mouse splenocytes McKallip et al., 
2002b
1 TGFp human lymphocytes Gardner et al., 2002
protein
Differentiation B lymphocytes Carayon et al., 1998
Table 4: Overview of modulation of cannabinoid receptor expression by cel
activation. CBtR and CB2R mRNA expression can be increased or decreased by 
several different factors. Results from this current study are highlighted.
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3.8.5 CBiR-CB2R heterodimerisation
Several papers have suggested that the CBiR can form heterodimers. For 
instance, specific association of the CBjR with other receptors such as the LPA1 
receptor (Wright et al., 2005), D2 receptor (Keam et al, 2005), orexin 1 receptor 
(Hilairet et a l, 2003) and possibly opioid receptors (Rios et a l, 2006) has been 
reported. The CBiR may also exist as homodimers as discussed earlier, as could 
the CB2R (Filppula et a l, 2004). However, to the best of my knowledge there 
have been no reports on CBiR-CB2R dimerisation. In order to investigate CBiR- 
CB2R association, HT-29s were used as they have previously been reported to 
express both receptors (Ihenetu et a l, 2003b, Wright et a l, 2005). Using 
immunoprecipitation, the CB2R was detected in anti-CBjR IP samples from HT- 
29s. This preliminary data suggests that the CBiR and CB2R associate in cells 
that express both receptors and thus may form heterodimers or even larger 
oligomers. However, further investigation is needed to corroborate this data. 
For instance, it must be verified that the CBiR can be detected in anti-CB2R IPs, 
and ideally that the association also occurs in primary cells. In particular, it 
remains to be seen whether the modified CBiR detected in T lymphocytes can 
associate with the CB2R. Techniques such as fluorescent resonance energy 
transfer or bioluminescence resonance energy transfer could be used to determine 
whether the two receptors are closely associated or not. It would also be 
interesting to study whether agonist binding would affect dimer formation as in 
other studies (Keam et a l, 2005, Wright et a l, 2005).
The implications of CBiR-CB2R association are numerous, especially as the 
CB2R is being detected in more cell types and hence it is becoming clear that not 
only immune cells express both receptors. For instance, given that it is well 
established that GPCR heterodimerisation can alter the pharmacology normally 
attributed to the individual receptor (Maggio et a l, 2005, Prinster et a l, 2005), it 
may account for some of the cannabinoid pharmacology seen in certain cell types 
that has, up until now, been explained by the existence of additional cannabinoid- 
like receptors (Wiley & Martin, 2002, Begg et a l, 2005). The existence of 
dimers may also change with cellular activation and/or differentiation as receptor 
expression can be altered under these circumstances as already discussed.
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Equally, dimer formation could also be increased in disease states. For example, 
primary human colonic epithelial cells only express the CBiR but the CB2R can 
be detected in these cells in sections taken from Crohn’s disease patients (Wright 
et al., 2005). Therefore, under normal physiological conditions cells may only 
express one type of cannabinoid receptor but under pathological conditions begin 
to express both. This could greatly affect how the cells respond to cannabinoids 
not only because of the activation of the individual receptor being upregulated 
but also because of the activation of dimers.
3.8.6 Do primary T lymphocytes express other proteins of the
cannabinoid system?
In addition to expressing both cannabinoid receptors, PBLs also express both 
FAAH and MAGL, two enzymes involved in endocannabinoid inactivation 
(Goparaju et a l , 1998, Cravatt & Lichtman, 2002, Dinh et a l , 2002). FAAH has 
previously been detected in human T lymphocytes (Maccarrone et a l , 2003c). 
However, although MAGL mRNA has been detected in a wide range of tissues 
including mouse and rat spleen (Karlsson et a l , 1997, Karlsson et a l , 2001) and 
has been purified from several different cell types (Goparaju et a l , 1998), to my 
knowledge there have been no reports looking at its expression in T 
lymphocytes. Interestingly, FAAH appeared as a doublet and ran at a slightly 
higher molecular weight in Jurkats and CEMs compared to the primary PBLs. 
This suggests that in these cell lines FAAH may undergo some post-translational 
modifications. That the FAAH expressed in cell lines may be different from that 
in primary cells underlines the need carry out experiments in primary cells, 
especially if FAAH is being considered as a therapeutic target (Di Marzo et a l ,
2004). It would also be interesting to investigate whether FAAH and/or MAGL 
expression is affected by T lymphocyte activation. LPS has been reported to 
downregulate FAAH gene expression in human peripheral lymphocytes 
(Maccarrone et a l , 2001) and it is also regulated by leptin and progesterone 
(Maccarrone et a l , 2003a, Maccarrone et a l , 2003c). Thus it is certainly 
possible that FAAH protein levels may be altered by cellular activation.
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3.9 Conclusions
In this part of the study it was determined that CB2R protein is upregulated 
following human T lymphocyte activation. The mode of cellular activation 
appears to influence how long the CB2R is upregulated for. One of the main 
aims of the next part of this study will be to investigate whether this difference in 
CB2R expression translates into a difference in cannabinoid-mediated effects on 
T lymphocyte function. For now, it does suggest that the role of cannabinoids in 
the T lymphocyte-mediated immune response may change as the T lymphocyte 
becomes active. Furthermore, as different modes of activation appear to 
influence cannabinoid receptor expression there is potential for a highly 
regulated and complex system.
Only an 83kD protein was detected in naive and activated T lymphocytes using 
the Cayman Chemicals CBiR antibody. Data collected from the colonic 
epithelial cell line HT-29s and two human leukaemic T lymphocyte cell lines, 
Jurkats and CEMs, suggest it is a modified form of the CBiR but the nature of 
this modification has not been identified. It remains unclear whether the 
modified receptor could be functional or not and this issue will be addressed in 
the next part of this study. However, it is not iV-glycosylated. In addition to 
expressing the CB2R and a modified CBiR, activated human T lymphocytes also 
express both FAAH and MAGL, two enzymes involved in endocannabinoid 
degradation. Preliminary evidence also suggests that the CBjR and CB2R may 
form heterodimers in cells which express both receptors but this needs to be 
further investigated.
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4.1 Background
Cannabinoids have been linked to many different intracellular signalling 
pathways. These include the activation of the MAPKs, ERK1/2 (Bouaboula et 
al., 1995b, Bouaboula et al., 1996, Galve-Roperh et al., 2002, Derkinderen et al., 
2003, Samson et al., 2003), which is induced by cannabinoids in many different 
cells types including Jurkats (Herrera et al., 2005, Ghosh et al., 2006). 
Cannabinoids have also been shown to modulate cAMP production (Pertwee, 
1997, Kaminski, 1998, Howlett et al., 2002, Demuth & Molleman, 2006). For 
example, they inhibit forskolin-stimulated cAMP production in lymphocytes 
(Diaz et al., 1993, Condie et al., 1996, Mechoulam et al., 1995) as well as cAMP 
response element (CRE) DNA binding activity, a part of the cAMP signalling 
cascade downstream of PKA (Koh et al., 1997, Herring & Kaminski, 1999, 
Kaplan et al., 2005b).
Just as they have been linked to numerous signalling pathways, cannabinoids 
have also been shown to affect a number of different immune cell functions, such 
as migration and proliferation. Several studies have suggested that 2-AG acts as 
a chemoattractant for immune cells including the HL-60 cell line which had been 
differentiated into macrophage-like cells (Kishimoto et al., 2003), CB2R- 
expressing myeloid precursor cells (Jorda et al., 2003), B lymphocytes (Jorda et 
al'., 2002, Rayman et al., 2004) and eosinophils (Oka et al., 2004). However, the 
response appears to be cell-type and cannabinoid-specific as other cannabinoids, 
including AEA, have been shown to have no effect on basal cell migration in 
some studies (Kishimoto et al., 2003, Joseph et a l, 2004, Oka et al., 2004).
Cannabinoids have been shown to both enhance and suppress immune cell 
numbers. For instance, A9-THC has been reported to suppress mitogen-induced 
proliferation of murine splencoytes in vitro (Pross et a l, 1990, Schatz et al, 
1993, McKallip et a l, 2002a) and human T lymphocyte proliferation induced by 
allogeneic dendritic cells (Yuan et a l, 2002). However, some studies have also 
shown that cannabinoids can increase proliferation of immune cells (Derocq et 
al, 1995, Derocq et a l, 1998, Valk et a l, 1997). In particular, one study 
demonstrated that whilst high concentrations of A9-THC inhibited mitogen-
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induced proliferation of human peripheral blood lymphocytes, low 
concentrations increased it, suggesting that cannabinoid effects on lymphocyte 
proliferation may be concentration-dependent (Luo et al., 1992).
The main aim of this part of the study was to explore the effects of cannabinoids 
on migration and proliferation of activated T lymphocytes. In conjunction with 
this the effects of cannabinoids on ERK phosphorylation and cAMP production 
were first examined to determine whether cannabinoids activated intracellular 
signalling pathways downstream of the cannabinoid receptors. Day 5 SEB- 
activated PBLs were the main cell type used in this section of the study as it was 
shown in Results I  that this is when CB2R expression peaks. Some experiments 
were also repeated in day 11-12 SEB-activated PBLs in order to investigate 
whether the decrease in CB2R protein expression detected was reflected in any 
changes in functional effects of the cannabinoids. Some experiments were also 
carried out using the leukaemic T lymphocyte cell line Jurkats in order to 
corroborate data generated using the PBLs.
4.2 Cannabinoid-induced activation of signalling pathways in T 
lymphocytes
4.2.1 Effects of AEA, 2-AG and JWH-133 on ERK1/2
phosphorylation in T lymphocytes
Having established, in the first part of this study, that day 5 SEB-activated PBLs 
express the CB2R and a modified form of the CBiR it was necessary to establish 
whether the cannabinoids coupled to biochemical pathways in these cells, and if 
so whether the receptors were involved, before investigating the functional 
effects of cannabinoids in these cells. The rapid phosphorylation and activation 
of the ERK 1/2 MAPKs has been documented to lie downstream of the 
cannabinoid receptors in several different cell types (Bouaboula et al., 1995b, 
Bouaboula et a l , 1996, Galve-Roperh et al., 2002, Derkinderen et al., 2003, 
Samson et al., 2003) and thus seemed an appropriate signal to study. In addition, 
ERK has been reported to be involved in migration (Klemke et al., 1997, Huang 
et al., 2004) and proliferation (Stork & Schmitt, 2002) and thus this pathway was
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chosen as there was the possibility that its involvement in cannabinoid-mediated 
effects on PBL migration and proliferation could be investigated if any responses 
were detected. ERK 1/2 are activated by the upstream kinase MEK via 
phosphorylation in the activation loop (Kolch, 2000) and detecting this 
phosphorylation represents an indirect way of determining ERK 1/2 activation. 
PMA was used as a positive control for ERK 1/2 phosphorylation in most of the 
experiments as it is well established as a robust activator of ERK 1/2 (Brose & 
Rosenmund, 2002, Moelling et a l , 2002).
Day 5 and 12 PBLs and Jurkats were stimulated with the non-CBiR/CB2R 
selective agonists AEA and 2-AG. The reported Ki values of AEA for the CBiR 
and CB2R are 89nM and 371nM respectively, revealing a slight preference for 
CBiR at lower concentrations (Howlett et al., 2002). Similarly, the Ki values 
for 2AG are 472nM and 1400nM (Howlett et a l , 2002). These two cannabinoids 
were chosen to be used in this study because of their physiological relevance as 
endocannabinoids. In addition, 2-AG would later also be used in the functional 
studies. Stimulation of all three cell types with AEA at concentrations unlikely 
to discriminate between the CBiR and CB2R, resulted in a transient increase in 
ERK1/2 phosphorylation above basal (Fig. 4.1). This response was 
concentration-dependent, with maximal phosphorylation elicited by lOpM of 
AEA. As full concentration response curves were not carried out it is not 
possible to determine E C 5 0  values in each of the cell types but the curves in Fig. 
4AD show that AEA appears to be more potent in Jurkats compared to PBLs. 2- 
AG also elicited concentration-dependent increases in ERK phosphorylation in 
all three cell types (Fig. 4.2).
A CB2R-selective synthetic agonist, JWH-133 was also used. The reported Ki is 
3.4nM at the human CB2R expressed in HEK293 cells (compared to 677nM for 
the CBiR expressed in rat brain; Howlett et al, 2002). JWH-133 also stimulated 
ERK1/2 phosphorylation in day 5 and 12 PBLs and Jurkats in a concentration- 
dependent and transient manner (Fig. 4.3). Again, although E C 5 0  values could 
not be calculated, the curves in Fig. 43D  show that JWH-133 appears to be more 
potent in Jurkats compared to PBLs. This data suggests that the CB2R expressed 
in day 5 PBLs is indeed active and coupled to downstream effectors. That all
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three cannabinoids tested induced concentration-dependent increases in ERK1/2 
phosphorylation in the day 12 PBLs (Fig. 4.11?, 4.25 and 4.35), when CB2R 
expression is severly downregulated but the modified CBiR is still expressed, 
suggests that either enough CB2R is still expressed to signal to downstream 
effectors or that the modified CBiR is a functional receptor.
The ability of AEA and 2-AG to induce ERK 1/2 phosphorylation in naive human 
T lymhocytes was also briefly investigated. In the first part of this study no 
CB2R protein and only the modified form of the CBiR was detected in these 
cells. Preliminary evidence suggests that neither AEA nor 2-AG stimulated 
ERK1/2 phosphorylation, even at 10pM (Fig. 4.4). However, PMA stimulated a 
robust and easily detectable increase in levels of phosphorylated ERK1/2 (Fig. 
4.4). Another kinase which has been shown to be activated downstream of the 
cannabinoid receptors is PKB (Gomez et al., 2000, Galve-Roperh et al., 2002, 
Molina-Holgado et al., 2002, Sanchez et al., 2003). Phosphorylation at Ser473 is 
an important step in PKB activation and thus can be used as an indirect measure 
of its activation status (Vanhaesebroeck & Alessi, 2000, Song et al., 2005). 
Phosphorylation was not stimulated in the nai've T lymphocytes by either AEA or 
2-AG (Fig. 4.4). To verify that this phosphorylated form of PKB could be 
detected by immunoblotting a sample of unstimulated Jurkats, which are known 
to constitutively express high levels of phosphorylated PKB (Astoul et al., 2001), 
were also resolved on the gel and were detected. These results suggest that the 
modified CBjR expressed in these cells may not be functional.
AEA and 2-AG are normally rapidly taken up by cells and inactivated. Several 
enzymes can degrade the endocannabinoids. For example, FAAH hydrolyses 
both AEA and 2-AG and MAGL metabolises 2-AG (Goparaju et al., 1998, 
Cravatt & Lichtman, 2002, Dinh et al., 2002). Both of these enzymes were 
shown to be expressed in PBLs and Jurkats in Results I. Therefore, it was 
investigated whether degradation of AEA and 2-AG affects their ability to 
stimulate ERK 1/2 phosphorylation. The potent FAAH and MAGL inhibitor 
MAFP, which has a reported I C 5 0  of l-3nM, was used for this (De Petrocellis et 
al, 1997, Goparaju et al., 1999, Saario et al., 2004).
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Preliminary evidence from experiments carried out on day 12 PBLs and Jurkats 
(Fig. 4.5) showed that pre-treating cells with MAFP (lpM) nearly abolished the 
increase in ERK 1/2 phosphorylation induced by various concentrations of AEA 
and 2-AG completely. This suggested that the responses detected were actually 
due to AEA and 2-AG metabolites, rather than the endocannabinoids themselves, 
as preventing this degradation attenuated the responses. These experiments were 
then repeated using day 5 PBLs as these cells were used for the majority of other 
experiments. MAFP treatment of the cells alone caused a slight increase in 
ERK 1/2 phosphorylation at 2 minutes but had no effect by 10 minutes, the length 
of time of pre-treatment (Fig. 4.6^4). A decrease in ERK1/2 phosphorylation 
was detected when day 5 PBLs were pre-treated with MAFP (lpM) and then 
stimulated with AEA (Fig. 4.62?). This was consistent with the effects detected 
in day 12 PBLs and Jurkats. However, this response was not concentration- 
dependent and was mimicked when cells were pre-treated with the vehicle 
equivalent of MAFP (ethanol, final concentration 0.076%; Fig. 4.6C). 
Furthermore, MAFP also affected the ERK 1/2 phosphorylation stimulated by 
JWH-133, a synthetic, stable cannabinoid (Fig. 4.5C). This data indicates that 
the decrease in ERK 1/2 phosphorylation is not due to pre-treatment of the cells 
with MAFP and suggests that the responses are in fact mediated by 2-AG and 
AEA rather than breakdown products.
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Figure 4.1: AEA stimulates phosphorylation of ERK1/2 in PBLs and Jurkats. Day 5
(A) and day 12 (B) SEB-activated PBLs and Jurkats (C) were stimulated with various 
concentrations of AEA (as indicated) for 2 minutes or 10pM AEA for various times (as 
indicated). Cells were subsequently lysed as  described in Materials and Methods and 
WCLs (3.2x106 cells per lane for PBLs, 1.6x106 cells per lane for Jurkats) resolved by 
SDS-PAGE gel, transferred to nitrocellulose membranes, and immunoblotted with a 
phospho-specific ERK antibody with affinity for the active Thr202/Tyr204-phosphorylated 
form of ERK, and protein was visualised with ECL. The blots were stripped and 
reprobed with pan ERK or pan PKB antibody to verify equal loading and efficiency of 
protein transfer. Vehicle controls were also carried out (V, 2 minute stimulation with 
ethanol equivalent to 10pM AEA). Unstimulated cells (control, C) were also lysed to 
ascertain basal levels of ERK phosphorylation and PMA (100nM, 5 min) was used a 
positive control for ERK stimulation. Data are representative of 3 separate experiments. 
D) Optical densitometry was carried out on the blots and values expressed a s  fold 
change over vehicle. Data are depicted a s  mean ±S.E.M and are derived from 3 
individual experiments.
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Figure 4.2: 2-AG stimulates phosphorylation of ERK1/2 in PBLs and Jurkats. Day
5 (A) and day 12 (B) SEB-activated PBLs and Jurkats (C) were stimulated with various 
concentrations of 2-AG (as indicated) for 2 minutes or 10pM 2-AG for various times (as 
indicated). Cells were subsequently lysed as  described in Materials and Methods and 
WCLs (3.2x106 cells per lane for PBLs, 1.6x106 cells per lane for Jurkats) resolved by 
SDS-PAGE gel, transferred to nitrocellulose membranes, and immunoblotted with a 
phospho-specific ERK antibody with affinity for the active Thr202/Tyr204-phosphorylated 
form of ERK, and protein was visualised with ECL. The blots were stripped and 
reprobed with pan ERK or pan PKB antibody to verify equal loading and efficiency of 
protein transfer. Vehicle controls were also carried out (V, 2 minute stimulation with 
ethanol equivalent to 10pM 2-AG). Unstimulated cells (control, C) were also lysed to 
ascertain basal levels of ERK phosphorylation and PMA (100nM, 5 min) was used a 
positive control for ERK stimulation. Data are representative of 3 separate experiments. 
D) Optical densitometry was carried out on the blots and values expressed as  fold 
change over vehicle. Data are depicted a s  mean ±S.E.M and are derived from 3 
individual experiments.
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Figure 4.3: JWH-133 stimulates phosphorylation of ERK1/2 in PBLs and Jurkats.
Day 5 (A) and day 12 (B) SEB-activated PBLs and Jurkats (C) were stimulated with 
various concentrations of JWH-133 (as indicated) for 2 minutes or 100nM JWH-133 for 
various times (as indicated). Cells were subsequently lysed as  described in Materials 
and Methods and WCLs (3.2x106 cells per lane for PBLs, 1.6x10® cells per lane for 
Jurkats) resolved by SDS-PAGE gel, transferred to nitrocellulose membranes, and 
immunoblotted with a phospho-specific ERK antibody with affinity for the active 
Thr202/Tyr204-phosphorylated form of ERK, and protein was visualised with ECL. The 
blots were stripped and reprobed with pan ERK or pan PKB antibody to verify equal 
loading and efficiency of protein transfer. Vehicle controls were also carried out (V, 2 
minute stimulation with ethanol equivalent to 100nM JWH-133). Unstimulated cells 
(control, C) were also lysed to ascertain basal levels of ERK phosphorylation and PMA 
(100nM, 5 min) was used a positive control for ERK stimulation. Data are representative 
of 2 (A), 1 (B) or 3 (C) separate experiments. D) Optical densitometry was carried out 
on the blots and values expressed a s  fold change over vehicle. Data are depicted as 
mean ±S.E.M and are derived from 2 (day 5 PBLs), 1 (day 12 PBLs) or 3 (Jurkats) 
individual experiments.
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Figure 4.4: AEA and 2-AG do not stimulate ERK1/2 or PKB phosphorylation in 
naive human T lymphocytes. Naive T lymphocytes were isolated and purified as 
described in Materials and Methods. Cells were stimulated with 0.1-10pM AEA or 2-AG 
or vehicle (V, ethanol equivalent to 10pM AEA/2-AG) for 2 minutes and lysed. WCLs 
(3.2x106 cells per lane) were resolved by SDS-PAGE gel, transferred to nitrocellulose 
membranes, and immunoblotted with a phospho-specific ERK antibody with affinity for 
the active Thr202/Tyr204-phosphorylated form of ERK or a phospho-specific PKB 
antibody with affinity for the Ser473 phosphorylated form of PKB, and visualised with 
ECL. One of the blots was stripped and reprobed with pan PKB antibody to verify equal 
loading and efficiency of protein transfer. Unstimulated cells (control, C) were also lysed 
to ascertain basal levels of phosphorylated ERK and PKB and PMA (100nM, 5 min) was 
used as a positive control for ERK stimulation. A Jurkat WCL (1.6x106cells) was loaded 
as  a positive control for phospho-PKB blotting. X indicates empty lanes. Data is 
representative of a single experiment.
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Figure 4.5: Preliminary evidence suggesting that the ERK1/2 responses induced by 
AEA and 2-AG are sensitive to MAFP pre-treatment. Day 12 SEB-activated PBLs (A) 
and Jurkats (B) with and without MAFP pre-treatment (1pM, 10 minutes) were stimulated 
for 2 minutes with AEA or 2-AG (0.1-10pM) and lysed as  described in Materials and 
Methods. WCLs (3.2x106 cells per lane for PBLs, 1.6x106 cells per lane for Jurkats) 
were resolved by SDS-PAGE gel, transferred to nitrocellulose membranes, and 
immunoblotted with a phospho-specific ERK antibody with affinity for the active, 
Thr202/Tyr204-phosphorylated form of ERK, and protein visualised with ECL. The blots 
were stripped and reprobed with a pan ERK antibody to verify equal loading and 
efficiency of protein transfer. Vehicle controls were also carried out (V1= ethanol 
equivalent to 10pM AEA for 2 minutes, V2= ethanol equivalent of 1pM MAFP for 10 
minutes) and CXCL12 (CXC, 10nM, 2 minutes) was used a s  a positive control for ERK 
phosphorylation. Data are representative of 2 separate experiments.
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Figure 4.6: ERK1/2 responses to AEA in day 5 PBLs are insensitive to MAFP pre­
treatment. Day 5 SEB-activated PBLs were treated a s  follows: A) cells were stimulated 
with MAFP for 10 minutes (0.001-1 pM) or with 1pM for various times as indicated. B) 
cells with and without MAFP pre-treatment (0.001-1 pM, 10 minutes) were stimulated 
with 10pM AEA for 2 minutes. C) cells were pre-treated either with 1pM MAFP (top blot) 
or the equivalent concentration of ethanol (vehicle, bottom blot) for 1 0  minutes and then 
stimulated with various concentrations of AEA or JWH-133 for 2 minutes. Cells were 
then lysed as  described in Materials and Methods and WCLs (3.2x106 cells per lane) 
were resolved by SDS-PAGE gel, transferred to nitrocellulose membranes, and 
immunoblotted with a phospho-specific ERK antibody with affinity for the active 
Thr202/Tyr204-phosphorylated form of ERK, and protein visualised with ECL. The blots 
were stripped and reprobed with either pan PKB or ERK antibody to verify equal loading 
and efficiency of protein transfer. Vehicle controls were also carried out (V1= ethanol 
equivalent 1pM MAFP for 10 minutes, V2= ethanol equivalent to 10pM AEA for 2 
minutes, V3= ethanol equivalent to 100nM JWH-133 for 2 minutes). Unstimulated cells 
(control, C) were also lysed to ascertain basal levels of ERK phosphorylation and PMA 
(100nM, 5 min) was used as a positive control for ERK stimulation. Data are 
representative of 3 separate experiments.
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4.2.2 The role of the cannabinoid receptors in cannabinoid-
induced ERK1/2 phosphorylation
Cannabinoid receptor-dependent, as well as independent ERK activation by 
cannabinoids has been described (Bouaboula et al., 1995b, Derocq et a l , 1998, 
Liu et a l , 2000, Berdyshev et al., 2001, Galve-Roperh et al., 2002), therefore it 
was important to verity whether the ERK 1/2 phosphorylation induced by the 
cannabinoids in this study was receptor mediated. Both of the cannabinoid 
receptors are GPCRs that couple to Gi/o-proteins (Matsuda et al., 1990, 
Bayewitch et al., 1995). The Gai/o-protein inhibitor pertussis toxin (PTX) was 
used to examine the role of the receptors in signalling. AEA and 2-AG-induced 
ERK 1/2 phosphorylation in day 5 and day 12 PBLs was completely abrogated by 
PTX pre-treatment (Fig. 4.7A and B), consistent with a role for the receptors in 
this response. However, in Jurkats, PTX pre-treatment did not completely 
abolish the ERK1/2 response (Fig. 4.7Q, suggesting that in Jurkats there may be 
an additional receptor-independent component. It was also confirmed, using 5 
PBLs, that PTX pre-treatment did not affect receptor protein expression (Fig. 
4.7D). CXCL12-induced ERK1/2 phosphorylation has previously been shown to 
be PTX-sensitive (Sotsios et al., 1999) and hence this chemokine was used to 
verify that PTX was active.
As day 5 SEB-activated PBLs express not only the CB2R but also an 83kD form 
of the CBiR, which may or may not be functional, two receptor antagonists were 
used to investigate the role of each receptor in cannabinoid-induced ERK 1/2 
phosphorylation. AM251 is a CBiR-selective antagonist, with a reported Ki of 
7.5nM and 2290nM at the CBiR and CB2R, respectively (Palmer et a l, 2002). 
AM630 is a CB2R-selective antagonist with a reported Ki of 31.2nM at the CB2R 
(compared to 5152nM for the CBjR; Palmer et a l, 2002). Day 5 PBLs were pre­
treated with the inhibitors prior being stimulated with AEA, 2-AG or JWH-133. 
AM251 inhibited the AEA and JWH-133 responses, as did vehicle control 
(0.00008% ethanol; Fig. 4.8). The 2-AG response was less affected by AM251 
pre-treatment but again vehicle control also inhibited the response. Likewise, 
although AM630 inhibited AEA, 2-AG and JWH-133-induced ERK 1/2
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phosphorylation, this effect was mimicked by the vehicle control (0.004% 
DMSO). At this time it is unclear why the vehicle controls had these effects but 
it means that conclusions about which receptor is activated by these cannabinoids 
cannot be drawn from these experiments.
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Figure 4.7: AEA and 2-AG-induced ERK1/2 phosphorylation is PTX-sensitive. Day
5 (A, D) and day 12 (B) SEB-activated PBLs and Jurkats (C) were incubated for 16 
hours with 1 0 0 ng/ml of PTX (+) or 50% glycerol as  a control (-) at 37°C in an 
atm osphere of 5% C 0 2. A-C) cells were then stimulated with either AEA (10pM), 2-AG 
(10pM) or JWH-133 (JWH, 100nM) for 2 minutes and subsequently lysed (A-C) as 
described in Materials and Methods and WCLs (3.2x106 cells per lane for PBLs, 1.6x106 
cells per lane for Jurkats) resolved by SDS-PAGE gel, transferred to nitrocellulose 
m em branes and immunoblotted with a phospho-specific ERK antibody with affinity for 
the active Thr202/Tyr204-phosphorylated form of ERK, and protein was visualised with 
ECL. The blots were stripped and reprobed with pan PKB antibody to verify equal 
loading and efficiency of protein transfer. Vehicle controls were also carried out by 
stimulating cells with ethanol equivalent to 10pM AEA/2-AG (V1). CXCL12 (CXC) a 
chemokine that also couples to ERK via Gi/o proteins was used to verify that PTX was 
active (V2=vehicle control for CXCL12) in (A) and (B). Unstimulated cells (control, C) 
with and without PTX pre-treatment were also lysed to verify the effect of PTX on basal 
ERK phosphorylation and PMA (100nM, 5 min) was used as a positive control for ERK 
phosphorylation in (C). D) cells were lysed and Cayman Chemicals antibodies were 
used to verify that PTX pre-treatment had no effect on receptor expression. HT-29 and 
Jurkat WCLs were used as positive controls for CBtR and CB2R expression 
respectively. Data are representative of three separate experiments.
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Figure 4 8 : The effects of the inhibitors AM251 and AM630 on cannabinoid-
induced ERK1/2 phosphorylation are mimicked by vehicle controls. Day 5 SEB- 
activated PBLs with and without AM251 (10nM) or AM630 (50nM) pre-treatment (10 
minutes) were stimulated for 2 minutes with AEA (10pM), 2-AG (10pM) or JWH-133 
(100nM) and subsequently lysed as described in Materials and Methods. WCLs 
(3.2x10 cells per lane for PBLs, 1.6x10® cells per lane for Jurkats) were resolved by 
SDS-PAGE gel, transferred to nitrocellulose membranes, and immunoblotted with a 
phospho-specific ERK antibody with affinity for the active, Thr202/Tyr204- 
phosphorylated form of ERK, and protein visualised with ECL. The blots were stripped 
and reprobed with a pan PKB antibody to verify equal loading and efficiency of protein 
transfer. Vehicle controls were also carried out (V1= ethanol equivalent to cannabinoid, 
V2= ethanol equivalent of 10nM AM251 for 10 minutes, V3= DMSO equivalent of 50nM 
AM630 for 10 minutes) and PMA (100nM, 5 minutes) was used as  a positive control for 
ERK phosphorylation. Data are representative of three separate experiments.
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4.2.3 Pathways coupling cannabinoids to ERK1/2
phosphorylation in T lymphocytes
A number of pathways have been described to link GPCRs to ERK activation 
(Marinissen & Gutkind, 2001, Werry et al., 2005) and several proteins have been 
shown to specifically link cannabinoids to ERK activation (Bouaboula et a l, 
1996, Sanchez et al., 1998, Liu et a l, 2000, Galve-Roperh et a l, 2002, Davis et 
a l, 2003, Derkinderen et a l, 2003, Samson et a l, 2003) as discussed in the 
Introduction. Therefore, a selection of inhibitors was used to determine some of 
kinases that lie upstream of cannabinoid-induced ERK 1/2 phosphorylation in day 
5 PBLs. MEK is the dual specificity kinase that activates ERK 1/2 via 
phosphorylation of a Thr-Glu-Tyr-motif in the activation loop (Kolch, 2000). 
The MEK1 inhibitor PD98059 (Alessi et a l, 1995) was used and attenuated 
AEA-induced increases in ERK1/2 phosphorylation in a concentration-dependent 
manner in day 5 PBLs (Fig. 4.9A). ERK1/2 phosphorylation was almost 
completely abolished at 20pM PD98059. The PD98059 compound was also 
tested on CXCL12-induced ERK 1/2 phosphorylation to verify that it was active 
(Fig. 4.9A). Thus, AEA-induced ERK1/2 phosphorylation is MEK-dependent in 
day 5 PBLs. Similarly AEA, 2-AG and JWH-133-dependent ERK 1/2 
phosphorylation in Jurkats was also abolished by PD98059 pre-treatment (Fig. 
4.10).
PKC is one of the many signalling molecules that has been shown to couple 
GPCRs to ERK1/2 activation. It has also been reported to lie upstream of 
cannabinoid-induced ERK phosphorylation in CB2R-transfected CHO cells and 
ECV304 human umbilical vein endothelial cells (Bouaboula et a l, 1996, Liu et 
al, 2000). In the current study several PKC inhibitors were used to investigate 
whether PKC lies upstream of AEA-induced ERK phosphorylation in day 5 
PBLs. Ro-32-0432 displays some selectivity for certain isoforms at nanomolar 
concentrations but at the micromolar concentrations used here serves as a general 
PKC inhibitor (Wilkinson et a l, 1993; for details on the I C 5 0 S  of all the PKC 
inhibitors used at the individual isoforms please refer to Appendices). AEA- 
induced ERK1/2 phosphorylation was completely abolished by 30pM Ro-32-
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0432 (Fig. 4.95), indicating that the response is PKC-dependent. ERK1/2 
phosphorylation was also inhibited by the PKC8 inhibitor rottlerin (Gschwendt et 
al., 1994), but not the PKCa and pi selective inhibitor G66976 (Martiny-Baron et 
al., 1993), suggesting that AEA selectively activates certain PKC isoforms (Fig. 
4.9Q.
The role of PI3K in cannabinoid-induced ERK1/2 phosphorylation in Jurkats was 
also examined using the non-selective PI3K inhibitor LY294002 (Ward et al., 
2003) as PI3K has been shown to be involved in cannabinoid-induced ERK 
activation in some studies (Bouaboula et al., 1997, Galve-Roperh et a l, 2002, 
Samson et al., 2003, Sanchez et al., 2003). At IOjiM LY294002 completely 
prevented AEA, but not 2-AG, induced ERK 1/2 phosphorylation (Fig. 4.10), 
indicating that this response is at least partly PI3K-dependent in Jurkats but that 
there may be agonist-specific differences.
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Figure 4.9: AEA-induced ERK1/2 phosphorylation in day 5 PBLs is MEK and PKC- 
dependent. Day 5 SEB-activated PBLs were pre-treated with either PD98059 (PD, A) 
for 1 hour, Ro-32-0432 (RO, B) for 10 minutes, Go6976 (Gb, C) for 30 minutes or 
Rottlerin (Rott, C) for 30 minutes at the various concentrations indicated and then 
stimulated with AEA (10pM), vehicle (V, ethanol equivalent to 10pM AEA) or CXCL12 
(CXC, 10nM) for 2 minutes. Sam ples were subsequently lysed as  described in Materials 
and Methods and WCLs (3.2x106 cells per lane) resolved by SDS-PAGE gel, transferred 
to nitrocellulose membranes, and immunoblotted with a phospho-specific ERK antibody 
with affinity for the active Thr202/Tyr204-phosphorylated form of ERK, and protein was 
visualised with ECL. The blots were stripped and reprobed with pan PKB or pan ERK 
antibody to verify equal loading and efficiency of protein transfer. Unstimulated cells 
(control, C) were also lysed to ascertain basal levels of ERK phosphorylation. In certain 
cases  PMA (100nM, 5 min) was used a positive control for ERK stimulation. Data are 
representative of three separate experiments.
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Figure 4.10: Cannabinoid stimulated ERK1/2 phosphorylation in Jurkats is MEK 
and PI3K-dependent. Jurkats were pre-treated with either PD98059 (PD, 20pM) for 1 
hour or LY294002 (LY, 10pM) for 30 minutes and then stimulated with AEA (10pM), 2- 
AG (10pM) or JWH-133 (100nM) for 2 minutes. Sam ples were then subsequently lysed 
as  described in Materials and Methods and WCLs (3.2x106 cells per lane) resolved by 
SDS-PAGE gel, transferred to nitrocellulose membranes, and immunoblotted with a 
phospho-specific ERK antibody with affinity for the active Thr202/Tyr204-phosphorylated 
form of ERK, and protein was visualised with ECL. The blots were stripped and 
reprobed with pan PKB or pan ERK antibody to verify equal loading and efficiency of 
protein transfer. Unstimulated cells (control, C) were also lysed to ascertain basal levels 
of ERK phosphorylation and PMA (100nM, 5 min) was used a positive control for ERK 
stimulation. CXCL12 (CXC, 10nM) was used to verify that PD98059 was active. 
Vehicle controls were also carried out ( V1= vehicle control for CXCL12; V2= ethanol 
equivalent to 10pM AEA/2-AG). Data are representative of three separate experiments.
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4.2.4 Modulation of cAMP pathways by cannabinoids in PBLs
As well as activating ERK, cannabinoids have been shown to affect a number of 
other signalling pathways, including the production of cAMP. Generally 
cannabinoids suppress forskolin-induced cAMP production (Pertwee, 1997, 
Kaminski, 1998, Howlett et al., 2002, Demuth & Molleman, 2006) but they have 
also been shown to increase forskolin-induced (Glass & Felder, 1997, Felder et 
al., 1998) and basal (Maneuf & Brotchie, 1997, Steffens et al., 2005a) cAMP 
production. Preliminary data shows that neither JWH-133 nor 2-AG affected 
basal production of cAMP in day 5 SEB-activated PBLs, although forskolin, a 
known AC stimulator (Sunahara & Taussig, 2002), induced a robust increase in 
intracellular cAMP levels (Fig. 4.1L4). However, 2-AG significantly increased 
forskolin-induced cAMP production (Fig. 4.115). The CB2R-selective agonist, 
JWH-133, did not mimic this effect (Fig. 4.115).
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Figure 4 11: 2-AG modulates the production of cAMP in day 5 PBLs. Day 5 SEB- 
activated PBLs (2x106/sample) were treated as  follows: A) with JWH-133 (JWH, 
100nM), 2-AG (10pM) or vehicle (V1, ethanol equivalent to 10pM 2-AG) for 10 minutes 
or forskolin (FSK, 25pM) or vehicle (V2, ethanol equivalent to 2 5 | j M  forskolin) for 15 
minutes B) with JWH-133 (100nM), 2-AG (10pM) or vehicle (ethanol equivalent to 1 0 |j M  
2-AG) for 10 minutes and then stimulated with forskolin (25pM) for 15 minutes. Cells 
were then lysed in 0.1N HCI/0.2% triton and intracellular cAMP levels were determined 
using a cAMP ELISA kit a s  described in Materials and Methods. Data are depicted as 
mean ±range and are derived from a single experiment (n=2). Data was analysed by 
ANOVA with Bonferroni correction (*, p<0.05 compared to forskolin; **, p<0.001 
compared to control).
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4.3 Cannabinoid-induced modulation of T lymphocyte 
migration
4.3.1 2-AG and JWH-133 do not induce chemotaxis in T 
lymphocytes
One of the functions of cannabinoids in the immune system is to modulate cell 
migration. For instance, during the course of this study, it was published that 
although AEA did not act as a chemoattractant for naive CD8+ T lymphocytes, it 
inhibited their migration to the chemokine CXCL12 and this was suggested to be 
a CB2R-mediated effect (Joseph et al., 2004). However, many of the studies on 
migration were carried in rat or murine cells or transformed cell lines and may 
not accurately represent what happens in normal human cells. Therefore, day 5 
SEB-activated PBLs were used to explore the effect of 2-AG on activated T 
lymphocytes. The effects of 2-AG on migration of day 12 cells was also studied 
in order to determine whether they respond differently given that CB2R 
expression is reduced compared to day 5 PBLs. A modified Boyden chamber 
system was used to investigate chemotaxis. In this assay, the ligand in question, 
for instance 2-AG, is placed in the lower chamber of the apparatus and a 
membrane placed on top. The cells are then placed in wells in the upper chamber 
of the apparatus and allowed to migrate. At the end of the assay the number of 
cells that have migrated are determined.
Before examining whether cannabinoids act as chemoattractants for activated T 
lymphocytes it was necessary to establish that the PBLs are capable of 
responding to chemotactic stimuli. The stimulus chosen as a positive control was 
CXCL12. CXCL12 is a chemokine that acts through the CXCR4 receptor, 
although it has recently also been shown to bind the orphan receptor RDC1 
(Balabanian et al., 2005). It has been well established to induce chemotaxis of T 
lymphocytes (Sotsios et a l, 1999) and both CXCR4 and RDC1 have been shown 
to be involved (Balabanian et a l, 2005). The ability of CXCL12 to couple to 
intracellular signalling pathways was first verified to establish that it was active. 
CXCL12 induced both a time and concentration-dependent increase in ERK 1/2 
and PKBSer473 phosphorylation in day 5 and 12 SEB-activated PBLs. CXCL12
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also induced robust, concentration-dependent, chemotaxis of day 5 and day 12 
PBLs (Fig. 4.12) as measured using the chemotactic index. This is the ratio of 
cells migrating towards the ligand versus cells randomly migrating across the 
membrane. An index of 1 indicates basal migration.
Although the cells were capable of migrating, as indicated by their ability to 
chemotax in response to CXCL12, 2-AG did not induce chemotaxis in day 5 or 
day 12 PBLs (Fig. 4.13). The CB2R-selective agonist, JWH-133 was also tested. 
Like 2-AG, JWH-133 did not induce migration of either day 5 or day 12 PBLs 
(Fig. 4.13). These results were somewhat unexpected as 2-AG has been shown 
to induce migration in several different cell types (Jorda et a l , 2002, Jorda et a l , 
2003, Kishimoto et a l , 2003, Oka et a l , 2004, Rayman et a l , 2004). Therefore, 
these experiments were repeated in Jurkats and CEMs in order to investigate 
whether the inability of 2-AG and JWH-133 to elicit chemotaxis was specific to 
primary T lymphocytes. Neither 2-AG nor JWH-133 induced chemotaxis in 
Jurkats or CEMs (Fig. 4.14). Again CXCL12 was used as a positive control to 
verify that the cells were able to migrate and it indeed stimulated robust 
chemotaxis (Fig. 4.14). Notably, there was some difference in the extent of 
chemotaxis elicited by CXCL12 in the two sets of Jurkat experiments (Fig. 
AAA A). This is likely to reflect two different batches of Jurkats being used at 
different times in the study which respond slightly differently to the CXCL12. 
This data suggests that 2-AG does not induce migration of T lymphocytes, 
contrary to data in other cell types.
One of the key steps in cell migration is the polymerisation of actin (Ridley et 
a l , 2003). One way to measure the production of polymerised, F-actin, in cells 
is to label it with fluorescently tagged phalloidin. This assay involves labelling 
stimulated, permeabilised cells with FITC-conjugated phalloidin and detecting 
the fluorescence using flow cytometry. CXCL12 was used as a positive control 
to verify that changes in F-actin content in the cells could be detected using this 
method. CXCL12 (lOnM) stimulated an increase in F-actin content in both day 5 
and day 12 PBLs at 60 seconds as previously reported (Fig. 4.15; Bleul et a l , 
1996, Sotsios et al., 1999). This is consistent with its ability to stimulate 
migration. Neither 2-AG nor JWH-133 stimulated increases in F-actin levels
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above vehicle control in day 5 or day 12 PBLs (Figs. 4.16-17). This correlates 
well with the finding that they do not act as chemoattractants in these cells.
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Figure 4.12: CXCL12 is coupled to intracellular signalling pathways and induces 
chemotaxis of PBLs. Day 5 (A) and day 12 (B) SEB-activated PBLs were stimulated 
with CXCL12 for either 2 minutes at various concentrations or with 10nM for different 
lengths of time and cells lysed a s  described in Materials and Methods. Vehicle controls 
were also carried out (V, 2 minute stimulation with medium). WCLs (3.2x106 cells per 
lane) were resolved by SDS-PAGE gel, transferred to nitrocellulose membranes, and 
immunoblotted with a phospho-specific ERK antibody with affinity for the active 
Thr202/Tyr204-phosphorylated form of ERK or a phospho-specific PKB antibody with 
affinity for the Ser473 phosphorylated form of PKB, and visualised with ECL. The blots 
were stripped and reprobed with pan PKB or pan ERK antibody to verify equal loading 
and efficiency of protein transfer. Unstimulated cells (control, C) were also lysed to 
ascertain basal levels of ERK phosphorylation and PMA (100nM, 5 min) was used a 
positive control. Data are representative of three separate experiments. Cells 
(2x105/200pl) were also added to the upper cham bers of a 96-well chemotaxis plate, 
above lower cham bers containing CXCL12 (0.1-10nM). Chemotaxis across a 5pm pore 
size membrane was determined after 3 hours as described in Materials and Methods. 
Data are depicted as mean ±S.E.M (n=3). Data was analysed by ANOVA with 
Bonferroni correction. The red horizontal line at a chemotactic index of 1 represents 
basal migration and has been included for ea se  of comparison.
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Figure 4.13: Neither 2-AG nor JWH-133 induces chemotaxis in activated PBLs. Day
5 (A) and day 12 (B) SEB-activated PBLs (2x105/200pl) were added to the upper 
cham bers of a 96-well chemotaxis plate, above lower cham bers containing 2-AG (0.1- 
10pM), JWH-133 (0.001-10pM) or CXCL12 (CXC, 10nM). Chemotaxis across a 5pm 
pore size membrane was determined after 3 hours as described in Materials and 
Methods. Data are depicted as  mean ±S.E.M and are derived from three separate 
experiments (n=3). Data was analysed by ANOVA with Bonferroni correction (*, 
p<0.001 compared to basal migration). The red horizontal line at a chemotactic index of 
1 represents basal migration and has been included for ease  of comparison.
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Figure 4 14: Neither 2-AG nor JWH-133 induces chemotaxis in Jurkats or CEMs. A)
Jurkats (2x105/200pl) were added to the upper cham bers of a 96-well chemotaxis plate, 
above lower cham bers containing 2-AG (0.1-10pM), JWH-133 (0.001-10pM) or CXCL12 
(CXC, 10nM). Chemotaxis across a 5pm pore size m embrane was determined after 1.5 
hours as described in Materials and Methods. Data are depicted as  mean ±S.E.M and 
are derived from three separate experiments (n=3). B) CEMs (2x105/200pl) were added 
to the upper chamber of a 96-well chemotaxis plate, above lower cham bers containing 
2-AG (0.1-10pM), JWH-133 (0.001-10pM) or CXCL12 (CXC, 1nM). Chemotaxis across 
a 5pm pore size membrane was determined after 3 hours as  described in Materials and 
Methods. Data are depicted as mean ±S.E.M and are derived from two separate 
experiments (n=2). Data w as analysed by ANOVA with Bonferroni correction (*, 
p<0.001 compared to basal migration). The red horizontal line at a chemotactic index of 
1 represents basal migration and has been included for e a se  of comparison.
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Figure 4.15: CXCL12 induces robust increases in F-actin content in PBLs. 2x106 
day 5 (A) and day SEB-activated 12 (B) PBLs were stimulated with 10nM CXCL12 or 
vehicle (medium) for 60 seconds. The cells were then fixed and permeabilised as 
described in Materials and Methods and stained with FITC-conjugated phalloidin for 30 
minutes. Fluorescence was detected using flow cytometry and the median fluorescence 
intensity of each sample used in analysis. During each experiment sam ples of 
unstained and unstimulated (control) cells were also run through the flow cytometer to 
ascertain autofluorescence and basal levels of F-actin. Data are depicted as mean 
±S.E.M and are derived from nine separate experiments pooled together (n=9). Data 
was analysed by Student’s t test (*, p<0.001). Representative histograms are also 
shown.
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Figure 4.16: 2-AG does not induce actin polymerisation in PBLs. 2x106 day 5 (A)
and day 12 (B) SEB-activated PBLs were stimulated with varying concentrations (as 
indicated) of 2-AG for 30 seconds, with 2-AG (500nM or 5|jM) for 15-120 seconds or 
with vehicle (V, ethanol equivalent to 5pM 2-AG) for 30 seconds. The cells were then 
fixed and permeabilised a s  described in Materials and Methods and stained with FITC- 
conjugated phalloidin for 30 minutes. Fluorescence was detected using flow cytometry 
and the median fluorescence intensity of each sam ple used in analysis. During each 
experiment sam ples of unstained and unstimulated (control, C) cells were also run 
through the flow cytometer to ascertain autofluorescence and basal levels of F-actin. 
Data are depicted as  mean ±S.E.M and are derived from three separate experiments 
pooled together (n=3). Representative histograms are also shown.
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Figure 4.17: JWH-133 does not induce actin polymerisation in PBLs. 2x10 day 5 
{A) and day 12 (B) SEB-activated PBLs were stimulated with varying concentrations of 
JWH-133 for 30 seconds, with WH-133 (100nM) for 15 seconds-30 minutes or with 
vehicle (V, ethanol equivalent to 100nM JWH-133) for 30 seconds. The cells were then 
fixed and permeabilised as  described in Materials and Methods and stained with FITC- 
conjugated phalloidin for 30 minutes. Fluorescence was detected using flow cytometry 
and the median fluorescence intensity of each sample used in analysis. During each 
experiment sam ples of unstained and unstimulated (control, C) cells were also run 
through the flow cytometer to ascertain autofluorescence and basal levels of F-actin. 
Data are depicted as  mean ±S.E.M and are derived from three (A) or 4 (B) separate 
experiments pooled together (n=3 (A), 4 (B)). Representative histograms are also 
shown.
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4.3.2 2-AG and JWH-133 inhibit CXCL12-induced chemotaxis 
of PBLs
In addition to stimulating basal migration, cannabinoids have also been 
suggested to modulate ligand-induced migration in several leukocytes including 
rat and murine peritoneal macrophages (Sacerdote et a l , 2000, Steffens et a l , 
2005b) and naive human CD8+ T lymphocytes (Joseph et al., 2004). To examine 
whether 2-AG or JWH-133 could modulate ligand-induced migration of PBLs, 
cells were pre-treated with the cannabinoids and then allowed to migrate towards 
CXCL12. Both JWH-133 (lOOnM) and 2-AG (5pM) significantly inhibited 
CXCL12-induced migration of day 5 and day 12 PBLs (Fig. 4.18). The effect 
induced by 2-AG is concentration-dependent in day 5 PBLs, with maximal 
inhibition elicited by 5pM 2-AG (Fig. 4.19).
When CXCL12 is placed in both the upper and lower parts of the chemotaxis 
chamber, thereby removing the concentration gradient, migration is still 
increased above basal, indicating that CXCL12 not only induces directed cell 
migration (chemotaxis) but also increases random cell migration or motility 
(chemokinesis). Having established that 2-AG inhibits CXCL12-induced 
migration it was important to assess its relative effects on CXCL12-induced 
chemotaxis and chemokinesis. When medium alone was placed only in the 
lower section of the chamber and the cells in the upper chamber simply treated 
with vehicle, they exhibited some basal migration, with approximately 32,000 
cells migrating through the filter (Fig. 4.20). This basal migration was 
unaffected by any of the pre-treatments carried out on the cells (Fig. 4.20). 
Addition of CXCL12 to the lower chamber only, induced a robust chemotactic 
response as predicted (Fig. 4.20). When CXCL12 was placed in both the upper 
and lower chambers, an increased number of cells migrated to the bottom of the 
chamber compared to basal, unstimulated levels (Fig. 4.20). However, fewer 
numbers of cells migrated under such circumstances compared to addition of 
CXCL12 in the lower chamber alone. Hence, CXCL12 induces both 
chemokinesis and chemotaxis. When 2-AG was added to the upper chamber, it 
inhibited the CXCL12-induced chemotactic migration (CXCL12 in lower
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chamber only) but had no effect on the CXCL12-induced chemokinetic 
movement (CXCL12 in upper and lower chambers; Fig. 4.20).
It was next investigated whether 2-AG and JWH-133 were affecting CXCL12- 
induced chemotaxis at the level of actin polymerisation. Day 5 PBLs were pre­
treated with 2-AG, as in the chemotaxis assay, stimulated with CXCL12 and the 
F-actin content measured as before. Again, CXCL12 elicited a robust increase in 
F-actin content in the cells and this was indeed inhibited by pre-treating the cells 
with 2-AG (5pM), consistent with the finding that 2-AG inhibits CXCL12- 
induced migration. However, the same level of inhibition was also detected 
when the cells were pre-treated with vehicle (Fig. 4.21). Thus, the inhibition of 
CXCL12-stimulated actin polymerisation may be an artefact of the experiment 
and this set of experiments was not pursued further.
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Figure 4.18: 2-AG and JWH-133 inhibit CXCL12-induced chemotaxis in PBLs. Day
5 (A) and day 12 (B) SEB-activated PBLs (2x1 05/200|jI) incubated for 30 minutes at 
37°C with either 2-AG (5[jM), JWH-133 (100nM) or vehicle (ethanol) were added to the 
upper cham bers of a 96-well chemotaxis plate, above lower cham bers containing 
CXCL12 (0.1-10nM). Chemotaxis across a 5pm pore size membrane was determined 
after 3 hours a s  described in Materials and Methods. Data are depicted a s  mean 
±S.E.M. and are derived from a single experiment (n=4), representative of two others. 
Data was analysed by Student’s t test (*, p<0.05; **, p<0.01; ***, p<0.001). The red 
horizontal line at a chemotactic index of 1 represents basal migration and has been 
included for ea se  of comparison.
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Figure 4.19: 2-AG inhibition of CXCL12-induced chemotaxis in day 5 activated 
PBLs is concentration-dependent. Day 5 SEB-activated PBLs (2x105/200|jI) 
incubated for 30 minutes at 37°C with 2-AG (0.1-10|jM) or vehicle (ethanol equivalent to 
10pM 2-AG) were added to the upper cham bers of a 96-well chemotaxis plate, above 
lower cham bers containing 10nM CXCL12. Chemotaxis across a 5pm pore size 
membrane was determined after 3 hours as described in Materials and Methods. Data 
are depicted as  mean ±S.E.M. and are derived from a single experiment (n=6 ). Data 
was analysed by ANOVA with Bonferroni correction (*, p<0.001 compared to vehicle). 
The red horizontal line at a chemotactic index of 1 represents basal migration and has 
been included for ease  of comparison.
171




^  o) 75000-










■ ■  control
10nM
CXCL12
Figure 4.20: 2-AG does not affect CXCL12-induced chemokinesis in day 5 activated 
PBLs. Day 5 SEB-activated PBLs were pre-treated with 5pM 2-AG or vehicle (ethanol 
equivalent to 5pM 2-AG) for 30 minutes at 37°C. After this incubation period CXCL12 
(10nM) was added to som e of the cell suspension. Cells were then placed in the upper 
cham bers of a 96-well chemotaxis plate above lower cham bers containing medium 
alone (control) or 10nM CXCL12. Chemotaxis across a 5pm pore size membrane was 
determined after 3 hours a s  described in Materials and Methods. Data are depicted as 
mean ±SD and are derived from two separate experiments (n=2). Data was analysed 
by ANOVA with Bonferroni correction (*, p<0.05; **, p<0.001).
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Figure 4 21: 2-AG has no effect on CXCL12-induced increases in F-actin content in 
day 5 activated PBLs. Day 5 SEB-activated PBLs were pre-treated with 5pM 2-AG or 
vehicle (ethanol equivalent to 5pM 2-AG) for 30 minutes. 2x106 cells, with or without 
pre-treatment, were then stimulated with 10nM CXCL12 for 30 seconds before being 
fixed and permeabilised a s  described in Materials and Methods and stained with FITC- 
conjugated phalloidin for 30 minutes. Fluorescence was detected using flow cytometry 
and the median fluorescence intensity of each sam ple used in analysis. During each 
experiment sam ples of unstained and unstimulated cells were also run through the flow 
cytometer to ascertain autofluorescence and basal levels of F-actin. Data are depicted 
as  mean ±S.E.M and are derived from three separate experiments (n=3).
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4.4 Cannabinoid-induced modulation of T lymphocyte 
proliferation
4.4.1 JWH-133 effects on IL-2-induced PBL proliferation
It currently remains unclear exactly what effect cannabinoids have on T 
lymphocyte cell number as reports on the effects of cannabinoids on lymphocyte 
proliferation have been mixed (Klein et oh, 1998a, Croxford & Yamamura,
2005). In order to investigate the effects of cannabinoids on proliferation of 
activated T lymphocytes, day 5 SEB-activated PBLs were used as this was when 
CB2R protein expression was highest. The proliferation assays were carried out 
in the presence of IL-2 exogenously added IL-2 was first removed for 24 hours 
prior to the start of the experiment so that all the cells accumulated in the G0-G1 
phase of the cell cycle.
In the first set of experiments the cells were counted using a Coulter counter after 
72 hours of treatment. Samples were set up in duplicate and each sample was 
run through the machine twice to ensure an accurate reading. The cells are 
normally maintained in the presence of 50U/ml IL-2 to induce clonal expansion 
and proliferation. As is clear in Fig. 4.22 at this concentration of IL-2 there was 
significant proliferation of these cells. However, during the experiment cells 
were treated with only 25U/ml IL-2 as this concentration of IL-2 still maintains 
growth of the cells but would hopefully allow any effect of the cannabinoids to 
be detected as they might be masked at higher concentrations of IL-2. JWH- 
133 was used in this part of the study as it is a CB2R-selective agonist and would 
therefore indicate whether the CB2R was involved in any responses. JWH-133 
stimulated an increase in cell number above that of IL-2 alone (Fig. 4.227?) 
indicating that it is pro-proliferative. The response was not concentration- 
dependent over the range of concentrations studied.
One study examining the effects of cannabinoids on proliferation of CaCo-2 
human colonic epithelial cells re-applied the cannabinoids daily (Ligresti et ah,
2003) and therefore it was tested whether applying JWH-133 only once, at the 
start of the experiment, or daily would have any effect on the response elicited.
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The repeated application of JWH-133 made almost no difference (Fig. 4.22Q. 
This was not surprising given that JWH-133 should be stable. At lOOnM JWH- 
133 there is a significant difference in cell number between the two types of 
application, but this is likely to be due to experimental error.
Day 11 SEB-activated PBLs were used to explore whether cells expressing less 
CB2R, but the same level of modified CBiR, as the day 5 PBLs would also 
respond in the same manner to JWH-133 in terms of proliferation. Day 11, 
rather than day 12, PBLs were chosen as the cells would not need to be 
maintained longer than 14 days, which is the normal length of their culture. 
JWH-133 had no effect on IL-2-induced proliferation of day 11 PBLs (Fig. 
4.23B). Again, applying JWH-133 only once, compared to daily, had no effect 
(Fig. 4.23C). Notably, these cells on the whole proliferated less, even in 
response to IL-2, compared to day 5 PBLs (Fig. 4.23A).
As day 5 and day 11 PBLs responded differently to JWH-133 the effects of 
JWH-133, and several other cannabinoids, over a broader concentration range, 
were explored. Counting the cells using the Coulter counter is a very low 
throughput assay and therefore XTT assays were used for this. Although the 
XTT assay does not determine cell number per se it still allows a comparison 
between different experimental conditions to be made and only takes into 
account viable cells. Once again, in both day 5 and day 11 PBLs IL-2 induced 
proliferation as an increase in absorbance value was recorded compared to OU/ml 
IL-2 (Fig. 4.24A and 4.25A) reflecting an increase in cell number with increasing 
concentrations of IL-2. JWH-133 was used again in order to verify whether the 
responses detected by counting the cells could also be detected by the XTT 
assay. In addition, ACPA, a CBiR-selective agonist (Hillard et al., 1999) and 
met-AEA, a stable AEA analogue (Ramer et al., 2001) were used. Although 
there was a great deal of variation between experiments, all three cannabinoids 
appear to induce modest proliferation in day 5 PBLs (Fig. A2AB-D). The 
cannabinoids also appear to induce an even more modest increase in proliferation 
in day 11 PBLs (Fig. A25B-D).
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Figure 4.22: JWH-133 increases IL-2-induced day 5 PBL proliferation as measured 
using the Coulter counter. Day 5 SEB-activated PBLs, which had been starved 
overnight of exogenously added IL-2, were set up at 1x105 cells/well in a 24-well plate 
and the appropriate concentration of JWH-133 and/or IL-2 added. Each condition was 
set up in duplicate. After 72 hours the cells were counted using the Coulter Counter as 
described in Materials and Methods with each sam ple being counted twice. A) cells 
were treated with increasing concentrations of IL-2 (0-100U/ml). A represents the 
number of cells started with. B,C) cells were treated with JWH-133 (0.01-1pM) or 
vehicle (V, ethanol equivalent to 1pM JWH-133) either only once at the start of the 
experiment (single; B,C) or daily (repeated; C) in the presence of 25U/ml IL-2. Data are 
depicted as  mean ±S.E.M and are derived from a single experiment (n=4), 
representative of one other. Data was analysed by ANOVA with Bonferroni correction 
(*, p<0.05; **, p<0.001 compared to the number of cells started with (A) or control (B)).
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Figure 4.23: JWH-133 has no effect on IL-2-induced day 11 PBL proliferation as 
measured using the Coulter counter. Day 11 SEB-activated PBLs, which had been 
starved overnight of exogenously added IL-2, were set up at 1x105 cells/well in a 24-well 
plate and the appropriate concentration of JWH-133 and/or IL-2 added. Each condition 
was set up in duplicate. After 72 hours the cells were counted using the Coulter Counter 
as  described in Materials and Methods with each sam ple being counted twice. A) cells 
were treated with increasing concentrations of IL-2 (0-100U/ml). B,C) cells were treated 
with JWH-133 (0.01-1pM) or vehicle (V, ethanol equivalent to 1pM JWH-133) either only 
once at the start of the experiment (single; B,C) or daily (repeated; C) in the presence of 
25U/ml IL-2. Data are depicted as  mean ±S.E.M and are derived from a single 
experiment (n=4), representative of one other. Data was analysed by ANOVA with 
Bonferroni correction (*, p<0.001 compared to the number of cells started with).
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Figure 4 24: Cannabinoids modestly increase IL-2-induced day 5 PBL proliferation 
as measured by XTT assay. Day 5 SEB-activated PBLs, which had been starved 
overnight of exogenously added IL-2, were set up at a density of 5x104 cells/well in a 96- 
well tray and the appropriate concentration of cannabinoid and/or IL-2 added. After 72 
hours, PMT-XTT solution was added to the wells and the plate allowed to develop. 
Changes in absorbance were m easured using a plate reader. A) cells were treated with 
increasing concentrations of IL-2 (0-100U/ml). Cells were treated with 0.001 pM-10pM 
JWH-133 (B), AC PA (C), met-AEA (D) or vehicle (V, ethanol) for 72 hours in the 
presence of 25U/ml IL-2. Data are depicted as  mean ±S.E.M and are derived from 4 
separate experiments pooled together (n=12). Data was analysed by ANOVA with 
Bonferroni correction (*, p<0.01; **, p<0.001 compared to OU/ml IL-2).
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Figure 4.25: Cannabinoids have little effect on IL-2-induced day 11 PBL 
proliferation as measured by XTT assay. Day 11 SEB-activated PBLs, which had 
been starved overnight of exogenously added IL-2, were set up at a density of 5x104 
cells/well in a 96-well tray and the appropriate concentration of cannabinoid and/or IL-2 
added. After 72 hours, PMT-XTT solution was added to the wells and the plate allowed 
to develop. C hanges in absorbance were m easured using a plate reader. A) cells were 
treated with increasing concentrations of IL-2 (0-100U/ml). Cells were treated with 
0.001 pM-10pM JWH-133 (B), ACPA (C), met-AEA (D) or vehicle (V, ethanol) for 72 
hours in the presence of 25U/ml IL-2. Data are depicted as mean ±S.E.M and are 
derived from 4 separate experiments pooled together (n=12). Data was analysed by 
ANOVA with Bonferroni correction (*, p<0.05; **, p<0.001 compared to OU/ml IL-2).
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4.5 Summary
• AEA, 2-AG and JWH-133 induce ERK1/2 phosphorylation in day 5 and 
12 SEB-activated PBLs and Jurkats. This response was determined to be 
receptor mediated as a Gai/o-protein was involved, but the roles of the 
modified CBiR and CB2R specifically could not be determined.
• In the day 5 PBLs it was determined that AEA-stimulated ERK1/2 
phosphorylation is MEK and PKC-dependent.
• 2-AG was also shown, in day 5 PBLs, to elevate levels of forskolin- 
induced cAMP production.
• Neither 2-AG nor JWH-133 induce migration of day 5 or 12 SEB- 
activated PLBs but inhibit CXCL12-induced chemotaxis of these cells.
• JWH-133 exerts a pro-proliferative effect on day 5 but not day 11 SEB- 
activated PBLs.
4.6 Discussion
The main aim of this part of the study was to investigate the effects that 
cannabinoids have on the function of activated T lymphocytes. However, first it 
was important to establish whether the receptors detected in activated PBLs were 
biochemically functional by examing cannabinoid-induced activation of a 
signalling pathway, namely ERK1/2.
4.6.1 AEA, 2-AG and JWH-133 induce ERK1/2 phosphorylation
Cannabinoids have been shown to positively couple to a number of downstream 
intracellular signalling pathways, including the phosphorylation and activation of 
ERK1/2 in a number of different cell types (Bouaboula et al., 1995b, Bouaboula 
et al., 1996, Galve-Roperh et a l , 2002, Derkinderen et a l , 2003, Samson et a l ,
2003). However, there have also been reports of cannabinol, one of the natural 
cannabinoids, not stimulating acute ERK phosphorylation and inhibiting 
PMA/Ionomycin-induced activation of nuclear ERK phosphorylation in murine 
splenocytes (Faubert & Kaminski, 2000, Faubert Kaplan & Kaminski, 2003).
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In this study both the endocannabinoids AEA and 2-AG and the CB2R-selective 
agonist JWH-133 induced acute ERK 1/2 phosphorylation in day 5 and 12 SEB- 
activated PBLs and Jurkats. Given that cannabinoids have been reported to 
positively couple to ERK activation, including in Jurkats (Herrera et al., 2005, 
Ghosh et al., 2006), the ability of AEA, 2-AG and JWH-133 to stimulate 
ERK1/2 phosphorylation in PBLs was not unexpected.
4.6.1.1 Is cannabinoid-induced ERK1/2 phosphorylation in
activated PBLs and Jurkats receptor-mediated?
In Results I  it was shown that by day 12 post-isolation the PBLs still express a 
modified CBiR but very little CB2R protein. Thus, the fact that the cannabinoids 
continue to couple to ERK 1/2 phosphorylation in these cells is an indication that 
either: i) the modified CBjR is functional and coupled to biochemical pathways, 
ii) that very low CB2R occupancy is required to generate a signal, iii) that the 
cannabinoids are acting via non CB1/2R cannabinoid-like receptors or iv) that the 
cannabinoids are acting via cannabinoid receptor-independent mechanisms.
The data presented in this study indicate that the modified CBiR may not be 
functional. Although AEA and 2-AG stimulated ERK 1/2 phosphorylation in 
both day 5 and day 12 PBLs neither endocannabinoid induced this response in 
naive T lymphocytes. In the first part of this study only a modified CBiR 
protein, but not the CB2R, was detected in these cells, suggesting that this 
modified receptor is either not functional or is but does not couple to ERK 1/2 
activation. The ability of AEA and 2-AG to phosphorylate another kinase, PKB, 
which has been shown to lie downstream of cannabinoids (Gomez et al., 2000, 
Galve-Roperh et al., 2002, Molina-Holgado et a l, 2002, Sanchez et al., 2003) 
was also examined. Again, neither endocannabinoid stimulated an increase in 
PKBSer473 phosphorylation, suggesting that the modified CBjR may not be 
functional although additional signalling pathways need to be studied in order to 
verify this.
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As the modified CBiR does not appear to be coupled to ERK1/2 phosphorylation 
the question remains whether the cannabinoids are acting through the CB2R in 
activated PBLs and Jurkats. Other studies have reported that low receptor 
occupancy is required for cannabinoid effects. For instance, 95% maximal 
inhibition of acetylcholine release by the synthetic cannabinoid WIN55212-2 in 
rat hippocampal slices occurs at only 7.5% CB]R occupancy (Gifford et al., 
1999) and 2-AG and noladin ether were shown to require occupancy of less than 
50% of the CB2R expressed on transfected CHO cells to regulate ERK activation 
(Shoemaker et al., 2005b). Thus, it appears that cannabinoids could couple to 
signalling pathways even if low levels of receptor proteins are expressed which 
could explain why the cannabinoids continue to induce ERK1/2 phosphorylation 
even in day 12 PBLs when CB2R expression is low.
The fact that AEA and 2-AG-induced ERK1/2 phosphorylation is mimicked by 
JWH-133 also supports the notion that they are acting via the CB2R as JWH-133 
is a CB2R-specific agonist with a Ki of 3.4nM at the CB2R compared to 677nM 
at the CBiR (Howlett et al., 2002). However, it must be highlighted that it is 
CB?R-selective rather than specific and at the higher concentrations used here, 
such as lOOnM, may also be activating the CBiR and possibly additional 
receptors.
Thus, several inhibitors were used in order to investigate whether the 
cannabinoids were acting in a CB2R-dependent manner. Pre-treatment of the 
cells with the Gai/o-protein inhibitor PTX abolished cannabinoid-induced 
ERK1/2 phosphorylation in day 5 and 12 PBLs indicating that a Gi/o-protein was 
involved. This is consistent with a possible role for the CB2R but does not rule 
out involvment of other receptors such as the abn-cannabidiol sensitive receptor 
(Begg et a l , 2005). In fact, a putative role for such an additional receptor is 
supported by the finding that AEA, which is generally considered to be a weak 
CB2R agonist, and can even act as an antagonist (Gonsiorek et a l , 2000), is 
coupled to ERK 1/2 phosphorylation in these cells. Furthermore, in Jurkats, PTX 
did not completely abrogate the response to AEA, 2-AG or JWH-133, suggesting 
that there may also be a role for a PTX-insensitive receptor. The recent finding 
that the orphan GPCR GPR55, which does not couple to Gi-proteins, may be an
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additional cannabinoid receptor could account for this. However, this is unlikely 
as it has been shown that JWH-133 does not stimulate GPR55 (Baker et al.,
2006).
Two antagonists, AM251, a CBiR specific antagonist and AM630, a CB2R 
specific antagonist (Palmer et a l , 2002) were also used to examine the role of the 
cannabinoid receptors in the ERK 1/2 responses. Unfortunately, the effects 
detected with these two compounds were mimicked by the vehicle controls and 
the results were thus inconclusive. It is not clear why the vehicle controls 
mimicked the effects of these inhibitors as in each case the levels of vehicle, 
either ethanol or DMSO, were very low. Other antagonists do exist, such as the 
SR141716A and SRI 44528 compounds, and these could be used to further this 
work. In addition, the development of new water-soluble cannabinoids has been 
reported (Pertwee et a l , 2000, Martin et a l , 2006). Such antagonists should 
avoid any problems with vehicle control. Alternatively, siRNA could be used to 
silence the individual receptors to elucidate what role they play and also whether 
the modified CBiR is functional.
Thus, at present it is unclear through which receptor the cannabinoids are 
coupling to ERK 1/2 phosphorylation in activated T lymphocytes and further 
work is required to determine whether the CB2R and/or modified CBiR play a 
role.
4.6.1.2 Are the effects of AEA and 2-AG mediated by their 
metabolites?
Physiologically both AEA and 2-AG are rapidly taken up by cells and are 
degraded by a number of enzymes including FAAH and MAGL (Goparaju et a l , 
1998, Cravatt & Lichtman, 2002, Dinh et a l , 2002). Both of these enzymes were 
found to be expressed in PBLs and Jurkats in Results I. Hence, it was 
investigated whether AEA and 2-AG degradation affects their ability to stimulate 
ERK1/2 phosphorylation, even over the short time course studied here. The 
potent FAAH and MAGL inhibitor MAFP was used (De Petrocellis et a l, 1997,
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Goparaju et al., 1999, Saario et a l, 2004). Initial experiments revealed that 
when day 12 PBLs or Jurkats were pre-treated with MAFP, AEA and 2-AG- 
induced ERK 1/2 phosphorylation was attenuated. Given that MAFP should be 
preventing AEA and 2-AG degradation when these cannabinoids come into 
contact with the cells, this response suggests that what was assumed to be AEA 
and 2-AG-induced ERK 1/2 phosphorylation is actually caused by AEA and 2- 
AG metabolites. However, MAFP has also been shown to bind irreversibly to 
the CBiR (Deutsch et al., 1997) and act as a CBiR antagonist (Fernando & 
Pertwee, 1997). To my knowledge there have been no reports published 
concerning its effects on the CB2R. Therefore, MAFP could be preventing the 
binding of AEA and 2-AG to the modified CBiR and hence attenuating the 
ERK1/2 response. The latter theory does require the modified CBjR to be 
functional, which appears not to be the case.
Further investigation was carried out in day 5 PBLs and showed the same 
downregulation of AEA-induced ERK 1/2 phosphorylation with MAFP pre­
treatment as in the day 12 PBLs and Jurkats. However, the response was not 
concentration-dependent and more importantly was also mimicked by vehicle 
control. Furthermore, MAFP also abolished JWH-133-induced ERK1/2 
phosphorylation.
This additional data suggests that the response to MAFP detected was an artefact 
and that AEA and 2-AG stimulation of ERK 1/2 phosphorylation in T 
lymphocytes is likely to be mediated by the cannabinoids themselves rather than 
their metabolites. However, it must be remembered that AEA and 2-AG are not 
simply degraded by FAAH and MAGL but that other metabolic pathways exist 
and these should also investigated before firm conclusions are drawn. For 
instance, both AEA and 2-AG are oxygenated by COX-2 to produce a range of 
prostamides and prostaglandin-glycerol esters, respectively (Kozak et al., 2002a) 
and it has been reported that such metabolites may exert their own effects. For
^  I
example, PGE2-G was reported to trigger Ca mobilisation and increase levels 
of ERK 1/2 phosphorylation in a PKC-dependent manner in the murine 
macrophage-like cell line, RAW264.7 (Nirodi et al., 2004). Similarly, AEA and 
2-AG can also be metabolised by lipoxygenases and 15-HETE-G has been
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shown to activate PPAR-a (Kozak et ah, 2002b). As COX-2 has been reported 
to be expressed at low levels in naive T lymphocytes and at higher levels upon 
activation (Pablos et al., 1999) and 5-lipoxygenase also appears to be expressed 
in primary T lymphocytes (Los et al., 1995), the effect of COX-2 and 
lipoxygenase inhibitors on AEA and 2-AG-induced phosphorylation of ERK 1/2 
in T lymphocytes should be also be examined.
4.6.1.3 Why are such high concentrations of AEA and 2-AG
required to induce ERK1/2 phosphorylation?
Maximal stimulation of ERK 1/2 phosphorylation with either AEA or 2-AG 
occurred at 10pM although their reported Ki values are much lower than this for 
both receptors. This has been seen in other studies and it has often brought into 
question whether these responses would occur physiologically given that 
reported concentrations of AEA and 2-AG in most tissues are in the pmol/g and 
nmol/g range, respectively (Goutopoulos & Makriyannis, 2002, Sugiura et al., 
2002). One argument is that local concentrations of AEA and 2-AG may in fact 
be higher than thought. Both endocannabinoids act as autocrine or paracrine 
mediators and they are also hydrophobic, so their concentration at the lipid 
bilayer, near the receptors, may be higher than in the extracellular environment 
(Ambrosi et al., 2005). Furthermore it is know that levels can rise during, for 
instance, pathological conditions (Goutopoulos & Makriyannis, 2002, Sugiura et 
al., 2002). Regulatory mechanisms may also exist in vivo that may affect the 
concentrations of cannabinoid required to activate the receptors. For instance, 
the concentration of AEA required to activate the VR1 is reduced by factors such 
as phosphorylation by PKC (Ross, 2003).
It is also possible that the high concentrations required in the experiments 
presented here and in other studies to stimulate maximal responses are due to 
experimental conditions. For example, 2-AG is known to be relatively unstable 
in media and is quickly converted to 1(3)-AG (Rouzer et al., 2002). Thus, even 
though every care was taken to prepare and use 2-AG as quickly as possible in 
every experiment, it is possible that what was believed to represent lOpM was
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actually less. Furthermore, both 2-AG and AEA have been reported to adhere to 
plastics (Rouzer et al., 2002, Karlsson et al., 2004, Ortega-Gutierrez et al.,
2004). Therefore, it is possible that the actual concentrations of AEA and 2-AG 
that reaches the cells are lower than thought.
4.6.1.4 Several kinases couple the cannabinoids to ERK1/2
activation in activated PBLs and Jurkats
A number of different pathways can link GPCRs to ERK activation (Marinissen 
& Gutkind, 2001, Werry et a l , 2005), therefore several inhibitors were used to 
determine some of the kinases upstream of ERK 1/2 phosphorylation by AEA in 
day 5 SEB-activated PBLs. MEK is the dual specificity kinase directly upstream 
of ERK (Kolch, 2000) and its involvement was verified using the MEK1 
inhibitor PD98059 (Alessi et al., 1995). AEA-induced ERK1/2 phosphorylation 
was shown to be MEK dependent in day 5 PBLs and Jurkats.
Cannabinoid-induced ERK activation was also shown to be PKC-dependent in 
CB2R-transfected CHO cells and ECV304 human umbilical vein endothelial 
cells (Bouaboula et al., 1996, Liu et al., 2000). The PKC inhibitor Ro-32-0432, 
at concentrations were it would not be selective for any one isoform (Wilkinson 
et a l, 1993), suppressed the AEA-induced response in day 5 PBLs indicating 
that PKC lies upstream of ERK1/2 phosphorylation. Two additional inhibitors 
were used to further investigate whether AEA activated particular PKC isoforms. 
T lymphocytes express PKCa, P, 8, s, 0, and £ isoforms (Tan & Parker, 2003). 
Rottlerin, at lOpM, a concentration which should selectively inhibit PKC8 
compared to other PKC isorms (Gschwendt et al., 1994, Villalba et al., 1999), 
attenuated AEA-induced ERK 1/2 phosphorylation, indicating that AEA exerts at 
least some of its actions through this PKC isoform. It is important to note that at 
lOpM rottlerin can also inhibit another kinase, calcium/calmodulin-dependent 
protein kinase (CaM kinase) III. Cannabinol has been shown to couple to 
another member of the CaM kinase family, CaM kinase II (Jan & Kaminski,
2001), which has also been linked to ERK activation in other systems (English et 
al., 1999). Thus it is not possible at this time to rule out a role for CaM kinase III
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in the AEA-induced ERK 1/2 response. AEA did not appear to activate PKCa or 
pi as treatment of the cells with the inhibitor G66976, which is selective for these 
isoforms over the concentrations used (Martiny-Baron et a l , 1993), had no effect 
on ERK 1/2 phosphorylation. The relevance of AEA activating PKC, apart from 
its involvement in ERK 1/2 phosphorylation and activation, is that PKC 
phosphorylation of the CBiR blocks ion channel modulation, thus activation of 
PKC downstream of the cannabinoids could be part of a negative feedback loop 
to control receptor activation (Garcia et al., 1998). This may not be critical in T 
lymphocytes which only express a modified CBiR, which may in fact not be 
active, but may be more relevant in other cell types.
Another kinase shown to be upstream of ERK in cannabinoid-induced signalling 
is PI3K (Bouaboula et a l, 1997, Galve-Roperh et a l, 2002, Samson et a l, 2003, 
Sanchez et a l, 2003). The involvement of PI3K in AEA and 2-AG-induced 
ERK 1/2 phosphorylation in Jurkats was investigated using the non-selective 
PI3K inhibitor LY294002 (Ward et a l, 2003). The results indicate a role for 
PI3K in AEA-induced ERK phosphorylation and to a lesser extent 2-AG-induced 
ERK1/2 phosphorylation. This suggests that the role of PI3K may be partly 
agonist dependent. Such agonist-directed trafficking of responses by 
cannabinoids has previously been shown in CHO-CB2R cells. Shoemaker et al 
(2005b) showed that whilst 2-AG, noladin ether and CP55,940 each regulated 
three different intracellular pathways, namely AC inhibition, ERK stimulation
94-and induction of Ca transients, with equivalent efficacy, the rank order of 
potencies differed depending on the pathway studied.
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Figure 4 26: Model of ERK1/2 activation in PBLs and Jurkats. Currently it is not clear 
whether the modified CBtR detected in these cells in functional or not but cannabinoid- 
induced ERK1/2 phosphorylation in these cells is likely to be CB2R-mediated. In day 5 
SEB-activated PBLs it w as shown that AEA-induced ERK1/2 phosphorylation is MEK 
and PKC-dependent whilst in Jurkats a role for PI3K w as elucidated. These results 
corroborate data from other studies.
4.6.2 2-AG appears to enhance forskolin-induced cAM P
production  in activated PBLs
Another pathway that was briefly studied was cannabinoid modulation of acute 
cAMP production. This was one of the first pathways downstream of the 
cannabinoids to be defined and it has been demonstrated that although 
cannabinoids generally inhibit forskolin-induced cAMP production (Pertwee, 
1997, Kaminski, 1998, Howlett et al., 2002, Demuth & Molleman, 2006), they 
can also increase forskolin-induced (Glass & Felder, 1997, Felder et al., 1998) 
and basal (Maneuf & Brotchie, 1997, Steffens et al., 2005a) cAMP production. 
These differences are suggested to result from differential coupling of the CBiR 
to Gi/o and Gs-proteins (Glass & Felder, 1997, Bonhaus et al., 1998, Jarrahian et 
al., 2004) and the specific isoform distribution of AC (Rhee et al., 1998). A9-
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THC has been shown to suppress forskolin-stimulated cAMP production in 
human PBMCs as well as the murine thymoma-derived T lymphocyte cell line 
EL4.IL-2 (Diaz et a l, 1993, Condie et al., 1996) and 2-AG inhibited forskolin- 
induced cAMP production in murine splenocytes (Mechoulam et al., 1995). 
Further evidence that cannabinoids can inhibit cAMP production in T 
lymphocytes has come from studies examining the effects of cannabinoids on 
CRE, a part of the cAMP signalling cascade downstream of PKA. Several 
cannabinoids, including A9-THC and 2-methylarachidonyl-(2’fluoroethyl)amide, 
a stable AEA analogue, inhibit CRE DNA binding activity in murine thymocytes 
and splenocytes (Koh et a l , 1997, Herring & Kaminski, 1999, Kaplan et a l , 
2005b).
In this study, preliminary evidence suggests that neither JWH-133 nor 2-AG 
affect basal cAMP levels. However, 2-AG robustly increased forskolin-induced 
cAMP production. This effect was not mimicked by the CE^R-selective agonist 
JWH-133, suggesting that this response is not CE^R-mediated and that 2-AG is 
acting through an alternative mechanism. Stimulation of cAMP production is 
associated with Gs-protein activity and the CB2R does not couple to this G- 
protein (Glass & Felder, 1997), corroborating the idea that 2-AG is not acting 
through the CB2R. 2-AG may instead be acting via the modified CBiR 
expressed in these cells. There have been reports that the CBiR can couple to 
Gs-proteins (Glass & Felder, 1997, Bonhaus et a l , 1998, Jarrahian et a l , 2004), 
which would account for the increase in forskolin-induced cAMP stimulated by 
2-AG. However, this is purely speculative at this stage as it remains to be 
determined whether the modified CBiR is functional. Cannabinoids have been 
shown to exert several receptor-independent effects, including the stimulation of 
cAMP production. For example, it has previously been reported when AEA and 
A9-THC increased forskolin-induced cAMP levels in both CHO-K1 wild type 
and CB2R-transfected cell (Slipetz et a l , 1995). Thus 2-AG could be acting in a 
receptor-independent manner in this assay. Regardless of the mechanism, 2-AG 
is likely to be coupling to AC-VII to induce the increase in cAMP production 
detected. Both AC-VI and AC-VII are ubiquitously expressed (Sunahara & 
Taussig, 2002) and activation of the cannabinoid receptors has been shown to 
inhibit AC-VI but stimulate AC-VII (Rhee et a l , 1998). This suggests that 2-AG
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is probably coupling to AC-VII in the day 5 PBLs. These experiments would 
need to be repeated and also extended to verify how 2-AG may be exerting its 
effect on cAMP production.
4.6.3 What are the effects of JWH-133 and 2-AG on migration of 
activated PBLs?
Having established that cannabinoids couple to intracellular signalling pathways 
in activated PBLs the next stage of this study was to determine their effects on T 
lymphocyte functions. Several reports have suggested that cannabinoids affect 
spontaneous cell migration. For instance, it has been reported that 2-AG acts as a 
chemoattractant for immune cells including HL-60 cells differentiated into 
macrophage-like cells (Kishimoto et al., 2003), CB2R-expressing myeloid 
precursor cells (Jorda et al., 2003), B lymphocytes (Jorda et al., 2002, Rayman et 
al., 2004) and eosinophils (Oka et al., 2004) and the CB2R was implicated in 
these responses. Although 2-AG is generally considered to induce migration, 
results using other cannabinoids have been mixed, indicating that cannabinoid 
effects on basal migration may be both ligand and cell-type specific.
4.6.3.1 Neither 2-AG nor JWH-133 induce migration of activated 
PBLs
In this study, 2-AG did not induced chemotaxis in day 5 or 12 PBLs, although 
these were all shown to be capable of migrating towards the chemokine 
CXCL12. As this contradicts several reports which suggest that 2-AG is a 
chemoattractant, this data was verified in two T lymphocyte cell lines, Jurkats 
and CEMs. Once again 2-AG did not induce chemotaxis in these cells although 
the cells migrated towards CXCL12. Thus, 2-AG does not act as a 
chemoattractant for T lymphocytes.
Although in general 2-AG has been shown to act as a chemoattractant there has 
been a report that it has no effect on spontaneous migration of human 
undifferentiated HL-60 cells (Kishimoto et al., 2003). Both HL-60 cells and the
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T lymphocytes used in the current study express the CB2R, which has been 
implicated in the chemoattractant properties of 2-AG. Therefore, it may be that 
the effects of 2-AG are cell-type specific. Notably, it has been established that 2- 
AG is rapidly converted to 1(3)-AG in media (Rouzer et al., 2002) and it could 
be argued that the lack of response to 2-AG is due to its conversion to 1(3)-AG 
over the 3 hour assay. However, this same conversion would also have occurred 
in all the studies which conclude that 2-AG is a chemoattractant as a similar, or 
longer, time frame was used in each instance. In the future it will be important to 
determine whether the effects of 2-AG on cell migration detected in these in vitro 
studies are due to 2-AG itself or 1(3)-AG, especially as 1(3)-AG has been shown 
to exert its own effects (Stella et al., 1997).
JWH-133, a CB2R-selective agonist, also did not induce migration of PBLs, 
Jurkats or CEMs, which extends and confirms the report published recently 
which suggests that AEA and JWH-133 do not induce migration of naive human 
CD8+ T lymphocytes (Joseph et al., 2004). JWH-133, and 2-AG, also failed to 
induce actin polymerisation in the day 5 and 12 PBLs, one of the key steps in cell 
migration (Ridley et al., 2003), although 2-AG has been shown to stimulate this 
response in HL-60 cells differentiated into macrophage-like cells (Gokoh et al., 
2005b). This is consistent with their inability to induce chemotaxis in PBLs. 
Thus it may be that T lymphocytes do not migrate in response to any 
cannabinoids, although a wider selection of ligands would have to be tested to 
confirm this.
4.6.3.2 2-AG and JWH-133 inhibit CXCL12-induced migration
In addition to inducing basal migration, cannabinoids have also been suggested 
to modulate ligand-induced migration in several cell types, including some 
leukocytes. For instance, CP55,940 inhibited fMLP-induced migration of rat 
peritoneal macrophages (Sacerdote et a l , 2000) and JWH-133 and AEA 
inhibited CXCL12-induced motility of naive human CD8+ T lymphocytes 
(Joseph et a l , 2004). The data from the current study corroborates these findings 
by showing that JWH-133 also inhibits CXCL12-induced chemotaxis of a mainly 
CD4+ population of activated T lymphocytes, although further investigation is
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need to confirm whether it is the CD4+ or CD8+ T lymphocytes in the population 
responding. In addition, it also shows that 2-AG exerts the same response and 
that chemotaxis, rather than chemokinesis, is specifically affected. During the 
preparation of this manuscript another study was published which again showed 
that cannabinoids inhibited CXCL12-induced migration, this time of Jurkats and 
naive CD4+ and CD8+ T lymphocytes (Ghosh et al., 2006). Thus, whilst 
cannabinoids appear not to act as chemoattractants for T lymphocyte migration, 
they are clearly capable of inhibiting CXCL12-induced migration. It remains to 
be determined whether they will also affect migration of T lymphocytes toward 
other chemoattractants.
4.6.3.2.1 How could the cannabinoids be mediating this effect?
Joseph et al (2004) concluded that cannabinoid inhibition of CXCL12-induced 
migration was CE^R-dependent as the response to AEA was mimicked by the 
CB2R-selective agonist, JWH-133, but not a CBiR-selective agonist, 
docosatetraenyltheanolamide. Similarly, Ghosh et al (2006) used the CB2R- 
selective agonist JWH-015 to show that the CB2R was involved, although they 
used high micromolar concentrations of this potent compound, which brings into 
question its selectivity. The findings from the current study also suggest a role 
for the CB2R in this response as JWH-133 mimicked the effect of 2-AG. 
However, given that JWH-133 is CB2R-selective rather than specific and at 
lOOnM may also activate the CBiR, further work needs to be carried out in order 
to verify the involvement of the CB2R in this response. Interestingly, 2-AG and 
JWH-133 inhibited CXCL12-induced migration of both day 5 and day 12 PBLs. 
This suggests that if the response is CB2R-mediated that only low receptor 
numbers may be necessary for cannabinoids to exert their actions, as discussed 
earlier with respect to ERK phosphorylation. As well as the CBiR and CB2R, 
additional cannabinoid receptors have been reported to exist such as the abn- 
cannabidiol sensitive receptor (Begg et al., 2005). Activation of the abn- 
cannabidiol sensitive receptor has been reported to stimulate migration of both 
human umbilical vein endothelial cells (Ming Mo et al., 2004) and murine 
microglial cells (Walter et a l , 2003). Whether it may be involved in the 
cannabinoid-mediated effects observed in the current study is unclear as reports
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on whether 2-AG can activate abn-cannabidiol sensitive receptor have been 
mixed (Walter et al., 2003, Begg et al., 2005). Other cannabinoid targets include 
the orphan receptor GPR55 (Baker et a l, 2006). However, as mentioned earlier, 
JWH-133 has been reported not to activate GPR55 (Baker et al., 2006) and is 
therefore unlikely to be involved in the effects on CXCL12-induced migration 
reported here.
Whether 2-AG affected CXCL12-induced actin polymerisation was briefly 
investigated as actin polymerisation. However, the inhibitory effect of 2-AG was 
mimicked by the vehicle control, suggesting that this effect was likely to be an 
experimental artefact. Thus, the likely mechanisms by which cannabinoids may 
interfere with chemokine driven directed cell migration are unclear at present. 
Cannabinoids have been widely shown to inhibit cAMP production (Demuth & 
Molleman, 2006) and it has been suggested that it is this inhibition of cAMP 
signalling that may be involved in their downregulation of chemokine-induced 
migration (Joseph et al., 2004). However, given that 2-AG actually increased 
forskolin-induced cAMP production in day 5 PBLs and had no effect on basal 
cAMP production, this is unlikely to be the case. In addition, JWH-133 had no 
effect on forskolin-induced cAMP production but, like 2-AG, inhibited 
CXCL12-induced chemotaxis, further indicating that the effects on cAMP are 
not involved.
CXCL12 binds the receptor CXCR4 and another possibility is that cannabinoid 
receptor-CXCR4 dimers or oligomers form in the presence of cannabinoids and 
that this alters the signalling induced by CXCL12. There is evidence to suggest 
that the CBiR can exist as homodimers (Wager-Miller et a l , 2002, Mackie, 
2005, Xu et al., 2005) as well as form heterodimers with GPCRs (Hilairet et al., 
2003, Keam et al., 2005, Wright et al., 2005, Rios et al., 2006). CB2R 
homodimers have also been suggested to exist (Filppula et al., 2004) and CXCR4 
has also been shown to homo and heterodimerise (Percherancier et al., 2005). It 
is also well established that ligand binding can regulate dimer formation and that 
heterodimer formation can alter the downstream signalling of the component 
receptors (Terrillon & Bouvier, 2004). Another possibility is that cannabinoids 
are causing heterologous desensitisation of CXCR4. It has previously been
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demonstrated that activation of receptors such as opioid receptors on the surface 
of leukocytes can inhibit chemokine receptor function through this mechanism 
(Steele et a l, 2002). Cannabinoid treatment could also be affecting CXCR4 
expression. One study has shown that in vitro A9-THC can inhibit TNFa- 
induced increases in CCR2 mRNA expression in mouse splenocytes although the 
authors failed to mention how long they stimulated with A9-THC (Steffens et al., 
2005b). It was recently reported that cannabinoids had no effect on CXCR4 
expression in Jurkats over one hour (Ghosh et a l, 2006). Thus, it seems unlikely 
that cannabinoids would be affecting CXCR4 expression in this study. However, 
an additional receptor for CXCL12 was recently identified, RDC1, which is also 
expressed in T lymphocytes, especially CD4+ T lymphocytes, and is involved in 
CXCL12-induced migration of T lymphocytes (Balabanian et al, 2005, Infantino 
et a l, 2006). Thus, 2-AG and JWH-133 could also be affecting the ability of 
CXCL12 to induce migration through this receptor.
Cannabinoids may also be competing for or regulating pathways involved in cell 
migration. For example, the CBiR has been reported to sequester Gi/o-proteins, 
making them unavailable to other GPCRs (Vasquez & Lewis, 1999). CXCR4 is 
Gi/o-protein coupled and thus cannabinoids, especially if the CB2R shares this 
ability, could be inhibiting CXCR4 function from a point high up in the 
signalling cascade. However, given that 2-AG appears to inhibit CXCL12- 
induced chemotaxis but not chemokinesis this is unlikely.
One recently published study has investigated the effects of cannabinoids on the 
activity of Rho-family GTPases, which are involved in establishing cell 
polarisation (Fukata et a l, 2003) and found that these were differentially 
regulated by CB2R activation (Kurihara et a l, 2006). Furthermore, they also 
demonstrated that HL-60 cells differentiated into neutrophil-like cells stimulated 
with 2-AG extended one or more pseudopods in different directions rather than 
developing front/rear polarity in response to fMLP as normally exhibited by 
chemotaxing leukocytes (Kurihara et a l, 2006). This data could explain why 2- 
AG affected the chemotaxis, but not chemokinesis, of day 5 PBLs to CXCL12 if 
2-AG is affecting the ability of cells to migrate in a particular direction.
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The effects of cannabinoids on many of the signalling molecules involved in 
migration have not yet been studied. However, they have, for example, been 
shown to activate PI3K, a key enzyme involved in several aspects of migration, 
in several different cell types (Bouaboula et ol., 1997, Galve-Roperh et al., 
2002). This activation may not be sufficient to elicit migratory responses alone 
but may lead to non-polarised accumulation of the 3’ phosphorylated PI lipid 
products of PI3K which interfere with cellular navigation mechanisms. 
Alternatively, cannabinoid-activated PI3K may compete for PI lipid substrate 
available to chemokine-stimulated PI3Ks which again disrupts polarised PI lipid 
accumulation. Cannabinoids can also activate ERK 1/2 and PKC as shown in 
several studies, including this one, and ERK 1/2 can influence cell motility 
(Klemke et al., 1997, Huang et al., 2004, Larsson, 2006). However, this is 
unlikely to be involved in the inhibition of CXCL12-induced migration as Ghosh 
et al (2006) showed that JWH-015 inhibition of CXCL12-induced migration of 
Jurkats was unaffected by PD98059.
Furthermore, in vivo, cannabinoids may also affect cell adhesion (Gokoh et al., 
2005a, Grimaldi et a l, 2006) and/or production of chemokines (Jbilo et al., 1999, 
Smith et al, 2001). For instance, it was recently reported that 2-AG enhances 
the adhesion of HL-60 cells differentiated into macrophage-like cells to 
fibronectin in a CB2R-dependent manner (Gokoh et a l, 2005a). Cannabinoids 
have been shown to both increase and decrease the production of chemokines. 
For example, in mice treated with thioglycollate broth to induce peritonitis it was 
found that two synthetic cannabinoids HU210 and WIN55,212-2 blocked the 
migration of neutrophils into the peritoneal cavity and that this effect was caused 
by a delay in the production of chemoattractants CXCL1 and CXCL2/3 (Smith et 
al, 2001). On the other hand, CP55,940, a synthetic cannabinoid, was shown to 
increase CXCL8, CCL2 and CCL4 mRNA and protein production in wild type 
and CB2R overexpressing HL-60 cells (Jbilo et a l, 1999, Derocq et a l, 2000). 
Finally, they may also affect migration velocity as JWH-015 and 2-AG have 
been reported to reduce fMLP-stimulated migration velocity of human 
neutrophils (Kurihara et a l, 2006).
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4.6.4 Cannabinoids appear to modulate proliferation of
activated T lymphocytes
In this part of the study JWH-133 was shown to increase IL-2-induced day 5 
SEB-activated PBL numbers when this was measured using cell counting. The 
majority of studies have shown that cannabinoids act to decrease lymphocyte cell 
number. For instance, murine splenocytes treated with A9-THC have a reduced 
proliferative response to mitogens (Pross et al., 1990, Schatz et al., 1993, 
McKallip et al., 2002b), A9-THC also suppresses human T lymphocyte 
proliferation stimulated by allogeneic dendritic cells (Yuan et al., 2002), AEA 
inhibited mitogen-induced proliferation of human PBMCs (Schwarz et al., 1994) 
and NADA inhibited proliferation of activated T lymphocytes (Sancho et al.,
2004). Apoptosis has been suggested to account for at least some of the 
cannabinoid-induced suppression of cell number detected (Schwarz et al., 1994, 
Flygare et a l , 2005). However, some studies have also shown that cannabinoids 
can increase lymphocyte cell number. For example A9-THC, CP55,940 and 
WIN55,212-2 increased proliferation of activated human B lymphocytes in a 
PTX-sensitive manner (Derocq et a l , 1995) and 2-AG stimulated the 
proliferation of a M-CSF-dependent rat microglial ell line in the presence of M- 
CSF (Carrier et a l , 2004). One study has suggested that the differential effects 
of cannabinoids on lymphocyte proliferation may be concentration-dependent 
(Luo et a l , 1992). The authors showed that A9-THC increased PHA or 
concanavalin A-stimulated proliferation of human peripheral blood lymphocytes 
at low concentrations but inhibited proliferation at high concentrations (Luo et 
a l , 1992). Although admittedly the concentration range of JWH-133 tested in 
this first set of experiments was not very extensive a concentration-dependent 
effect was not noted. However, the use of JWH-133 did suggest that this 
response was CB2R-mediated, which would be consistent with reports that 
cannabinoid-stimulated proliferation of activated human B lymphocytes (Derocq 
et a l , 1995) and rat microglial cells (Carrier et a l , 2004) was CB2R-dependent.
The effect of JWH-133 on IL-2-induced day 5 PBL proliferation was not 
mimicked in day 11 PBLs. In these cells JWH-133 had no effect on IL-2- 
induced proliferation. As the increase in IL-2-induced proliferation appears to be
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CB2R-dependent and given that day 11 SEB-activated PBLs express less CB2R 
protein than day 5 PBLs it is possible that the lack of response in day 11 PBLs is 
related to this lack of receptors. This is in stark contrast to results discussed 
earlier which showed that in day 12 PBLs cannabinoids still coupled to ERK1/2 
phosphorylation and inhibited CXCL12-induced chemotaxis. This could suggest 
that a higher receptor occupancy is required to affect proliferation than other 
functions. However, the day 11 PBLs generally proliferated less, even in 
response to IL-2, and therefore this lack of response may simply be a reflection 
of a general physiological phenomenon.
Counting cells using the Coulter counter is a very low throughput way of 
investigating cell proliferation so XTT assays were used to further investigate the 
effects of cannabinoids on IL-2-induced PBL proliferation. The assay works on 
the principle that XTT, which is a tetrazolium salt, will be converted to an orange 
formazan dye only in metabolically active cells. The colour change can be 
measured and the absorbance will reflect the number of cells present in the wells. 
Although actual cell numbers cannot be determined using this assay it still allows 
a comparison to be made between different experimental conditions. Again, both 
the day 5 and day 11 PBLs responded to IL-2 in a concentration-dependent 
manner. The effects of JWH-133, ACPA, a CBiR-selective agonist and met- 
AEA, a stable AEA analogue, were variable between experiments resulting in 
large error bars. There was a trend though for all three cannabinoids to increase 
IL-2-induced day 5 PBLs proliferation. The increases were only modest, 
however, and were not statistically significant compared to vehicle due to the 
large amount of variability. The response to JWH-133 again suggests the 
involvement of the CB2R. Although ACPA was used as a CBiR-selective 
agonist, it only increased proliferation at lOpM, when it would no longer 
discriminate between the two cannabinoid receptors (Hillard et al., 1999). In fact 
at the lower concentrations when ACPA is selective for the CBiR ACPA appears 
to be inhibiting proliferation slightly. The increase in IL-2-induced proliferation 
stimulated by the cannabinoids in day 11 PBLs was even smaller than in day 5 
PBLs. Again, there was a large amount of variability between experiments.
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Although the XTT assays do support the data from the cell counts to a certain 
extent they were not as helpful in determining the effects of cannabinoids on 
proliferation as hoped. The main problem encountered was the variability 
between experiments which showed that in some experiments the cannabinoids 
almost inhibited proliferation of, for instance, day 5 PBLs in response to IL-2, 
whereas in others they enhanced proliferation. This variability may reflect that 
XTTs are not as accurate a way of determining cell numbers or it could reflect a 
true variability in the response of cells to cannabinoids. It has been shown that 
the activation status of murine splenocytes greatly influences the ability of 
cannabinol to stimulate IL-2 production (Jan & Kaminski, 2001). Cannabinol 
enhanced IL-2 production in suboptimally activated cells but suppressed IL-2 
secretion in optimally activated cells. So subtle differences between individual 
sets of PBLs could result in different effects of the cannabinoids such as 
regulating the extent of proliferation they induce. This would suggest that the 
cannabinoids have the ability to respond very well to the exact cellular 
environment and/or status. This is also reflected in the fact that lymphocyte 
proliferation was shown to be differentially affected by A9-THC depending on 
mitogen used (Pross et al., 1987, Pross et al., 1992) and cell density (Pross et al, 
1987, Schatz et a l , 1993). Further experiments would need to be carried out to 
assess whether experimental conditions such as cell density affect the 
proliferative response induced by JWH-133 in the day 5 PBLs.
4.6.4.1 How could JWH-133 be mediating this effect?
Cannabinoids couple to several pathways that could be linked to the increase in 
IL-2-induced proliferation of day 5 PBLs. For instance, cannabinoids have been 
shown to couple to PI3K activation (Bouaboula et a l , 1997, Galve-Roperh et al,
2002) and PI3K has in turn been shown to be important in the regulation of T 
lymphocyte proliferation (Breslin et a l, 2005). Similarly, cannabinoids can 
couple to ERK activation in these cells and the ERK signalling cascade is linked 
to the control of proliferation (Stork & Schmitt, 2002). As day 12 PBLs also 
coupled to ERK1/2 phosphorylation in this study but JWH-133 failed to enhance 
proliferation as shown by cell counting, other signalling pathways would clearly 
also be involved in this response in day 5 PBLs. Cannabinoids have also been
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shown to modulate energy metabolism in a number of cell types (Guzman & 
Sanchez, 1999). For example, A9-THC, at nanomolar concentrations, enhanced 
glucose oxidation and phospholipid synthesis from glucose in murine 
splenocytes (Sanchez et al., 1997). The ability to enhance energy metabolism 
may play some part in the pro-proliferative actions of cannabinoids.
4.7 Conclusions
In this part of the study I have shown that AEA and 2-AG couple to ERK1/2 
phosphorylation in both activated PBLs and Jurkats. Although the responses are 
PTX-sensitive suggesting that they are receptor mediated the involvement of the 
CB2R and/or modified CBiR could not be specifically determined due to 
experimental difficulties. However, as the response is mimicked by JWH-133 it 
is a strong indication that the CB2R is involved. Evidence from naive T 
lymphocytes, which express only the modified CBiR, suggests that this receptor 
may not be functional although this needs to be confirmed by additional 
experiments. ERK is coupled to several cellular functions and thus cannabinoids 
could influence a number of activated T lymphocyte functions by activating 
ERK 1/2, including proliferation (Stork & Schmitt, 2002) and migration (Huang 
et al., 2004) as discussed.
2-AG was shown to enhance forskolin-induced cAMP production in day 5 PBLs. 
Again, there are many downstream effectors of cAMP and therefore any change 
in cAMP production has the potential to affect a myriad of cellular functions. 
For instance, cAMP has been shown to both activate and inhibit cell proliferation 
(Stork & Schmitt, 2002) and can also influence cell migration and cytoskeletal 
organisation (Howe, 2004). Thus, by elevating levels of cAMP, 2-AG could 
have a number of effects on activated T lymphocyte function. Further studies 
would need to be done to elucidate its exact role.
In this part of the study it was also determined that although neither 2-AG nor 
JWH-133 act as chemoattractants for T lymphocytes these cannabinoids do 
inhibit CXCL12-induced chemotaxis. The implications of this data are that 
cannabinoids may inhibit infiltration of activated T lymphocytes into sites of
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infection and may therefore be one of their immunosuppressive actions. In 
contrast, I have also determined that JWH-133 can increase IL-2-induced 
proliferation of day 5, but not day 11, PBLs in a CB2R-dependent manner. At 
first glance this suggests that the cannabinoids may be pro-inflammatory. 
However, it is possible that the response may vary depending on the cellular 
environment and activation status, indicating that cannabinoids may be 
immunomodulatory rather than strictly pro-inflammatory or immunosuppressive.
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5.1 Final Discussion
During the course of this study it has been shown that the 83kD protein detected 
by the Cayman Chemicals CBiR antibody in the colonic epithelial cell line HT- 
29s, leukaemic T lymphocyte cell lines, CEMs and Jurkats, naive purified 
primary human T lymphocytes and PBLs appears to be a modified form of the 
receptor. However, at present it remains unclear how it is modified although 
data indicates that it is not N-glycosylated. It is also unknown whether the 
protein represents a functional receptor or not. Immunoblotting of HT-29 
fractions suggested that it can be present at the membrane, however data 
indicates that it is not activated by the cannabinoids. For instance, neither AEA 
nor 2-AG induced ERK1/2 or PKB phosphorylation in naive purified T 
lymphocytes, cells which were shown to express only this modified 83kD form 
of the CBiR and no CB2R. Furthermore, ACPA, which is believed to be a CBjR- 
selective agonist, although it has also been described as a broad cannabinoid 
agonist in one study (Franklin & Stella, 2003), did not enhance proliferation 
except at very high concentrations, when it would certainly also bind the CB2R. 
Thus at present is appears that the 83kD form of the CBiR detected in PBLs may 
not represent a functional receptor. However, further experiments are required to 
confirm this.
Although the cannabinoids were originally believed to be immunosuppressive, 
impairing cell-mediated and humoral immunity and cellular defences against 
infectious agents such as viruses, more recent studies have shown that they can 
exert both pro and anti-inflammatory actions (Cabral & Dove Pettit, 1998, 
Croxford & Yamamura, 2005). Thus, they are now generally referred to as 
immunomodulatory. Given that they can exert a wide range of, often 
contradictory, actions it has been difficult to determine whether cannabinoids 
could be exploited therapeutically for immune-mediated diseases. Nonetheless, 
this avenue of research continues as studies have shown that cannabinoids may 
be beneficial in diseases such as multiple sclerosis, rheumatoid arthritis, allergic 
asthma and IBD (Croxford & Yamamura, 2005, Klein, 2005).
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One of the main difficulties in determining the usefulness of cannabinoids as 
therapeutic agents in the field of inflammatory diseases is that many studies 
investigating the effects of cannabinoids on immune cell function have been 
carried out on non-human primary cells such as murine or rat cells or 
transformed cell lines. Although these are certainly useful they also have their 
limitations as it has been shown that there are significant differences between 
mouse and human immunology in general (Mestas & Hughes, 2004) and there 
are differences between the cannabinoid receptor orthologues. For instance, the 
rat CB2R has a longer C-terminus compared to the human and mouse CB2R 
which may affect receptor desensitisation and internalisation following activation 
(Brown et a l , 2002) and there are also pharmacological differences between the 
human and rat CB2RS such as receptor selectivity of various cannabinoids 
(Mukheijee et al., 2004). The inactivation of 2-AG by COX-2 also appears to 
occur at different rates in human and rat plasma (Kozak et al., 2001). 
Furthermore, cannabinoids may have different effects on transformed and non­
transformed cells. For instance, they induce apoptosis of transformed neural 
cells but may protect non-transformed neurons from insults such as ischaemia 
and oxidative damage (Guzman et al., 2002). In addition, the Jurkats used in this 
current study express a modified CBiR was detected, although there are several 
reports stating that Jurkats express no (Bouaboula et al., 1993, Schatz et al., 
1997, McKallip et al., 2002a) or very little (Daaka et al., 1996) CBiR mRNA 
and no protein (Daaka et al., 1996). Also, it was shown that FAAH was resolved 
as a doublet in Jurkats and CEMs but not in PBLs, suggesting it may be 
differently post-translationally modified in primary and transformed cells. All in 
all these examples show that as well as there being potential differences between 
clones of a particular cell line, differences in the cannabinoid system exist 
between primary cells and cell lines and that it is important to use human cells if 
the data is to be extrapolated to potential therapeutic use. For these reasons the 
majority of the work in this study was carried out in primary human cells.
The question is then whether the data collected in this study indicates that 
cannabinoids exert immunostimulatory or immunosuppressive effects on 
activated T lymphocytes. The results suggest once again that the cannabinoid are
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mainly modulatory and have the potential to exert pro and anti-inflammatory 
effects depending on the function studied.
Although the results were preliminary, and further work does need to be carried 
out to confirm this finding, 2-AG enhanced forskolin-induced cAMP production 
in day 5 PBLs. Given that this was not mimicked by the CB2R-selective agonist 
JWH-133 and the modified CBiR expressed on these cells appears not to be 
functional, this suggests that 2-AG is acting via a cannabinoid receptor- 
independent mechanism. It was long believed that cAMP-dependent signalling 
pathways were involved in downregulating the immune response but this 
perception was largely based on studies that used high (>100pM) concentrations 
of cAMP analogues. More recently it has become apparent that cAMP signalling 
pathways can also be involved in immunostimulatory actions as shown in studies 
using lower (<100pM) concentrations of cAMP analogues (Kaminski, 1998). 
Thus, by elevating cAMP production 2-AG could be either stimulating or 
inhibiting leukocyte functions and this may depend particular end point studied.
It has previously been shown that bacterial activation of human PBLs decreases 
levels of FAAH and increases levels of endocannabinoids (Maccarrone et al., 
2001). In this study it has been shown that T lymphocyte activation by the 
superantigen SEB increases the expression of the CB2R protein. Thus, we can 
envisage a scenario were naive T lymphocytes are activated and upregulate 
expression of the both endocannabinoids and the CB2R. Given that cannabinoids 
inhibit CXCL12-induced chemotaxis of activated T lymphocytes, such as the day 
5 PBLs, most likely via the CB2R, the implications of this data are that 
cannabinoids may inhibit infiltration of activated T lymphocytes into sites of 
infection and therefore be immunosuppressive. This correlates with a study 
showing that infiltrating CD4+ T lymphocyte numbers were suppressed in mouse 
spinal cord by several synthetic cannabinoids, including JWH-015, a CB2R- 
selective agonist, in a murine model of multiple sclerosis (Arevalo-Martin et al., 
2003). The same response is detected in both day 5 and 12 PBLs, even when 
CB2R expression is low. This could reflect a low receptor occupancy 
requirement as discussed earlier but does raise the question of why the receptor is
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upregulated and then downregulated if this is not to affect how or the extent to 
which T lymphocytes respond to cannabinoids.
Notably, data collected suggests that whilst cannabinoids increase IL-2-induced 
proliferation of day 5 PBLs, day 11 PBL proliferation is unaffected. Thus it 
appears that the changes in CB2R receptor expression affects some but not all T 
lymphocyte functions. Further studies would need to be carried out to determine 
which other T lymphocyte functions are affected by the changes in receptor 
expression. That JWH-133 stimulated IL-2-induced proliferation of day 5 PBLs, 
which is an immunostimulatory response, was unexpected. Other studies have 
shown that cannabinoids inhibit lymphocyte proliferation (Pross et al., 1990, 
Schatz et al, 1993, McKallip et a l, 2002b, Yuan et a l, 2002) and the current 
and others (Joseph et a l, 2004, Ghosh et a l, 2006) have shown that cannabinoids 
inhibit CXCL12-induced migration T lymphocytes, an immunosuppressive 
response. Thus, cannabinoids may, during this early phase of the immune 
response when CB2R expression is high, have a regulatory role and depending on 
the microenvironment either inhibit infiltration into sites of inflammation or 
stimulate proliferation. In contrast, we can envisage that later in the immune 
response, when CB2R expression is lower and they no longer affect proliferation, 
cannabinoids continue to inhibit infiltration into sites of inflammation, which 
may play a role in the resolution phase of inflammation. Indeed, in the context 
of IBD, which was part of the original rationale or focus behind the project, these 
findings may be very important. It was published recently that levels of AEA are 
upregulated in inflamed colon of IBD patients as well as in animal models of 
IBD and that increasing levels of AEA resulted in ameliorated inflammatory 
scores in those animal models (D'Argenio et a l, 2006). Given the important role 
that T lymphocytes play in IBD (MacDonald & Monteleone, 2005), inhibition of 
their infiltration into sites of inflammation may represent one of the mechanisms 
by which AEA exerts this control on inflammation in IBD.
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5.2 Future Work
5.2.1 Further exploration into the nature of the 83kD protein 
detected
One of main unresolved issues arising from this work is the identity of the 83kD 
CBiR band detected. Although the data generated indicates that it is indeed a 
form of the receptor, how it has been modified and whether it is functional as a 
cannabinoid receptor remains unclear. Verifying whether the Jurkats used in this 
project express CBiR mRNA would help determine once and for all whether 
these Jurkats do express the CBiR and hence whether the 83kD protein detected 
is a CBiR. Immunoblotting of WCLs prepared from HT-29s in which the CBiR 
has been silenced using siRNA technology would also confirm whether or not 
the 83kD band detected represents a CBiR isoform. Recently an additional 
CBiR antibody raised against a portion of the C-terminus of the receptor has 
become commercially available and would be a useful tool in determining 
whether the 83kD protein is detected purely because of the epitope against which 
it was raised or is a high molecular weight form of the receptor. Equally, ligand 
binding experiments on Jurkat or PBL cell membranes, using a CBiR-selective 
agonist, would also help confirm whether or not the 83kD protein detected is a 
receptor. However, care would need to be taken in choosing such an agonist as 
ACPA, a commonly used compound, has recently been shown to be a general 
cannabinoid receptor agonist (Franklin & Stella, 2003). Selective agonists could 
also be used to determine whether the receptor expressed is functional and 
couples to downstream signalling events such as phosphorylation of ERK 1/2. 
Prelimary data also indicated that in HT-29s, which express both the CBiR and 
CB2R, these two receptors dimerise. Given that cannabinoid receptor 
dimerisation may affect how we understand cannabinoid pharmacology in cells 
that express both receptors, this should be further explored. In particular, in 
relation to this project, it will be important to determine whether the 83kD 
protein and the CB2R can dimerise in T lymphocytes.
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5.2.2 Investigating the effects of additional T lymphocyte 
activators on receptor expression
The temporal variation in CB2R protein expression following T lymphocyte 
activation is one of the main discoveries made during this study and given that 
this implies that cannabinoids may affect T lymphocyte function in different 
ways throughout the immune response, should be investigated further. A 
difference in the length of time of CB2R protein upregulation was detected when 
SEB or CD3/CD28-coated beads were used as T lymphocyte activators. This 
work could be extended to other activators, such as PHA. Furthermore, day 7-8 
SEB-activated PBLs, when CB2R expression starts to be downregulated, could 
be incubated with CD3/CD28-coated beads to examine whether protein 
expression would again be upregulated. This would confirm that the 
upregulation is connected specifically to T lymphocyte activation.
5.2.3 Exploring the mechanisms by which cannabinoid inhibit 
CXCL12-induced migration
During the course of this study it was determined that 2-AG and JWH-133 
inhibit CXCL12-induced migration of day 5 and 12 SEB-activated PBLs. As 
well as extending this data to additional cannabinoid agonists further work needs 
to be carried out to confirm the involvement of the CB2R and to verify whether 
the effect can be repeated in purified naive T lymphocytes. Given that they do 
not appear to express the CB2R it is expected that CXCL12-induced migration 
will not be affected. The use of the CBjR and CB2R antagonists AM251 and 
AM630 proved problematic in the signalling experiments but may be more 
successful in these functional studies. Alternatively siRNA technology could be 
used to silence the CB2R and water soluble cannabinoids are being synthesised 
which would hopefully eliminate problems with vehicle controls (Pertwee et al., 
2000, Martin et a l, 2006). Further work also needs to be carried out to 
determine the mechanism by which cannabinoids are eliciting this effect. For 
example the effects of cannabinoids on CXCL12-induced signalling could be 
examined and the study on cannabinoid effects on fMLP-induced polarization of 
neutrophils (Kurihara et a l, 2006) repeated in PBLs. Equally the experiments
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carried out during this study should be repeated with other chemoattractants in 
order to determine whether the response is CXCL 12-specific. It should also be 
investigated whether it is the CD4+ or CD8+ T lymphocytes, or both, that are 
responding.
5.2.4 Further investigation into the potentially pro-proliferative
actions of cannabinoids on activated T lymphocytes
Finally, although data indicated that JWH-133 is capable of increasing day 5, but 
not day 11, PBL proliferation, additional experiments are required to verily this 
and extend the observation to additional agonists. The involvement of the 
receptors in this response also needs to be studied. In addition, it has been 
suggested that experimental factors such as cell density can affect cannabinoid 
responses on cell number (Pross et al., 1987, Schatz et a l , 1993) and thus it 
would be important to determine whether this is true in activated T lymphocytes 
as this could affect in vivo responses. Again, it would also be interesting to 
determine whether it is the CD4+ or CD8+ T lymphocytes, or both, that are 
responding, especially as some differences in the responsiveness of particular T 
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7.1 Additional details on methods
7.1.1 Recipes for solutions/buffers used in immunoblotting
7.1.1.1 Lysis buffers
Lysis buffer 
50mM Tris pH 7.5 
150mM NaCl 
1% (v/v) Nonidet P-40 
10% (v/v) glycerol 
5mM EDTA 
ImM sodium vanadate *
ImM sodium molybdate * 
lOmM sodium fluoride *
40pg/ml phenylmethylsulfonyl fluoride *
0.7pg/ml pepstatin A *
lOpg/ml aprotinin *
lOpg/ml leupeptin *
lOpg/ml soybean trypsin inhibitor *
MilliQ H20
* added just before use
Hypotonic lysis buffer
lOmM HEPES pH 7.2
5mM EDTA
ImM sodium vanadate *
ImM sodium molybdate * 
lOmM sodium fluoride *
40pg/ml phenylmethylsulfonyl 
fluoride *
0.7pg/ml pepstatin A *
10 pg/ml aprotinin *
10 pg/ml leupeptin *
1 Opg/ml soybean trypsin inhibitor * 
MilliQ H20
7.1.1.2 5x SDS-sample buffer
10% (w/v) SDS 
50% (v/v) glycerol 
200mM Tris pH 6.8 
Bromophenol blue 




7.1.1.3 Stacking & resolving gels
To make 4 gels:
Resolving Stacking
10% 12% 5%
Acrylamide 6.67ml 8ml 1.67ml
MilliQ H20 5.8ml 4.5ml 6ml
1M Tris 7.5ml (pH 8.8) 7.5ml (pH 8.8) 1.25ml (pH 6.8)
10% (w/v) SDS 0.33ml 0.33ml 0.15ml
10% (w/v) ammonium 
persulphate *
66.7pl 66.7pl 50pl
TEMED * 26.7pl 26.7pl 20pl
* added just before use




0.1% (w/v) SDS 
MilliQ H20
Tris-buffered saline (TBS)









0.0375 % (w/v) SDS 
20% (v/v) methanol 
MilliQ H20
Stripping buffer
62.5mM Tris pH6.8 
2% (w/v) SDS
























5% marvel 1:500 Anti-rabbit, 1:7000 
1% marvel








FAAH 5% BSA 1:500 Anti-rabbit 1:7000 
1% marvel
iKBa 5% marvel 1:1000 Anti-rabbit, 1:10000
MAGL 5% BSA 1:1000 Anti-rabbit, 1:7000 
1% marvel
Pan ERK 5% marvel 1:1000 Anti-rabbit, 1:10000
Pan PKB 5% marvel 1:1000 Anti-goat, 1:10000
Phospho-
ERK1 /2Thr202yTyr204
5% marvel 1:1000 Anti-rabbit, 1:10000




7.2 Details on MEK, PKC and PI3K inhibitors used in Results II
7.2.1 IC50s
Compound Kinases affected I C 5 0  (pM) References
G66976 PKCa 0.0023 
PKCpi 0.0062 
PKC6 no effect 
PKCe no effect 
PKC? no effect
Martiny-Baron et al., 
1993
LY294002 PI3K 1.4 Vlahos et al, 1994
DNA-PK 0.66 
MTOR 8.9 
Casein kinase II 12.2
Knight et al, 2004
PD98059 MEK1 2-7 Alessi et al, 1995













Gschwendt et a l, 1994
PKC0 >100 Villalba et a l, 1999
Casein kinase II 30 
PKA 78 
CaM kinase III 5.3
Gschwendt et a l, 1994
PRAK 1.9 
MAPKAP-K2 5.4





G66976 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-l 3-methyl-5-oxo-5H- 
indolo(2,3 -a)pyrrolo(3,4-c)-carbazole
LY294002 2-(-4-morpholinyl)-8-phenyl-1 (4H)-benzopyran-4-one 
hydrochloride
PD98059 2-(2-amino-3-methoxyphenyl)-4H-1 -benzopyran-4-one
Ro-32-0432 Bisindoylmaleimide XI; 2-(8-[dimethylamino}methyl]-6,7,8,9- 
tetrahydropyroido[l ,2-a]indol-3-yl)-3-(l -methylindol-3- 
yl)maleimide
Rottlerin 3 ’-[(8-Cinnamoyl-5,7-dihydroxy-2,2-dimethyl-2//-l - 
benzopyran-6-yl)methyl] -2 ’ ,4’ ,6 ’ -trihydroxy-5 ’ - 
methylacetophenone
7.3 Chemical names of cannabinergic ligands used in this study
Cannabinergic ligand Chemical name
2-AG (5Z,8Z,11Z,14Z)-5,8,11,14-Eicosatetraenoic acid, 2- 
hydroxy-1 -(hydroxomethyl)ethyl ester
ACPA A-(2-Cyclopropyl)-5Z,8Z, 11Z, 14Z-eicosatetraenamide
AM251 A-(Piperidin-1 -yl)-5-(4-iodophenyl)-1 -(2,4- 
dichlorophenyl)-4-methy 1-1 //-pyrazole-3 -carboxamide
AM630 6-Iodo-2-methyl-1 -[2-(4-morpholinyl)ethyl]- l//-indol- 
3 -yl] (4-methoxyphenyl)methanone
AEA Arachidonoylethanolamide; A-(2-Hydroxyethyl)- 
5Z,8Z,1 lZ,14Z-eicosatetraenamide
JWH-133 (6aR, 10aR)-3 -(1,1 -dimethylbutyl)-6a,7,10,10a- 
tetrahydro-6,6,9,-trimethyl-6//-dibenyo[b,d]pyran
MAFP Methyl arachidonoyl fluorophosphonate;
(5Z,8Z, 11Z, 14Z)-5,8,11,14-eicosatetraenyl-methyl 
ester phosphonofluoridic acid




7.4 Details on cannabinoid  receptors
7.4.1 C annabinoid  recep tor am ino acid sequences
Below are the amino acid sequences for the human CBjR and CB2R. The 
potential extracellular (—), transmembrane (—) and intracellular (— ) domains 
are marked.
CBiR (human) amino acid sequence:
1 mksildglad ttfrtittdl lyvgsndiqy edikgdmask Igyfpqkfpl tsfrgspfqe
61 kmtagdnpql vpadqvnite fynkslssfk eneeniqcge nfmdiecfmv Inpsqqlaia
121 vlsltlgtft vlenllvlcv ilhsrslrcr psyhfigsla vadllgsvif vysfi dfhvf
-------------------ii----------- ii--------------------1
181 hrkdsrnvfl fklggvtasf tasvgslflt aidryisihr playkrivtr pkawafclm 
I   II- - - - - - - - - - - - - - - - - - II- - - - - - - -
241 wtiaiviavl pllgwncekl qsvcsdifph idetylmfwi gvtsvtllfi vyaymyilwk
--------------1  IH
301 ahshavrmiq rgtqksiiih tsedgkvqvt rpdqarmdir laktlvliIv vliicwgpll
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - II- - - - - - - - - - - - -
361 aiiwydvfgk mnkliktvfa fcsmlcllnstvnpiiyalr skdlrhafrs mfpscegtaq
421 pldnsmgdsd clhkhannaa svhraaesci kstvkiakvt msvstdtsae al 
 1
CB2R (human) amino acid sequence:
1 m eecwteia ngskdgldsn pmkdymilsg pqktavavlc tllgllsale nvavlylils
I--------------------------lh
61 shqlrrkpsy Ifigslagad flaswfacs fvnfhvfhgv dskavfllki gsvtmtftas
- - -- - -- - -- II- - - - - - - - - - - - - - - - - - - - - 1 I- - - - - - - - - - - - - - -
121 vgsllltaid rylclrypps ykalltrgra Ivtlgimvwl salvsylplm gwtccprpcs
 II- - - - - - - - - - - - - - - - - - - H- - - - - - - - - - - - - - - - - - - - - - - - - 1
181 elfplipndy llswllfiaf Ifsgiiytyg hvlwkahqhv aslsghqdrq vpgmarmrld
I- - - - - - - - - - - - - - - - - - - - - - - - II- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
241 vrlaktlglv lavllicwfp vlalmahsla ttlsdqvkka fafcsmlcli nsnrwnpviya
 II- - - - - - - - - - - - - - - - - - - - - - - - I I - - - - - - - - - - - - - - II- - - - - - - - - - - - - - - - - - - - - - - - - - -
301 Irsgeirssa hhclahwkkc vrglgseake eaprssvtet eadgkitpwp dsrdldlsdc
II- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1
253
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7.4.2 C annabinoid  recep to r antibodies used
Antibody Source Raised against
CB,R Cayman Chemicals Amino acids 1-14 of human CBiR
CB,R Santa Cruz Amino acids 1-150 of the human CBiR
CBiR Affinity Bioreagents Amino acids 1-99 of the human CBjR
CB2R Cayman Chemicals Amino acids 20-33 of the human CB2R
c b 2r Santa Cruz Amino acids 301-360 of the human CB2R
C a y m a n  C h e m ic a ls  
(a a  1 -1 4 )
A ffin ity  B io re a g e n ts  
( a a  1 -9 9 )
S a n ta  C ru z  
(a a  1 -1 5 0 )
CBtR
C a y m a n  C h e m ic a ls  
(a a  2 0 - 3 3 )/ r\ r\
c b 2r
S a n ta  C ru z  




7.5 Amino Acid Codes
Single letter code 3 letter code Amino Acid
A Ala Alanine
B Asx Asparagine/Aspartic acid
C Cys Cysteine
D Asp Aspartic acid

















Z Glx Glutamine/Glutamic acid
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